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i 
Abstract 
Bone formation by osteoblasts (OBs) and bone resorption by osteoclasts (OCLs) is a tightly 
coupled and balanced process. In chronic inflammatory diseases such as rheumatoid arthritis 
(RA), this balance is disturbed and OCL activity exceeds that of OBs, leading to net bone loss or 
osteoporosis. Glucocorticoids (GC) are frequently used in treatment of inflammatory diseases. 
However, the long term use of GCs can lead to the development of GC-induced osteoporosis 
(GIO). 
The p38 mitogen-activated protein kinases (MAPK) pathway is critical for the expression of 
many pro-inflammatory genes such as tumour necrosis factor (TNF). It is also involved in the 
differentiation and activation of OCLs. Termination of p38 MAPK signalling is partly dependent 
on dual specificity phosphatase 1 (DUSP1). DUSP1 expression is up-regulated by pro-
inflammatory stimuli, providing a negative feedback loop to limit the inflammatory response. It 
is also up-regulated by GCs, and contributes to their anti-inflammatory properties. 
This study investigated the role of DUSP1 in two forms of bone loss. To test the hypothesis that 
induction of DUSP1 contribute to GIO, the bone phenotype of a Dusp1-/- mouse strain was first 
characterised, then the responses of bone to chronic GC administration were investigated. The 
involvement of DUSP1 in inflammatory bone loss was next examined using in vitro assays of 
OCL function, and collagen-induced arthritis (CIA), an experimental model of RA. Dusp1-/- 
OCLs displayed enhanced responses to pro-inflammatory stimuli in vitro. Furthermore, Dusp1-/- 
mice showed more rapid development and more severe arthritis and responses to GC were 
decreased compared to controls. The exacerbated disease in Dusp1-/- mice was accompanied by 
increased inflammatory infiltration, activation of OCLs and articular bone ersoion. There was 
also evidence of increased expression of interleukin 17 (IL-17), a cytokine that has been 
implicated in inflammatory and auto-immune diseases. 
These observations highlight a role of DUSP1 as an important negative regulator of 
inflammatory osteolysis and as a mediator of therapeutic effects of GCs in CIA.  
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2 
1 Introduction 
1.1 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic progressive systemic inflammatory disease which affects 
about 0.5-1% of the adult population worldwide (Firestein, 2003) and can lead to disability and 
increased mortality (Aletaha et al, 2010). In the UK the treatment and care of RA costs the NHS 
an estimated £560 million per year and the additional cost for the economy through work-related 
disability and sick leave is £1.8 billion per year (Zhang & Anis, 2011). RA is characterised by 
inflammation of the joint synovium with tenderness and swelling, joint stiffness, joint 
destruction and the presence of self-reactive antibodies like rheumatoid factor (RF) or anti-cyclic 
citrullinated peptide (CCP) antibody. RA can affect all peripheral joints, with the joints of the 
hand, feet and knees being affected most commonly (Smolen & Steiner, 2003). The extent and 
severity of RA varies between patients, one or more joints can be involved and serum factors 
such as RF and anti-CCP antibody can be either present or absent (Aletaha et al, 2010). 
Circulating pro-inflammatory cytokines, acute phase proteins, immune complexes (ICs) and an 
altered lipid metabolism in RA patients can also lead to the development of a range of other 
extra-articular systemic symptoms like cardiovascular diseases, osteoporosis and fracture, or 
pulmonary fibrosis caused by interstitial lung disease (Figure 1.1) (Cojocaru et al, 2010; Hamblin 
& Horton, 2011). Furthermore, systemic osteoporosis is common in many different forms of 
chronic inflammation like chronic obstructive pulmonary disease, Crohn’s disease and other 
inflammatory bowel diseases or type 2 diabetes mellitus (Hela et al, 2005; Hofbauer et al, 2007; 
Jorgensen et al, 2007) 
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Figure 1.1 Extra-articular manifestations in rheumatoid arthritis 
Pro-inflammatory cytokines like tumour necrosis factor (TNF), interleukin (IL)-1 and IL-6 produced in 
the arthritic joint can increase the production of acute phase proteins like C-reactive protein (CRP) from 
the liver and contribute to the development of extra-articular symptoms increasing mortality and 
morbidity in patients. TNF, receptor activator of nuclear factor kappa B ligand (RANKL) and Dickkopf-
related protein 1 (Dkk-1) can also promote osteoporosis (McInnes & Schett, 2011). (HDL high-density 
lipoprotein; LDL low-density lipoprotein; HPA hypothalamic-pituitary-adrenal; SERT serotonin 
transporter). 
 
The incidence of RA is two to three times higher in women than in men; however, why the 
incidence is higher in women is not fully understood yet. However, genetic association with 
certain major histocompatibility complex (MHC) class II haplotypes has been shown. Despite 
the initial cause of RA still remaining unknown, many pathways and inflammatory processes 
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leading to joint destruction and other signs of RA have been identified and lead to the 
development of new therapeutics. 
RA is a systemic autoimmune disease in which activated auto-reactive cluster of differentiation 
(CD)4+ T cells are present in the joint and act to further activate B cells to differentiate into 
plasma cells that produce auto-antibodies. Autoimmunity is an immune response to self-antigens 
caused by ineffective central and peripheral tolerance. Lymphocyte precursor cells undergo a 
process of thymic selection where self-reactive T cells are deleted (central tolerance). Next T cells 
have to undergo a peripheral selection process, where their reactivity to self-antigens in 
peripheral tissues is tested. Self-reactive T cells undergo anergy (i.e. become functionally 
inactivated but remain alive and hyporesponsive) or deletion during peripheral selection. 
However, this process seems to be disturbed in autoimmune diseases, resulting in activated self-
reactive T cells (Su et al, 2012; Westerberg et al, 2008). 
Genetic studies of RA patients have shown a higher susceptibility to develop RA in patients with 
the MHC class II molecule human leukocyte antigen (HLA)-DR4 and HLA-DR1. MHC class II 
molecules are present on antigen presenting cells (APCs), bind peptides and present them to T 
cells. Around 80% of Caucasian RA patients express either HLA subtype. HLA-DR1 and DR4 
share the same epitope in their polymorphic region of the DRβ chain (Gregersen et al, 1987). 
Peptide:MHC class II complexes are recognised by CD4+ T cells, implicating T cells in the 
pathogenesis of RA. Patients with this MHC class II haplotype are also more likely to develop 
more severe symptoms of RA and to present with extra-articular diseases (Calin et al, 1989). 
Other autoimmune diseases have also been associated with certain HLA-DR phenotypes. HLA-
DR2 and 3 are predominant in systemic lupus erythematosus (SLE) and HLA-DR2 is 
predominant in multiple sclerosis. However, twin studies have shown that the incidence of 
autoimmune diseases is higher in identical twins than in HLA identical siblings, highlighting the 
Chapter One Introduction
 
5 
role of other factors apart from T cell recognition of self-peptide:MHC class II recognition and 
only modest genetic association (Svendsen et al, 2002). 
Whether inflammatory arthritis is triggered by an initial inflammation of the synovial membrane, 
synovitis, or by events elsewhere, such as the juxta-articular bone marrow and subchondral bone, 
and then expands to the joint, is still a topic of debate (Schett & Firestein, 2010). Indeed, 
accumulating evidence suggests that osteitis in the bone marrow can occur early in RA (Hetland 
et al, 2009; McQueen et al, 2003). 
 
1.2 Immunology of  rheumatoid arthritis 
The immune responses in vertebrates involve immunological recognition, immune effector 
function, immune regulation and immunological memory. Self-regulation of the immune 
response is important to prevent damage of self tissue. Failure of this self-regulation contributes 
to conditions like allergy and autoimmunity. RA is classified as an autoimmune disease due to the 
presence of auto-reactive T cells and a variety of auto-antibodies (Mewar & Wilson, 2006), like 
RF and anti-CCP antibodies. RF is an auto-antibody that reacts with the Fc region of 
immunoglobulin (Ig) G molecules and is often used as a serological marker for RA. However, 
RF is not present in all patients with RA yet it is present in other autoimmune diseases like 
Sjögrens syndrome and also in a small proportion of healthy individuals (Firestein, 2003). Other 
auto-antibodies like anti-CCP antibodies, specific for proteins containing citrullinated arginine 
side chains, have a high specificity to RA and are present before the clinical onset of disease 
(Rantapaa-Dahlqvist et al, 2003). Citrulline is a non-conventional amino acid that can be 
generated by post-transcriptional modification of arginine residues by the enzyme 
peptidylargenine deiminase (PAD). Furthermore, auto-antibodies specific for type II collagen are 
present in 10-30% of RA patients (Clague et al, 1994; Mewar & Wilson, 2006). Auto-antibodies 
Chapter One Introduction
 
6 
in the rheumatic joint can form ICs and contribute to disease activity by activating complement 
by recognition of Fc regions of auto-antibodies and stimulating cytokine production. 
One of the major symptoms of RA is the inflammation of the synovial lining which is present in 
the joint. The fundamental signs of inflammation were defined by Cornelius Celsus (ca. 50 BC) 
as: rubor (redness), dolor (pain), calor (heat), and tumor (swelling). In RA, patients present with joint 
swelling and tenderness. Inflammation of the synovium causes synovial fibroblasts to release 
pro-inflammatory cytokines like tumour necrosis factor (TNF), interleukin (IL)-1 and IL-6 
leading to vasodilation of nearby blood vessel in the joint and activation of the endothelial cells 
(McInnes & Schett, 2007). Neutrophils, macrophages and lymphocytes are recruited to the 
synovium (Figure 1.2). Invasion of macrophages and proliferation of synovial fibroblasts (SF) 
leads to synovial hyperplasia and pannus formation. Other pro-inflammatory cytokines are 
expressed by the cells in the synovium, including TNF, IL-15, IL-17, IL-18, chemokines and 
angiogenic factors leading to neo-angiogenesis, a characteristic of synovitis in early RA. 
Vasodilation, influx of cells, production of cytokines and neo-angiogenesis cause redness, 
swelling, pain and heat in the arthritis joint. Also osteoclasts (OCLs) are found in the synovium, 
especially at the site of contact between pannus and bone (Gravallese et al, 1998). SFs are 
reported to express macrophage colony stimulating factor (M-CSF) and receptor activator of 
nuclear factor kappa B ligand (RANKL), both needed for OCL differentiation and activation. 
RANKL is also produced by activated T cells amongst other cytokines can contribute to the 
regulation of osteoclastogenesis (Takayanagi et al, 2000b). It has been shown that TNF, IL-1 and 
IL-17 further promote the formation of OCLs in the presence of RANKL and M-CSF, making 
the arthritic joint an environment suited for OCL formation and activation and leading to bone 
erosions (Gravallese et al, 2000; Lam et al, 2000; Schett & Teitelbaum, 2009). As a consequence 
of bone errosions the synovium can access the bone marrow space and cause osteitis by 
formation of T cell and B cell aggregates in the bone marrow, which replace the marrow fat. 
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Blockade of RANKL by Denosumab, an anti-RANKL antibody, ameliorates bone resorption in 
RA but has no effect on inflammation (Cohen et al, 2008). 
 
Figure 1.2 Healthy versus arthritic joint 
The arthritic joint is characterised by synovial hyperplasia, angiogenesis, presence of neutrophils in the 
synovial space, pannus formation and presence of T cells, B cells, plasma cells, macrophages, activated 
OCLs and bone resorption. (Smolen & Steiner, 2003). 
 
1.2.1 Cytokines in rheumatoid arthritis 
A variety of innate and adaptive immune cells and an array of different antibodies, cytokines and 
chemokines contribute to the pathogenesis of RA (Table 1.1). However, it has been proposed 
that cytokine patterns may change over the course of RA as early RA is characterised by 
expression of IL-4, IL-13 and IL-15 while established RA is characterised by TNF and IL-17 
(Raza et al, 2005). In the rheumatic joint synovial fibroblasts (SF) are expanded and express high 
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levels of adhesion molecules, cytokines, metalloproteinases (MMPs), but also tissue inhibitors of 
MMPs (TIMPs). 
Cell type 
Cytokine and other highly 
expressed molecules 
Effect 
Th1 cell IFNγ, IL-2, RANKL Promotes M1 macrophage activation 
Th17 cell IL-17 Promotes OCL activation, SF activation 
B cell 
Anti-CCP and anti-collagen 
antibodies, RF 
Promotes IC formation, complement 
activation 
Dendritic cells IL-23 Promotes Th17 expansion 
Monocytes IL-1, IL-6  
Promotes acute phase protein synthesis 
in liver 
Macrophage TNF, IL-1, IL-6 
Promotes activation of SF, leukocytes, 
endothelial cells, suppresses Treg 
Neutrophils 
TNF, IL-1, IL-6, IL-15, IL-18 and 
BAFF, RANKL 
Promotes activation of SF, leukocytes, 
endothelial cells, OCL 
Synovial fibroblasts 
RANKL, M-CSF, TNF, IL-1, 
MMPs, TIMPs 
Promotes OCL formation and activation, 
cartilage degradation 
Endothelial cells Adhesion molecules Promotes leukocyte recruitment 
Osteoclasts RANK, TRAP, cathepsin K Bone resorption 
Table 1.1 Immune cells involved in rheumatoid arthritis 
Immune cells involved in RA, the cytokines and molecules they express and their effects in the 
pathogenesis of RA. (IFN interferon; BAFF B cell survival and activating factor; TRAP tartrate resistant 
acid phosphatase; Th T helper) 
 
TNF plays a critical role in RA and is mainly secreted by monocytes, macrophages and SFs. 
Furthermore, high protein and messenger ribonucleic acid (mRNA) levels of TNF are found in 
the synovium and synovial fluid of RA patients (Brennan et al, 1992; Chu et al, 1991; Partsch et 
al, 1997). TNF is a trans-membrane protein, which is cleaved by the desintegrin and 
metalloproteinase (ADAM) 17 to be released as a soluble pro-inflammatory cytokine. TNF can 
bind to two different receptors, TNF receptor type 1 (TNFR1) and 2 (TNFR2) (Lewis et al, 
1991). Upon TNF:TNFR ligation the receptors form trimers and are able to initiate three 
different intracellular signalling pathways: nuclear factor kappa B (NFκB) pathway, mitogen-
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activated protein kinase (MAPK) pathway, induction of cell death (Wajant et al, 2003). Both the 
NFκB and MAPK pathways promote the expression of pro-inflammatory cytokines. 
TNF acts in an autocrine as well as paracrine fashion to promote expression of IL-1, IL-6 and 
granulocyte macrophage colony-stimulating factor (GM-CSF) (Butler et al, 1995; Haworth et al, 
1991). It further promotes pain induction, angiogenesis and expression of endothelial cell-
adhesion molecules, which increases cell migration into the RA joint. TNF also suppresses 
regulatory T cell (Treg) proliferation, therefore contributing to a pro-inflammatory environment. 
Furthermore, TNF contributes to bone resorption by promoting OCL differentiation from 
macrophages in the presence of RANKL and M-CSF (Lam et al, 2000). Blockage of TNF has 
been shown to effectively reduce synovial inflammation, cartilage degradation and bone erosions, 
in both animal studies and RA patients (Zwerina et al, 2004). Infliximab, Adalimumab, and 
Etanercept are three different TNF blockers which are approved for the therapeutic use in RA 
patients. 
IL-17 is highly expressed in the rheumatic joints of both RA patients and in animal models 
(Lubberts et al, 2005). It is primarily secreted by activated Th17 and γδT cells (Rouvier et al, 
1993; Yao et al, 1995). However, bone erosions associated with IL-17 in RA are driven by Th17 
cells rather than γδT cells (Pollinger et al, 2011). IL-6 and IL-23 secreted by macrophages or 
dendritic cells (DCs) induces expression of IL-17 by Th17 cells in the presence of transforming 
growth factor (TGF) β (Infante-Duarte et al, 2000). IL-17 binds to IL-17 receptors which 
predominantly activates the NFκB pathway to induce gene expression of pro-inflammatory 
genes (Gaffen, 2009). IL-17 induces RANKL, TNF, and IL-1β expression by SF which in turn 
promotes osteoclastogenesis. Additionally the RANKL/osteoprotegerin (OPG) balance is 
disturbed by IL-17 also favouring bone resorption over bone formation (Lubberts et al, 2003). 
Further highlighting the important role of IL-17 in RA are animal models of IL-17 deficient 
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mice, which show reduced severity of collagen-induced arthritic (CIA) (Nakae et al, 2003), 
whereas, overexpression of IL-17 worsens disease. The acute joint inflammation induced by IL-
17 is dependent on the expression of TNF (Lubberts et al, 2001). Blockade of TNF however, 
has shown to increase Th17 cells despite ameliorating disease activity (Notley et al, 2008).  
Other cytokines that are upregulated in RA include IL-6, IL-1β, GM-CSF, M-CSF, and RANKL. 
IL-6 is produced by T cells, B cells, macrophages, DCs, and SFs. It promotes production of 
acute-phase proteins from the liver, leukocyte activation and macrophages differentiation. Also 
OCL formation is promoted and bone formation inhibited by IL-6 (Kudo et al, 2003). Blockade 
of IL-6 is therapeutically effective in mouse models of CIA (Takagi et al, 1998). The humanised 
monoclonal antibody Tocalizumab is successfully used to block IL-6 action in RA patients. IL-
1β induces expression of TNF, IL-6, MMPs and stimulates osteoclastogenesis and therefore 
contributes significantly to the pathogenesis of RA and therefore, the inhibition of IL-1 via IL-1 
receptor antagonists or IL-1 targeting antibodies in a CIA model reduces inflammation, cartilage 
degradation and bone erosions (Kim et al, 2003; Palmer et al, 2003). In RA patients, blockade of 
IL-1 is effective in reducing inflammation but is not as effective as the blockade of TNF 
(Zwerina et al, 2004). M-CSF and RANKL expressed by SFs and neutrophils in RA contribute to 
the differentiation and activation of OCLs. OCL differentiation will be described in more detail 
in section 1.5. 
Many pro-inflammatory cytokines in the rheumatic joint which drive the disease are expressed by 
cells of the innate immune system, highlighting that innate immune pathways are of critical 
importance throughout the course of RA. 
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1.3 Innate immune system 
Animals have evolved several strategies to defend themselves from invading pathogens. In 
vertebrates there are three levels of defence against pathogens: the epithelial barriers (skin and 
lining in the respiratory system), the innate and the adaptive immune system. Both the innate and 
adaptive immune systems are able to distinguish pathogenic from self-antigens and both are 
needed to effectively eliminate pathogens and generate immunological memory (Janeway, 1992). 
The innate immune system activates the adaptive response by presenting antigen and providing 
co-stimulation (CD80, CD86, and CD28) to lymphocytes on APCs and is therefore an essential 
component of all immunological responses (Medzhitov & Janeway, 2000). However, the innate 
immune system is only poorly effective without adaptive immunity and dysfunctions can 
contribute to diseases like immunodeficiency or allergies and asthma  
The innate immune system is the first line of defence against invading pathogens and can 
generate an immediate response (0-4 hours). Evolutionarily it appeared earlier than the adaptive 
immune system and it consists of both humoral and cellular components. In the early 90s 
Charles Janeway and colleagues proposed the presence of innate receptors as part of the innate 
immune system for detecting pathogenic antigens and discriminating them from self-proteins 
(Janeway, 1992). These receptors are encoded in the germline and are therefore inherited and 
present from birth. Innate receptors recognise conserved structures present in microorganisms, 
called pathogen-associated molecular patterns (PAMPs) and endogenous molecules released 
upon tissue injury called damage associated molecular patterns (DAMPs) (Akira et al, 2006; 
Piccinini & Midwood, 2010). DAMPs including heat-shock proteins (HSPs), tenacin-C and 
PAMPs like lipopolysaccharides (LPS), peptidoglycans, bacterial deoxyribonucleic acid (DNA) or 
double-stranded ribonucleic acid (RNA) are recognised by pattern-recognition receptors (PRRs). 
PRRs are mostly expressed on APCs (macrophage, DCs and B cells) or are present in the serum 
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(Goh & Midwood, 2012). PRRs can be divided into three functional groups: secreted, endocytic 
and signalling. 
Secreted PRRs (e.g. mannan-binding lectin (MBL)) are present in the serum and can bind 
PAMPs on the microbial cell wall. This interaction of PRR:PAMP is either recognised by 
phagocytes or by the complement system. The complement system consists of several serum 
proteins and proteases synthesised by the liver, and form part of the innate immune system. 
Upon activation by either antibody-bound microbes (classical pathway), or MBL-bound 
microbes (lectin pathway), or by an alternative pathway, proteases of the complement system 
cleave a cascade of proteins, which results in the formation of an membrane attack complex on 
the surface of the microbe leading to its killing and opsonisation by phagocytes. Proteins of the 
complement system can further act as cytokines and chemokines. 
Membrane bound endocytic PRRs are present on phagocytes and mediate the uptake of 
microbes into lysosomes. Proteolytic enzymes in the lysosomes degrade the pathogen and 
pathogen-derived proteins are subsequently processed in the endoplasmic reticulum to be 
presented by MHC class II molecules on the surface of APCs. 
Signalling PRRs like the toll-like receptors (TLRs) activate signal transduction pathways in the 
APC once activated by binding to PAMPs. The activation of these signalling pathways can result 
in a variety of immune responses, like activation of transcription factors, which in turn, control 
the transcription and expression of pro-inflammatory cytokines. TLRs are also known to induce 
upregulation of co-stimulatory molecules like, CD80 and CD86, on APCs, which provide signals 
for the activation of the adaptive immune response (Medzhitov et al, 1997). 
Besides the complement proteins and secreted PRRs present in the serum, other humoral 
components like cytokines released from innate immune cells and acute phase proteins released 
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by the liver are also part of the innate immune system. The cellular components of the innate 
immune system include all polymorphonuclear cells (PMN), eosinophils, basophils, neutrophils, 
mast cells and monocytes, macrophages, natural killer (NK) cells and DCs. 
The innate immune system has a critical role throughout the course of RA. High numbers of 
neutrophils are present in the synovial fluid in both animal models of RA and in RA patients. 
They are activated by ICs generated by auto-antibodies and secrete a wide variety of pro-
inflammatory cytokines like TNF, IL-1, IL-6, IL-18. Also mast cells are found in the arthritic 
joint of patients and in animal models. IgE anti-CCP antibodies bind to Fcε receptors on mast 
cells (Schuerwegh et al, 2010) leading to the activation and expression of proteases, pro-
inflammatory cytokines and chemokines. 
Auto-antibodies like RF and anti-CCP antibodies activate complement by formation of ICs. The 
synovial fluid of RA patients has been found to contain higher levels of complement proteins, 
especially C3a and C5a (Hogasen et al, 1995; Okroj et al, 2007). Furthermore, the involvement of 
the innate immune system is highlighted in animal models of RA; animals are injected with 
adjuvant derived from microbes, especially bacteria. These bacterial components are recognised 
by different TLRs and activate the innate immune response helping to break T cell tolerance. 
Moreover, the severity of inflammatory arthritis in TLR2 deficient mice is reduced (Joosten et al, 
2003). 
 
1.3.1 Neutrophils 
Neutrophils are the most abundant PMNs in humans and are rapidly recruited to sites of 
infection and inflammation (Cascao et al, 2010; Nathan, 2006; Wright et al, 2010). Like all other 
classical immune cells, neutrophils are derived from pluripotent haematopoietic stem cells in the 
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bone marrow. Resting neutrophils are short lived (undergoing apoptosis after 12-18 hours) and 
circulate in the blood. Cytokines like TNF, GM-CSF, interferon (IFN) γ, and also bacterial 
products like LPS, released at the site of infection into the circulation lead to the priming of 
neutrophils (Nathan, 2006). Primed neutrophils upregulate adhesion molecules (L-selectin, 
integrins), by which they attach to the vascular endothelial lining expressing intercellular 
adhesion molecules (ICAMs) and vascular cell adhesion molecules (VCAMs) at sites of 
inflammation, then they transmigrate and are recruited by chemotaxis into the tissue where they 
can release reactive oxygen species (ROS) and function as phagocytic cells and secrete cytokines 
and chemokines to recruit other immune cells (Cross et al, 2006). Activated neutrophils have a 
delay in apoptosis, however, this is only transient and apoptosis is required for the resolution of 
inflammation. Neutrophils are also able to act as APCs by expressing peptide bound MHC class 
II and therefore activate T cells and drive inflammation (Gosselin et al, 1993; Sandilands et al, 
2005). However, the cytotoxic molecules released by neutrophils to kill pathogens can also 
damage host tissue. Therefore the regulation of neutrophil activation and neutrophil apoptosis is 
crucial. 
In RA, neutrophils are found in high numbers in the synovial fluid, unlike macrophages, 
monocytes, mast cells and NK cells which reside in the pannus and synovium (Wright et al, 
2010). However, neutrophils can also be found in the pannus and synovial tissue. Neutrophils 
contribute to synovitis by producing prostaglandins, proteases and reactive oxygen intermediates 
(Cascao et al, 2010). Chemokines and cytokines produced further drive inflammation. TNF, 
IFNγ, IL-1β and GM-CSF are expressed in the synovial fluid in RA, prime and activate 
neutrophils, resulting in delayed apoptosis (Raza et al, 2006; Wright et al, 2010). Activated 
neutrophils express high levels of intracellular Mcl-1, an anti-apoptotic protein, and increase its 
stability. Hypoxia has also been shown to delay neutrophil apoptosis by activating the p38 
MAPK pathway and thereby inducing Mcl-1 (Leuenroth et al, 2000). In RA increased levels of 
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Mcl-1 are expressed by SF (Liu et al, 2005), synovial macrophage (Liu et al, 2006) and 
neutrophils (Cross et al, 2006). Furthermore, glucocorticoids (GCs) like dexamethasone, have 
been demonstrated to inhibit apoptosis of human neutrophils (Cox, 1995). 
IC formed in the synovial fluid can be recognised by the Fcγ receptors present on neutrophils, 
triggering degranulation and release of ROS promoting tissue damage (Wright et al, 2010). The 
proteases collagenase and gelatinase contained in neutrophilic granules are implicated in cartilage 
degradation (Wright et al, 2010). IL-17 expressed by T cells in RA acts as a chemo-attractant for 
neutrophils (Ferraccioli & Zizzo, 2011; Lemos et al, 2009). GM-CSF secreted by SF in RA 
triggers activated neutrophils to express oncostatin M (OSM), which has both pro- and anti-
inflammatory effects (Cross et al, 2004). Neutrophils in RA also express TNF and subsequently 
CCL18, which attracts T cells (Auer et al, 2007). In murine arthritis models neutrophils have 
been shown to produce PAD enzymes, which are key to the citrullination of arginine residues in 
peptides (Vossenaar et al, 2003). Anti-CCP antibodies are crucial in the onset of RA. Neutrophils 
in the synovial fluid phagocytose ICs. Activation of nicotinamide adenine dinucleotide 
phosphate oxidase (NOX) 2 in neutrophils leads to the production of ROS in an oxidative burst 
to kill pathogens that have been phagocytosed or can be released extracellularly. Mice with point 
mutations in the Ncf1 gene of NOX2, leading to defective oxidative bursts, develop severe CIA 
(Hultqvist & Holmdahl, 2005). Neutrophils also express membrane bound RANKL and express 
OPG, RANK and TNF. Neutrophils in RA synovial fluid just express RANKL and OPG and 
could therefore potentially promote the development of macrophages into OCLs in the pannus 
(Poubelle et al, 2007). 
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1.3.2 Monocytes 
Macrophage, OCL and myeloid DCs are all derived from the monocyte lineage. Monocytes 
circulate in the blood and can enter tissues at sites of infection were they can differentiate into 
macrophages or DCs. The monocyte population is heterogeneous and can be divided into two 
main groups in humans CD14+CD16- and CD14lowCD16+ and in mice CX3CR1lowCCR2+GR1+ 
and CX3CR1highCCR2-GR1- (Geissmann et al, 2003). 
CD16 is also known as FcγRIIIa, which can bind to IgG antibodies involved in IC formation in 
RA joints. Engagement of the activating FcγRIIIa activates an intracellular ITAM motif and 
results in activation of the MAPK pathway and the production of cytokines. Induction of 
collagen-induced and antibody-induced arthritis in mice deficient of the activating FcR γ-chain is 
prevented, despite presence of anti-collagen antibodies and inflammatory cytokines in the serum, 
highlighting the importance of FcγR activation in the development of inflammatory arthritis 
(Kagari et al, 2003; Kleinau et al, 2000). Healthy human peripheral blood monocytes stimulated 
in vitro with IC formed by anti-CCP antibodies in synovial fluid of RA patients showed an 
increased production of TNF (Mathsson et al, 2006). In human RA peripheral blood and 
synovial tissue the levels of CD14lowCD16+ monocytes are elevated. This subset of monocytes 
also produces higher amounts of TNF in response to LPS (Gierut et al, 2010). TLR2 and TLR4 
expression is increased on blood CD16+ and CD16- monocytes from RA patients and these cells 
therefore have an increased TNF and IL-8 response to microbial TLR2 and TLR4 ligands 
(Huang et al, 2007; Iwahashi et al, 2004). The expression of TLR2 and TLR4 on RA monocytes 
can be further increased by IFNγ (Radstake et al, 2004). 
Also IL-1α and β produced by monocytes is expressed in the synovium of RA patients. Mice 
deficient of IL-1α receptor agonists develop spontaneous erosive arthritis associated with the 
induction of Th17 cells (Koenders et al, 2008). However, therapeutic targeting of the IL-1 
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pathway only showed modest effects in RA patients (Bresnihan et al, 1998; Cohen et al, 2002; 
Gabay et al, 2010). Other proteins that are worth mentioning in the context of arthritis are 
DAMPs like tenascin-C and HMGB1, which are endogenous TLR ligands. Tenascin-C is an 
extracellular matrix glycoprotein expressed transiently upon tissue injury. However, persistent 
high levels of tenascin-C are found in chronically inflamed synovial tissue of RA patients 
(Hasegawa et al, 2007; Midwood et al, 2009). The fibrinogen-like globe domain of tenascin-C is 
believed to signal via TLR4 and induces the release of TNF and IL-6 in 
monocytes/macrophages and SFs (Midwood et al, 2009). Like tenascin-C, HMGB1 is released 
by cells upon injury and has a pro-inflammatory role by activating monocytes and is implicated in 
cartilage degradation. Blockade of HMGB1 suppresses CIA in mice. Upon activation of 
monocytes and macrophage in the RA joint, IL-6 is secreted, which promotes the release and 
synthesis of acute phase proteins like C-reactive protein and serum amyloid from the liver. IL-6 
is important in the induction of CIA as it can also drive T effector cell responses. 
 
1.3.3 Macrophages 
Macrophages are derived from circulating monocytes and are crucial for the innate immune 
response. Once monocytes leave the blood stream and enter specific tissues they mature into 
macrophages. GM-CSF and M-CSF secreted by activated T cells or by various stromal cells 
induce maturation of monocytes into macrophages. Macrophages are divided into two main 
groups of classically activated M1 macrophages and alternatively activated M2 macrophages. M1 
macrophages can be activated by IFNγ secreted by Th1 cells and LPS stimulation or derived 
from monocytes by stimulation with GM-CSF in vitro, while M2 macrophages can be activated 
by IL-4 produced by Th2 cells or derived from monocytes with M-CSF in vitro (Gordon & 
Taylor, 2005). 
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M1 macrophages produce pro-inflammatory cytokines and nitric oxide, resulting in microbial 
killing but also contribute to tissue destruction, whereas M2 macrophages upregulate expression 
of arginase and are involved in tissue remodelling and secrete anti-inflammatory cytokines. In 
vitro M1 macrophages polarised by GM-CSF express IL-1β, IL-12, IL-23 and TNF, while M2 
macrophages polarised by M-CSF express IL-10. Macrophages are found in almost all tissues, 
often associated with epithelial lining cells and are referred to as Kupffer cells in the liver and 
microglia in the nervous system or as Osteomacs in the bone where they interact with 
osteoblasts (OBs) (Chang et al, 2008). Their primary role is to detect invading pathogens by 
means of PRRs and as phagocytes, to remove apoptotic or necrotic cells, and as APCs which can 
present peptide bound MHC class II. FcR and complement receptors on the macrophages 
surface are able to bind antibodies engaged in neutralisation of antigens, opsonisation of bacteria 
or complement activation, resulting in phagocytosis of the antibody complex and lysis (Hume, 
2008). Resting macrophages have very low levels of MHC class II expression and do not express 
the co-stimulatory molecule CD80 (B7). Expression of these molecules is induced by 
phagocytosis of pathogens or antibody complexes. Macrophages can also be activated by Th1 
cells expressing IFNγ to produce pro-inflammatory cytokines. However, Leishmania infections 
of macrophages manipulate the cells to up-regulate activity of MAPK phosphatases, like dual 
specificity phosphatase 1 (DUSP1), leading to deactivation of extracellular signal-regulated kinase 
(ERK) and p38 MAPK resulting in failure to respond to IFNγ and inhibiting inducible nitric 
oxide synthase (iNOS) expression (Kar et al, 2010). The role of DUSP1 in macrophages is 
crucial to regulate p38 MAPK activation and pro-inflammatory cytokine production (Joanny et 
al, 2012; Turpeinen et al, 2011) 
In RA increased numbers of macrophages are found in the synovium and pannus and are an 
important source of pro-inflammatory cytokines. Macrophage activation in the RA joint has 
been proposed to occur via its PRRs. TLR2, 3, 4 and 6 expressed by macrophages, detect 
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endogenous fibronectin and heat shock proteins present in the joint (Brentano et al, 2005). Mice 
deficient of TLR2 and TLR4 also have a reduced incidence of CIA (Abdollahi-Roodsaz et al, 
2008; Joosten et al, 2003). TNF, IL-1, IL-6, IL-12, IL-15, IL-23, reactive oxygen intermediates 
and matrix degrading enzymes are released by activated macrophages in RA suggesting a 
predominantly M1 phenotype. Further apoptosis of macrophages is delayed in RA, resulting in 
prolonged activation and potential for tissue damage. In animal models of arthritis and in RA 
patients expression levels of the pro-apoptotic protein Bim (Bcl-2-interacting mediator of cell 
death) are reduced in macrophages. Studies in which Bim was administered as a protein reduced 
the incidence and severity of arthritis in mice (Scatizzi et al, 2010). 
One of the major pro-inflammatory cytokines produced by macrophages in RA is TNF. It is 
crucial in the pathogenesis of RA. TNF induces activation of synovial fibroblasts, endothelial 
cells and leukocytes. Overexpression of TNF in animal models triggers spontaneous erosive 
inflammatory arthritis whereas inhibition of TNF suppresses arthritis (Keffer et al, 1991). 
Therapeutic blockade of TNF yields clinical responses in 70% of patients with established RA. It 
reduced levels of IL-6 and acute phase proteins and leukocyte migration and induced recovery of 
Treg functions. Mice deficient in GM-CSF have been shown to be resistant to CIA, further 
highlighting the important role of macrophages in arthritis (Campbell et al, 1998). Treatment of 
RA patients with low dose of methotrexate, which inhibits T cell activation, also decreases the 
production of cytokines from macrophages (Johnson et al, 1988).  
 
1.3.4 Dendritic Cells 
Next to macrophage and B cells, DCs are the main APCs. Like macrophages DCs are also 
derived from the monocyte lineage. The main role of DCs is to recognise pathogens, present 
them to T cells and activate the adaptive immune response but also to maintain self-tolerance 
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(Banchereau & Steinman, 1998; Guermonprez et al, 2002; Steinman et al, 2003). DCs are 
therefore the main link between the innate and adaptive immune response. Like macrophages 
DCs are a heterogeneous population and resident in most tissues. DCs can be divided into 
conventional DCs (cDCs), which reside in the tissue like Langerhan cells in the skin, and 
plasmacytoid DCs, which are long lived and specialised in producing IFNγ upon recognition of 
viruses. Both subsets are able to activate T cells. Immature DCs are highly phagocytic and 
recognise pathogens via PRRs on the surface (Iwasaki & Medzhitov, 2010). Once a pathogen is 
detected and engulfed, it is processed and antigenic peptides are presented on MHC class II 
molecules. Mature DCs increase the expression of cytokines, MHC class II and co-stimulatory 
molecules. Also the expression of CCR7, a chemokine receptor, is increased and promotes 
migration of the DC from the tissue to secondary lymphoid organs (e.g. lymph nodes, spleen). 
Once in the lymph node DCs present the MHC:peptide complex together with co-stimulatory 
molecules to naïve T cells. Depending on the cytokine produced by the DCs and the 
environment, T cells develop into respective T helper (Th) cells and proliferate. Three different 
signals are required for T cell activation by APCs: 
 recognition of the MHC:peptide complex by the TCR (signal 1) 
 provision of co-stimulation via CD80 or CD86 which engages CD28 on T cells (signal 2) 
 expression of cytokines by DC to determine effector T cell type (signal 3) 
DCs induce peripheral tolerance in mature naïve T cells by providing only signal 1 alone, which 
leads to anergy or deletion of T cells. Activation of naïve T cells and their polarisation into 
different Th effector cells requires all three signals, while the third signal determines the effector 
cell population. DCs recognise pathogens via PRRs leading to uptake via endocytosis or 
phagocytosis and maturation of the DC. Internalised antigens are then processed and presented 
on MHC class I or class II molecules (Guermonprez et al, 2002). Lipids can also be presented on 
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MHC related CD1 molecules. DC activation can also be induced by pro-inflammatory cytokines 
expressed by the tissue at the infection site, although these indirectly activated DCs are unable to 
induce functional T cell responses (Joffre et al, 2009; Sporri & Reis e Sousa, 2005). Recognition 
by PRRs triggers intracellular signalling cascades resulting in maturation and cytokine expression 
by DCs. Different TLRs have been demonstrated to activate NFκB and MAPKs via MyD88 
promoting maturation and survival of DCs (Rescigno et al, 1998). The C-type-lectin receptors 
dectin-1 and dectin-2 activate NFκB, MAPK and NFAT signalling via Syk (LeibundGut-
Landmann et al, 2007; Robinson et al, 2009). Furthermore, activation of p38α in DCs has 
recently been shown to regulate IL-6 and IL-27 expression (Huang et al, 2012). Up-regulation of 
MHC and co-stimulatory molecules like CD80 and CD86 leads to engagement of TCRs and 
activation of CD4+ and CD8+ T cells. Interaction of CD80/86 on DCs with CD28 on T cells 
leads to T cell proliferation and survival, while interaction with CTLA-4 on T cells induces 
inhibition of T cell responses. Ligation of the late co-stimulatory molecule OX40 by OX40L is 
also involved in CD4+ T cell activation (Lane, 2000). The expression of various cytokines by 
DCs or activated T cells determines the proliferation into different T cell subsets (Figure 1.3). 
While expression of TGFβ alone promotes differentiation of FoxP3+ inducible regulatory T cells 
(iTreg), in the presence of IL-6 or IL-23 secreted by DCs, TGFβ promotes proliferation of Th17 
cells. Expression of IL-12 by activated DCs leads to induction of Th1 proliferation while IL-4 
promotes Th2 proliferation. 
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Figure 1.3 T cell polarisation by dendritic cell 
Upon interaction of naïve T cells with mature dendritic cells (DCs), cytokines expressed instruct 
differentiation into distinct effector cells. Expression of TGFβ activates the transcription factor FoxP3 
generating inducible regulatory T cells (iTreg) which secrete TGF and IL-10. In the presence of IL-6 or 
IL-23 the transcription factors RORγt or RORα are induced leading to Th17 cell differentiation, which 
are characterised by IL-17, IL-12 and IL-22 expression. IL-12 expression induces IFNγ and IL-2 
expressing Th1 cell differentiation via activation of T-bet, while IL-4 induces Th2 cells, which express IL-
4, IL_5, IL-10 and IL-13 via GATA3 activation. 
 
In RA DCs are found in the synovial tissue and synovial fluid and have been shown to express 
high levels of TGFβ, IL-1β, IL-6, IL-21 and IL-23, which provide support for Th17 proliferation 
and suppress Treg differentiation. Furthermore DCs drive the formation of ectopic germinal 
centres in the arthritic joints (Page et al, 2002; Weyand & Goronzy, 2003). Multiple animal 
models have highlighted the role of DCs in activation of T cell responses in arthritis. Modulation 
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of T cell immunity by DCs is an attractive target for therapy of autoimmune diseases. In recent 
years generation of tolerogenic DCs, which either delete T cells, induce Tregs or shift the Th cell 
profile from Th1 cells to Th2 cells have been investigated. Tolerogenic DCs have been shown to 
reduce or inhibit CIA (Harry et al, 2010; Morita et al, 2001; Popov et al, 2006; Stoop et al, 2010; 
Stoop et al, 2011). 
 
1.4 Adaptive immune system 
The adaptive immune system is the last level of defence against invading pathogens in 
vertebrates. It responds both by humoral and cellular reactions. The humoral response is 
mediated by B cells whereas the cellular response is mediated mainly by T cells but also NK cells. 
Unlike the innate immune system the adaptive immune system is antigen specific, has a memory 
and is therefore enhanced by second exposure to the same pathogen. The main receptors 
involved in innate immunity, like PRRs, are germ line encoded, whereas the T cell receptor 
(TCR) and B cell receptors (BCR) as well as the immunoglobulins (Ig) secreted by mature 
activated B cells undergo somatic recombination of gene fragments and have therefore a greater 
diversity and specificity to pathogens. Like the cells of the innate immune system T cells and B 
cells originate from hematopoietic stem cells in the bone marrow. Maturation of B cells occurs 
within the bone marrow, whereas immature T cells migrate to the thymus. Naïve B and T cells 
develop BCRs and TCRs by somatic recombination during maturation. Since random somatic 
recombination can give rise to receptors specific for self-antigen, naïve B and T cells undergo a 
selection process to differentiate between self and non-self antigens. This selection process 
happens in secondary or peripheral lymphoid organs like the lymph nodes, spleen or mucosa-
associated lymphoid tissues (e.g. Peyer’s patches in the gut). 
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This first encounter with an antigen is called the primary immune response and it also takes place 
in secondary lymphoid organs. TCRs recognise processed antigens bound to MHC molecules 
and presented by APCs (Janeway & Medzhitov, 2002), while BCRs recognise antigens directly. 
After recognition of a pathogenic antigen with a specific BCR or TCR naïve T and B cells 
undergo clonal expansion and become effector cells, which either secrete effector cytokines and 
perform effector functions, like cytotoxic killing by CD8+ T cells, or secrete antigen-specific 
antibodies, which can bind pathogens and lead to opsonisation or complement activation. APCs 
can also prime effector cells for future encounter with the same pathogen by inducing memory B 
and T cells. Memory cells are very long lived (up to several years) and are easily triggered by 
second exposure to the same pathogen (secondary immune response). The secondary immune 
response is quicker and larger than the primary immune response. However, antigen recognition, 
processing and display on MHC molecules by APC, which are then recognised by T cells which 
undergo clonal expansion to perform effector function takes time, which makes the adaptive 
immune response much slower than the fast acting innate immune response. The adaptive 
immune response is only very poorly effective without the innate immune response. 
Many aspects of the adaptive immune response have to be considered to understand and treat 
autoimmune diseases like RA. The production of pro-inflammatory cytokines by Th cells and the 
production of antibodies specific for RF and citrullinated peptides are very important for the 
development of RA. 
 
1.4.1 T cells 
T cells develop from the bone marrow derived haematopoietic common lymphoid progenitor 
cells, which can enter the thymus via the circulation. Experiments in 1960s by Jacques Miller 
highlighted the importance of the thymus in T cell development when he observed a reduction 
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in lymphocyte cells after thymectomy in three day old mice (Miller, 2002). Once in the thymus 
these precursor cells are also called double-negative thymocytes as they lack the expression of the 
surface molecules CD4 and CD8 (CD4-CD8-) (Takahama, 2006). In the thymus double-negative 
thymocytes rearrange the TCR genes to generate TCRs with different specificity. The TCR 
complex consist of CD3 signalling molecules, intracellular zeta chains and a heterodimer 
composed of variable α:β chains or γ:δ chains. In a process called positive selection, cells bearing 
TCRs compatible with self-MHC molecules, presented by thymic epithelial cells, receive a 
surviving signal, giving rise to a population of thymocytes restricted for recognition of self-MHC 
molecules (Anderson & Takahama, 2012). Next in a process called negative selection, cells which 
express TCRs that recognise self-peptide loaded self-MHC molecules on DCs present in the 
thymus, receive a signal leading to apoptosis, giving a self-tolerant population of thymocytes. 
Therefore, only thymocytes which recognise non-self peptides loaded on self-MHC molecules 
survive these selection processes and can develop into mature naïve T cells. Furthermore, T cells 
expressing TCRs with a γ:δ heterodimer (γδT cells) remain CD4-CD8- when exiting the thymus, 
while thymocytes with a α:β heterodimer undergo further maturation by expression CD4+CD8+ 
(double-positive) and proliferate extensively. Next double-positive cells lose expression of either 
CD4 or CD8 and following negative selection exit the thymus as single-positive CD4+ or CD8+ 
T cells (Matloubian et al, 2004). 
Mature T cells exit the thymus and enter into peripheral lymphoid organs. Upon encounter of 
non-self antigens T cells become activated, undergo clonal expansion, differentiate into specific 
effector T cells and can either migrate to sites of infection, where they can kill infected cells and 
activate macrophages or move into B cell areas of the lymphoid organ to activate antibody 
production. CD8+ T cells recognise antigens associated with MHC class I molecules which are 
ubiquitously expressed and specific for the presentation of cytosolic proteins. For instance in the 
case of intra-cellular viral infection, MHC class I molecules present the viral proteins expressed 
Chapter One Introduction
 
26 
by the infected cells. Upon recognition of peptide-MHC class I complex, CD8+ T cells adopt a 
cytotoxic phenotype and can kill the infected cells by several mechanisms including secretion of 
proteins that can lyse the target cells, or expression of Fas-ligand (FasL) which can induce 
apoptosis of the target cells. In RA synovial CD8+ T cells were found to express IFNγ and 
CD40L in the mantle zone of germinal centres but their precise role in RA remains unclear 
(Kang et al, 2002). 
Upon interaction and activation of naïve T cells with APCs, like DCs, in the peripheral lymphoid 
organs, CD4+ T cells further differentiate into several effector cell subsets, which orchestrate the 
adaptive response through cell-cell contacts with other effector cells and the secretion of 
cytokines. The main functional classes are Th1, Th2, Th17, and Tregs. Various different factors 
can influence lineage commitment including antigen type, load and affinity, interaction of co-
stimulatory and adhesion molecules (Constant et al, 1995; Luksch et al, 1999; Rulifson et al, 
1997). The main determinant, however, is the cytokine expression by APCs (Glimcher & 
Murphy, 2000). Th cells are mainly characterised by the cytokines which drive their respective 
differentiation and by the cytokines they produce (Mosmann et al, 1986). Many autoimmune 
diseases like, Lupus, RA and diabetes type I are driven by self-reactive Th cells, which express 
pro-inflammatory cytokines and provide T cell help for B cells to secrete auto-antibodies (Jager 
& Kuchroo, 2010). 
Cytokines like IL-1β, IL-6, IL-7, IL-12, IL-15, IL-19, IL-23 and TGFβ expressed by 
macrophages, DCs and SFs in the arthritic joints can promote Th1 and Th17 differentiation. T 
cells play a crucial role in the pathogenesis of RA as high numbers of T cells are present in the 
inflamed synovium. Genetic association with MHC class II alleles (HLA-DR4)(Calin et al, 1989; 
Nepom et al, 1989), and several animal models of arthritis proved the requirement of T cells 
(McInnes & Schett, 2007). Animal models of arthritis like CIA, showed increased production of 
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IFNγ by lymph node cells and decreased production of Th2 cytokines, indicating that RA is a 
Th1 driven disease (Mauri et al, 1996). Further, mice treated with IL-12 or IL-18, which are 
inducers of Th1 differentiation in mice, developed higher incidence and more severe disease 
compared with controls (Leung et al, 2000). More recent animal studies, however, highlight the 
role of IL-17 secreting Th17 cells (Ferraccioli & Zizzo, 2011; Hirota et al, 2007; Kotake et al, 
1999; Lubberts, 2008; Notley et al, 2008; Pollinger et al, 2011). 
 
1.4.1.1 Th1 cells 
It was first observed that murine CD4 T cell clones segregate into two subsets called Th1 and 
Th2 cells, which express either IL-2, IFNγ and TNF or IL-4, IL-5, IL-6, IL-10 and IL-13 
(Mosmann et al, 1986). Th1 cells differentiation from naïve CD4+ T cells is mediated by TCR 
triggering and IFNγ and IL-27 expressed by NK cells and APCs. Activation of the IFNγ 
receptor leads to induction of signal transducer and activator of transcription 1 (STAT1), which 
in turn activates expression of the T-box transcription factor (T-bet). Subsequently, T-bet 
activates runt-related transcription factor 3 (Runx3), which inhibits activation of GATA-binding 
protein 3 (GATA3), which is crucial for Th2 differentiation. Also the expression of the high 
affinity IL-12 receptor β2 (IL-12Rβ2) subunit is induced by T-bet (Murphy & Reiner, 2002). 
Binding of IL-12, expressed by APCs, to the IL-12R activates STAT4. STAT4 together with 
RUNX3 and T-bet activates IFNγ gene expression, which then provides a positive feedback 
loop resulting in a stable expression of T-bet (Wilson et al, 2009). IFNγ activates macrophages. 
In addition TNF is produced by Th1 cells and recruits macrophages to the site of inflammation. 
Th1 cells can also promote CD8+ T cell differentiation by secreting IL-2 and IFNγ. This 
provides an efficient immune response against intracellular pathogens. However, Th1 pro-
inflammatory cytokines are elevated in various autoimmune diseases like multiple sclerosis or 
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RA, and mediate immune responses against self. Therefore, Th1 responses are controlled by 
Tregs or other inhibitory mechanisms (Oldenhove et al, 2003). 
Several animal models of arthritis, like pristane-induced arthritis (PIA) or streptococcal cell wall-
induced arthritis (SCWA), showed a major role of IFNγ and IL-2 secreted by Th1 cells in disease 
progression, while IL-4 secreted by Th2 cells showed anti-inflammatory effects (Allen et al, 1993; 
Elson et al, 1995). However, in the murine CIA model, the role of IFNγ is more ambiguous as 
mice deficient of IFNγ or its receptor, develop more severe arthritis than wild type mice (Chu et 
al, 2003; Hirota et al, 2007; Manoury-Schwartz et al, 1997; Vermeire et al, 1997). Furthermore, 
systemic injections of high concentrations of IFNγ ameliorate CIA while local injections of IFNγ 
into the footpad of mice increases CIA onset (Mauritz et al, 1988; Nakajima et al, 1990). In RA 
patients levels of IFNγ and IL-2 are found in the synovial fluid and are able to activate and 
recruit macrophages and neutrophils (Raza et al, 2005).  
 
1.4.1.2 Th17 cells 
TGFβ expressed by APCs following activation, inhibits proliferation of Th1 and Th2 cells, but 
promotes Th17 and Treg differentiation via activation of the transcription factors fork-head box 
P3 (FoxP3) and retinoic-acid-receptor-related orphan receptor γt (RORγt), which is inhibited by 
FoxP3 in the absence of IL-6. In the presence of IL-6, however, RORγt expression is increased 
and Th17 cell differentiation is favoured. T cells subsequently express IL-21 which in turn 
activates STAT3 and induces expression of IL-23 receptor. IL-23 secreted by APCs further 
maintains IL-17 expression. 
In recent years, IL-17 secreting Th17 cells have been recognised as major contributors of 
autoimmunity. The role of Th17 cells in the pathogenesis of RA is now well established both in 
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animal models and in studies of patients. IL-17 is expressed in the synovial membrane of RA 
patients. The importance of Th17 responses over Th1 responses is supported by observations 
made in IL-12p35 deficient and IFNγ receptor deficient mice, which show accelerated disease 
(Murphy et al, 2003; Vermeire et al, 1997), whereas, mice deficient of IL-6 or IL-23p19 are 
resistant to development of CIA (Murphy et al, 2003; Wang et al, 2006). Furthermore, 
overexpression of IL-17 in joints worsens joint inflammation and bone erosions, inhibition of 
IL-17 on the other hand suppresses inflammation (Lubberts et al, 2003). IL-17 produced by T 
cells drives activation of neutrophils, macrophages and synovial fibroblasts, as well as neutrophil 
differentiation, maturation and MMP synthesis (Weaver et al, 2007). IL-17 together with IL-1β 
and TNF can activate synovial fibroblasts in RA and induces expression of RANKL, thereby 
supporting OCL activation. Further supporting a role of Th17 in arthritis development is the 
observation that in SKG mice, which spontaneously develop chronic autoimmune arthritis, the 
production of IL-6 by APC, which leads to the differentiation of Th17 cells, is crucial for 
development of disease (Hata et al, 2004; Hirota et al, 2007). 
Blockade of IL-6 showed a reduction in bone erosions and disease severity and a humanised 
antibody blocking the IL-6 receptor, Tocalizimab, shows therapeutic benefits in RA patients 
(McInnes & Schett, 2011). Also dual blockade of IL-17 and TNF or GM-CSF has been shown 
to reduce joint damage in arthritic mice (Koenders et al, 2011). Clinical trials with humanised 
anti-IL-17 antibodies showed an improvement of symptoms in RA patients (Genovese et al, 
2010). 
 
1.4.2 B cells 
B cells are derived from common lymphoid progenitor cells in the bone marrow. The 
characteristic of B cells is their ability to produce antibodies which are soluble immunoglobulin 
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proteins that are composed of two light and two heavy chains. The hyper-variable light chain 
allows the recognition of a huge number of antigens therefore conveying unique specificity. The 
light chain is epitope specific and binds to pathogens which neutralises their effects and marks 
them for phagocytosis by other cells of the immune system. The heavy chain determines the 
isotype of the antibody which is important for different effector functions. B cells can switch the 
heavy chain of an antibody (class switch) while the light chain remains unchanged resulting in an 
antibody that still recognises the same antigen but will initiate a different effector function due to 
the new isotype. B cells retain an immunological memory after antibody production by forming 
memory B cells which enable a quicker response when an antigen is encountered again. 
A number of auto-antibodies have been associated with RA, like RF, anti-CCP antibodies, and 
antibodies against collagen, which can promote IC formation and complement activation. 
Furthermore, IL-6, IL-10 and lymphotoxin β secreted by B cells activates DCs and macrophages. 
DCs and macrophages in the synovial membrane produce B cell survival and activating factors 
(BAFF). Also exposure of SFs to TNF and IFNγ in the arthritic joint can trigger the production 
of BAFF. 
Depletion of CD20+ B cells in a mouse model of CIA delayed the onset of arthritis and 
confirmed a critical role of B cells in early stages of the disease (Yanaba et al, 2007). Rituximab is 
an anti-CD20 monoclonal antibody which inhibits B cell activation, maturation and function and 
has been shown to ameliorate clinical symptoms in RA patients (Edwards & Cambridge, 2001; 
Silverman & Weisman, 2003). However, depletion of CD20 B cells targets only mature B cells 
and has no effect on plasma cells. Therefore the depletion of CD19 B cells has been proposed, 
as CD19 is expressed on pre-B cells, mature B cells and plasma cells (Tedder, 2009). 
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1.5 Bone 
Bone is the major site of haematopoiesis. Precursor cells for all classical innate and adaptive 
immune cells are present in the bone marrow. Furthermore, bone provides mechanical and 
structural support for muscles and organs. The major cells involved in bone homeostasis are 
bone resorbing OCLs, bone forming OBs and osteocytes. Osteocytes are terminally 
differentiated OBs, that are embedded into the canaliculi of compact bone and function as 
mechanosensors and are involved in maintenance of the bone matrix (Knothe Tate et al, 2004). 
Bone undergoes constant remodelling processes and an imbalance can result in disease states like 
osteoporosis, characterised by loss of bone density, or osteopetrosis, excess bone formation. 
Bone remodelling is a multi-cellular process involving pre-OCL, OCLs, pre-OBs and OBs. This 
group of cells is called the basic multicellular unit (BMU) (Jilka, 2003). In the initial phase of 
bone remodelling pre-OCL are recruited and differentiate into activated OCLs after RANKL 
stimulation, which is expressed by bone lining stromal cells an OBs. OCLs have a half-life of 7-
10days and once activated resorb bone and eventually undergo apoptosis. Osteoprogenitor (pre-
OBs) cells are recruited to the BMU and differentiate into active OBs. OBs secrete osteoid and 
mineralise the extracellular matrix to create new bone (Jilka, 2003; Matsuo & Irie, 2008). Figure 
1.4 shows a diagram of bone remodelling. 
 
Figure 1.4 Bone remodelling 
Bone undergoes constant remodelling. Activated osteoclast resorb bone, which is then remodelled by 
active osteoblast. Osteoblast can further differentiate into osteocytes and incorporate into the bone 
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OBs are of mesenchymal origin and are responsible for the formation of a bone matrix by 
production of type I collagen, proteoglycans, glycoproteins and the mineralisation of the matrix 
(Boskey, 1998). OBs and OCLs are tightly linked in the process of bone remodelling. OBs 
express RANKL and M-CSF that activate OCLs while factors released by osteoclastic resorption 
of the bone matrix affect activation of OBs (Ducy et al, 2000; Teitelbaum, 2000). 
 
1.5.1 Osteoclast differentiation and signalling 
OCLs are large multinucleated cells formed by the fusion of mononuclear cells of the 
macrophage lineage; these cells are characterised by the expression of tartrate-resistant acid 
phosphatase (TRAP) and the ability to resorb calcified matrices (Teitelbaum, 2000). Macrophage 
differentiation into OCLs requires the presence of OBs, which secrete M-CSF and RANKL 
(Udagawa et al, 1990; Yasuda et al, 1998). M-CSF and RANKL bind to membrane bound 
receptors on macrophages and induce commitment to the OCL lineage. However, as OBs also 
secrete osteoprotegerin (OPG), which hinders OCL differentiation by preventing 
RANK:RANKL interaction, a balance between stimulatory and inhibitory molecules is crucial. 
Mice lacking OPG develop severe osteoporosis. 
OCL differentiation involves many different molecules and signalling pathways. Defects and 
deficiencies of different genes (e.g. M-CSF, its receptor c-Fms and different transcription factors) 
lead to absence or defective OCLs, resulting in a lack of bone resorption and increased bone 
density (osteopetrosis). Bone lining cells and OBs are crucial for OCL differentiation and 
interaction involves cell-contact and soluble factors. The immunoglobulin-like receptor OCL-
associated receptor (OSCAR) is involved in the cell-cell-interaction between OBs and OCLs 
(Kim et al, 2002).  
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M-CSF secreted in the bone microenvironment by bone lining cells induces the formation of 
macrophage colony forming units from which monocytes, macrophages and OCLs derive. M-
CSF binds to its receptor c-Fms (also known as colony stimulating factor 1 receptor, Csf1r) (Dai 
et al, 2002; Yoshida et al, 1990). The expression of c-Fms receptor is enhanced by the 
transcription factor PU.1 after M-CSF signalling, by binding to the promoter region of the Csf1 
gene. Deficiency of PU.1 leads to a lack of both macrophages and OCLs, suggesting a role in 
early differentiation processes (Yoshida et al, 1990). M-CSF signalling encourages differentiation 
into OC precursor cells and up-regulation of the membrane receptor RANK. 
RANKL secreted by OBs or T cells binds to the receptor RANK, present on OCL precursors. 
Together with M-CSF, RANKL promotes OCL differentiation, proliferation, fusion of 
precursor cells and survival (Arai et al, 1999; Jimi et al, 1999; Yasuda et al, 1998). RANK is a 
member of the TNF receptor family (TNFR) and its cytoplasmic domain interacts with TNFR 
associated factor (TRAF) molecules (Wong et al, 1998). It has three binding sites for TRAF6 and 
two for TRAF2, 3, or 5 (Darnay et al, 1999). The importance of TRAF6 for OCL differentiation 
has been reported both in vivo and in vitro (Lomaga et al, 1999). The formation of the TRAF6 
trimer on RANK leads to the activation of NFκB and the MAPKs Jun N terminal kinase (JNK) 
and p38 (Kobayashi et al, 2001). 
RANK:RANKL interaction results in activation of p38 MAPK and inhibition of p38 MAPK 
prevents RANKL-induced differentiation (Matsumoto et al, 2000b). Moreover, p38 MAPK is 
essential for OCL differentiation in vitro and cathepsin K expression (Matsumoto et al, 2004a). 
However, OCL function seems to be independent of p38 MAPK suggesting a more important 
role of p38 MAPK in the initial phases of OCL activation (Li et al, 2002). p38 MAPK is also 
believed to express c-Fos, as overexpression of c-Fos restores RANKL-induced OCL 
differentiation in the presence of p38 inhibitors (Huang et al, 2006). p38 MAPK controls both 
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the expression and activation of NFATc1. p38 MAPK activation of NFATc1 is crucial for gene 
expression of cathepsin K (Matsumoto et al, 2004b). 
The MAPK JNK pathway activates c-Fos and c-Jun, which together form the transcription 
factor activator protein 1 (AP-1) (Wagner & Eferl, 2005). AP-1 is involved in up-regulating the 
expression of NFATc1 as c-Fos deficient cells lack NFATc1 induction by RANKL (Takayanagi 
et al, 2002). It has been shown that NFATc1 is highly induced after RANK:RANKL interaction 
in OCLs (Ishida et al, 2002). NFATc1 is activated by calcineurin upon intracellular Ca2+ 
signalling. Calcineurin dephosphorylates serine residues of NFATc1 so it can enter the nucleus. 
It binds to the promoters of genes involved in OCL activity, like TRAP, cathepsin K and β3-
integrins (Asagiri et al, 2005; Matsumoto et al, 2004a; Takayanagi et al, 2002). NFATc1 has a role 
both in OBs and OCLs, and administration of calcineurin inhibitors affect bone formation and 
suppress OCL differentiation in vivo apart from the immunosuppressive functions (Asagiri et al, 
2005; Koga et al, 2005). 
NFκB is activated very rapidly via TRAF6 following RANK:RANKL interaction (Boyle et al, 
2003). Two pathways are involved in NFκB activation, the canonical and non-canonical pathway. 
NFκB is inhibited by the inhibitor of κB (IκB) in unstimulated cells. In the canonical pathway 
IκB-kinase (IKK) phosphorylates IκB, which leads to the activation of NFκB and ubiquitin-
dependent degradation. This pathway involves the NFκB p50 protein. The non-canonical 
pathway involves the activation of p52, which dimerises with RelB. Both pathways are important 
for OCL differentiation as mice with a double knockout for p50 and p52 have no mature OCLs 
(Iotsova et al, 1997). NFκB binds to the κB site in the promoter of the NFATc1 gene (Asagiri et 
al, 2005).  
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1.5.2 Osteoclast function 
Fully differentiated active OCLs can resorb bone by attaching to its surface, rearranging its 
cytoskeleton and becoming polarised (Chellaiah et al, 2000). β3-integrins are expressed by OCLs 
and recognise the amino-acid motif RGD (Arginin-Glycine-Aspartate) on osteopontin present in 
bone. The heterodimer αvβ3 integrin is mainly involved in bone attachment of OCLs (Teitelbaum 
& Ross, 2003). After attachment to the bone surface by forming podosomes, the OCL polarises 
by rearranging fibrilar actin (F-actin), forming a tight “sealing zone” and by forming a ruffled 
membrane at the site of contact. The actin rearrangement creates an isolated extracellular space 
on the bone surface which will be resorbed by the OCL. The actin ring is surrounded by αvβ3 
integrins as a result of signalling via its cytoplasmic domain (Faccio et al, 2003). 
 
Figure 1.5 Osteoclast activity 
Active osteoclasts attach to bone via αvβ3 integrins and form a ruffled membrane from where H+ and Cl- 
are pumped into the sealed zone and lower the pH to 4.5 which activates cathepsin K to resorb bone. An 
F-actin ring seals the resorption lacunae from the environment, Cl-/HCO3- pumps maintain the pH in the 
cell 
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Intracellular acidic vesicles are transported along microtubules to this site and the GTPase 
Rab3D initiates fusion of with the cell membrane (Pavlos et al, 2005). These vesicles release their 
acidic content into the resorptive space but also place H+-ATPases at the ruffled membrane, 
which pump protons into the isolated extracellular space, while Cl-channels secrete Cl-, resulting 
in HCl formation and reducing the pH to 4.5 (Teitelbaum, 2000). Other enzymes that are 
exocytosed into the resorption site include MMPs, TRAP and pro-cathepsin K. Pro-cathepsin K 
becomes active in the acidic microenvironment and degrades type I collagen (Li et al, 1999). The 
products of bone resorption are endocytosed and transported through the OCL to be released 
into the circulation at the anti-resorptive surface. Cl-/HCO3-exchangers on this surface maintain 
a physiological pH inside the OC during bone resorption. After resorption of the bone OCLs 
undergo apoptosis in response to the elevated extracellular Ca2+ concentration in the resorption 
lacunae. In vitro OCL precursor cells isolated from the bone marrow or spleen can be 
differentiated into OCL like cells by addition of M-CSF and RANKL. If cultured on dentine 
these OCLs form resorption pits, lacunae, similar to resorption of the bone in vivo. The number 
and size of the lacunae is a quantitative measure of OCL activity (Udagawa et al, 1990).  
Under physiological conditions the activity of OBs and OCLs is balanced, however, in many 
chronic inflammatory conditions like RA, this balance is disrupted and leads to overactive OCLs, 
which leads to bone loss (Herman et al, 2008a). 
 
1.5.3 Osteoclast in rheumatoid arthritis 
In RA OCLs are found at the interface between inflammatory synovial tissue and periosteal 
surface of articular bone leading to bone resorption, permitting invasion of synovial cells and 
resulting in pannus formation (Gravallese et al, 1998; Gravallese et al, 2000). Bone erosions 
usually occur at the site of the synovial membrane inserting into the periosteal surface. 
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Osteoclastogenesis is an early event in experimental inflammatory joint models, as TRAP+ 
mononuclear cells appear within 2 days and mature into multinuclear OCLs within 5 days of 
induction of adjuvant-induced arthritis (AIA) and CIA (Schett et al, 2005). Differentiation of 
OCL from monocyte/macrophage precursors requires binding of M-CSF to its receptor c-Fms 
and RANKL binding to RANK. Both cytokines are up-regulated in RA synovial membrane and 
blockage of either the interaction of M-CSF:c-Fms or RANK:RANKL can prevent bone 
erosions. Recent clinical trials with Denosumab, a humanised anti-RANKL antibody, showed 
that it protects from human RA joint destruction (Cohen et al, 2008). 
Activated T cells in the inflamed synovium also express RANKL and intra-articular pro-
inflammatory cytokines TNF, IL-1β and IL-17 further stimulate SFs to express RANKL and M-
CSF.(Takayanagi et al, 2000a). Also, IL-23 expressed by activated APCs, promotes RANKL 
expression by Th17 cells, which in turn promotes osteoclastogenesis (Ju et al, 2008). 
Furthermore, IL-17 expressed by Th17 cells, promotes OCL activity and bone erosions in 
arthritic mice and IL-17 present in the synovial fluid of RA patients promotes osteoclastogenesis 
in vitro (Kotake et al, 1999; Lubberts et al, 2003; Pollinger et al, 2011). 
Other inflammatory cytokines which are present in the arthritic joint also promote OCL activity. 
TNF is a potent driver of OCL formation and activity, acting additively with RANKL (Danks et 
al, 2011; Li et al, 2004; Vattakuzhi et al, 2012). Osteoclastogenesis induced by TNF activates the 
α isoforms of p38 MAPK. Bone marrow cells derived from p38α MAPK deficient mice show 
reduced OCL formation after TNF stimulation compared to wild type mice (Bohm et al, 2009). 
In RA, activation of p38α in OCLs contributes to TNF-induced bone destruction. TNF 
promotes OCL formation through its type 1 (p55) receptor, whereas its type 2 (p75) receptor is 
anti-osteoclastogenic (Abu-Amer et al, 2000). Like TNF, IL-1 also promotes osteoclastogenesis 
by inducing RANKL expression and is highly expressed in RA. IL-1 deficient mice are protected 
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from osteolysis in TNF driven synovial inflammation, indicating that TNF might trigger OCL 
activity via induction of IL-1 (Zwerina et al, 2007). Furthermore, pro-inflammatory cytokines 
promote expression of surface molecules on macrophage, which assist osteoclastogenesis. 
OSCAR is inducible in peripheral monocytes of RA patients suggesting that mononuclear cells 
entering the rheumatic joint are predisposed to commit to the OCL lineage (Herman et al, 
2008b). On the other hand some pro-inflammatory cytokines produced by Th1 cells antagonise 
OCL formation, like IFNγ (Takayanagi et al, 2000b) but also IL-12 has been shown to suppress 
osteoclastogenesis (Horwood et al, 2001). 
Bone formation in response to bone resorption in RA is not functional and only little is known 
of OB function in RA. However, TNF is known to inhibit OB differentiation and activates 
secretion of DKK-1, which is a Wnt inhibitor and therefore blocks bone and cartilage formation 
(Bertolini et al, 1986; Diarra et al, 2007). Furthermore, TNF down-regulates the OB transcription 
factor Runx2. 
 
1.6 Mitogen activated protein kinase (MAPK) signalling pathway 
The activation of various signalling pathways is crucial for driving pro-inflammatory gene 
expression. Activation of most PRRs, FcRs, and pro-inflammatory cytokine receptors trigger the 
activation of either the NFκB and/or the MAPK signalling pathways.  
The MAPK signalling pathway is highly evolutionarily conserved from yeast to mammals and 
involved in a vast variety of cellular processes like cell survival and differentiation, apoptosis, 
physical and chemical stress or inflammatory responses. It transduces signals from the cell 
membrane to the nucleus. Active MAPK enzymes phosphorylate specific other proteins at their 
serine and threonine residues and can translocate into the nucleus to activate transcription 
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factors leading to gene expression. The three main families of MAPKs are ERK, JNK, and p38 
MAPK. p38 MAPK and JNK also have a role in post-translational stabilisation of mRNA, 
especially of TNF, COX2 and IL-2 in T cells (Brook et al, 2000; Chen et al, 2000; Lasa et al, 
2000). MAPKs are activated by a characteristic signalling cascade. Activation of a G-protein 
coupled receptor or receptor tyrosine kinases leads to the initiation of a MAPK kinase kinase 
(MKKK), which then activates a MAPK kinase (MKK), which in turn phosphorylates a MAPK 
(Figure 1.6). Activation of MAPKs requires dual phosphorylation of threonine and tyrosine 
residues and. This phosphorylation motif (T-X-Y) in the activation loop is highly conserved. By 
dephosphorylating this T-X-Y motif MAPK phosphatases (MKPs), like dual specificity 
phosphatases (DUSPs), are able to inactivate the different MAPKs. 
 
Figure 1.6 MAPK signalling cascade 
Activation of the mitogen-activated protein kinases ERK, p38 and JNK follow an intricate cascade of 
signalling enzymes. The cascade is divided in three levels: MKKKs (Ras/Raf, TAK1/TAB2), MKKs 
(MEK1, MEK2, MKK3, MKK4, MKK6, MKK7), and MAKPs. 
 
All three MAPKs are expressed in the rheumatoid synovium where they are key regulators of 
pro-inflammatory cytokine and MMP production. (Schett et al, 2000). Furthermore, p38 
inhibitors are effective in CIA, highlighting the importance of controlling MAPK activation to 
dampen inflammatory responses. However, other studies have shown that p38 MAPK inhibitor 
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inhibited TNF and IL-1 production from RA synovial membrane cultures but also reduced the 
production of IL-10 and increased IL-6 secretion. 
1.6.1 p38 MAPK signalling 
Four different p38 genes are identified in mammals, MAPK 14 encodes p38α, MAPK11 encodes 
p38β, MAPK12 encodes p38γ and MAPK13 encodes p38δ. p38 MAPK can activate 
transcription factors but is also involved in post-transcriptional regulation via mRNA 
stabilisation of COX2 and TNF and many other (Brook et al, 2000; Lasa et al, 2000). In the p38 
MAPK signalling cascade G-proteins of the Rho family activate several MKKKs like ASK1 and 
TAK1 (Cuenda & Rousseau, 2007). Upon stimulation these MKKKs activate MKK4 or MKK3 
and MKK6, which are highly specific for p38 MAPKs (Kyriakis & Avruch, 2001). p38 MAPK is 
activated by phosphorylation of its T-G-Y motif in the activation loop. However, p38 can also 
be activated independently of MKKs through autophosphorylation after interaction with a 
TRAF6/TAB1 complex (Ge et al, 2002). p38 MAPK activation via TRAF6 is of particular 
importance in OCL activation as mentioned in section 1.5.1. 
 
1.6.2 JNK signalling 
The JNK proteins are encoded by 3 different genes and alternative spliced transcripts from these 
genes give rise to the 10 different isoforms (Gupta et al, 1996). The JNKs are activated by stress 
signals like UV radiation or cytokines like IL-1 and TNF. One of the main MKKKs of the JNK 
pathway is TGFβ activated kinase 1 (TAK1). TAK1 mediates JNK phosphorylation by 
interacting with TAK1 binding protein 2 (TAB2) following responses to the inflammatory 
cytokines IL-1, TGFβ and TNF and following activation of the receptors TLR3, 4 and 9, B cell 
receptor and T cell receptor (Asagiri et al, 2005; Weston & Davis, 2007). Activated TAK1/TAB2 
phosphorylates MKK 4 and 7. MKK7 is specific for JNK activation and responds mainly to IL-1 
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and TNF stimuli (Davis, 2000; Tournier et al, 2001). JNK activation leads to the phosphorylation 
of transcription factors in the nucleus but also mRNA stabilisation in the cytoplasm. JNK is 
involved in the stabilisation of IL-2 mRNA in activated T cells by regulating the expression and 
binding activity of RNA-binding proteins that bind to JNK responsive elements in its 5’ 
untranslated region (Chen et al, 2000). One of the major transcription factors activated by JNK 
is AP-1. AP-1 is a heterodimer composed of proteins from the Jun, Fos and activating 
transcription factor (ATF) families. One of the four Fos proteins (c-Fos, FosB, Fra-1, Fra-2) 
heterodimerises with one of the Jun proteins (c-Jun, JunB, JunD). However, Jun can also 
homodimerise to become an active transcription factor. JNK phosphorylates serine residues 63 
and 73 at the amino terminal of c-Jun. The activation of the other Jun and Fos proteins also 
follows phosphorylation of serine residues in the active site of the transcription factor (Davis, 
2000). 
 
1.6.3 ERK signalling 
The ERK signalling pathway is important for cell proliferation and differentiation. This pathway 
is activated by receptors containing receptor tyrosine kinase (RTK) activity in their cytoplasmic 
domains. Ligand binding to the receptor phosphorylates the RTK domain leading to activation 
of membrane bound Ras proteins via interaction of adapter proteins like Grb2 with the G-
protein Sos (son of sevenless). Activated Ras can then bind and activate Raf proteins, that 
phosphorylate either MEK1 or MEK2 (Cobb, 1999; Cobb & Goldsmith, 2000). MEK1 and 
MEK2 are specific for ERK1 and ERK2 activation. Activated ERKs translocate to the nucleus 
and activate transcription factors like Runx2 (Ducy et al, 1997; Franceschi et al, 2003; Ge et al, 
2007). 
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1.7 Dual specificity phosphatase 1 (DUSP1) 
MAPK signalling pathways are involved in many different cells and functions, therefore it is very 
important to tightly regulate this pathway. MAPKs are activated by dual phosphorylation of a 
threonine and tyrosine residue in the activation loop of the kinase. Serine/threonine 
phosphatases as well as tyrosine phosphatases are able to dephosphorylate activated MAPKs. 
The DUSP family is a large subclass of protein phosphatases of which around 16 mammalian 
DUSPs are able to inactivate MAPKs (Jeffrey et al, 2011). This group of MAPK-specific DUSPs 
can be further divided into groups according to sequence similarity, subcellular localisation and 
substrate specificity. DUSP1, 2, 4 and 5 localise to the nucleus and show a highly conserved 
sequence similarity. DUSP6, 7 and 9 are found in the cytoplasm and preferably recognise 
ERK1/2 in vitro, whereas, DUSP8, 10 and 16 preferentially recognise JNK and p38 MAPK. 
DUSP1 is involved in dephosphorylation of all three major MAPKs and is located in the nucleus 
(Dickinson & Keyse, 2006). However, DUSP1 preferentially inhibits p38 MAPK and JNK 
(Franklin & Kraft, 1997). Furthermore, acetylation of lysine residues of DUSP1 following TLR 
stimulation further promotes interaction with p38 MAPK resulting in increased 
dephosphorylation. DUSP1 binds to the activated MAPKs via its amino-terminal domain and 
leads to its catalytic activation (Slack et al, 2001). Not only does interaction of DUSP1 with 
activated MAPKs lead to dephosphorylation and inactivation of MAPKs, but also binding to 
ERK1 and ERK2 was shown to phosphorylate DUSP1 on two serine residues at its carboxyl-
terminal domain, which in turn leads to increased stability of DUSP1 (Brondello et al, 1999). 
High levels of DUSP1 are found in tumours such as pancreatic, breast and prostate cancer 
(Ducruet et al, 2005), however, its precise role remains unknown. In contrast DUSP1 expression 
is decreased in tumours of the colon and bladder (Loda et al, 1996). DUSP1 activation in breast 
cancer cells seems to inhibit proliferation (Chen et al, 2011). The role of DUSP1 in inhibiting the 
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MAPK pathway likely has a significant effect on cell proliferation and apoptosis in tumours 
(Wancket et al, 2012). 
Next to its role in controlling cell proliferation DUSP1 has been recognised as an important 
negative regulator of immune responses. Dusp1 gene expression is inducible by different stimuli 
like IL-1 , TNF, activation of TLRs 2, 3, 4, 5 and 9 or GCs and is dependent on p38 MAPK 
activation, suggesting a negative feedback mechanism to control p38 activity (Abraham & Clark, 
2006; Lasa et al, 2002; Li et al, 2009; Salojin et al, 2006). In vivo experiments on DUSP1 deficient 
mice confirmed the overexpression of inflammatory cytokine IL-1, IL-6 and TNF after LPS 
challenge and prolonged activity of p38 MAPK and JNK (Chi et al, 2006; Hammer et al, 2006; 
Zhao et al, 2006). However, IL-10, an anti-inflammatory cytokine, also induces DUSP1 
expression in macrophages. Furthermore, Dusp1 -/- mice challenged with LPS show increased IL-
10 expression compared to wild type mice (Chi et al, 2006; Hammer et al, 2005; Zhao et al, 
2006). 
 
1.8 Glucocorticoids 
Glucocorticoids (GCs) play an important role in various metabolic processes like cell 
differentiation, growth control, glucose metabolism, stress responses, apoptosis, and modulation 
of inflammatory responses. GCs have been used as anti-inflammatory drugs in various 
inflammatory and autoimmune diseases since the 1950s. Its use in RA was first reported by 
Philip Hench and Edward Kendall, who were later awarded a Nobel Prize for the discovery of 
cortisone and its therapeutic effects in RA. The rational for using GCs in the treatment of RA 
and other diseases is their potent immunosuppressive effects. 
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Endogenous GCs are expressed primarily by the adrenal cortex. Corticotrophin-releasing 
hormone (CRH) expressed by the hypothalamus triggers the secretion of adrenocorticotrophic 
hormone (ACTH) from the pituitary gland, which in turn activates GC synthesis in the adrenal 
cortex. This complex is known as the hypothalamic-pituitary-adrenal (HPA) axis. In several 
chronic inflammatory diseases like SLE, Sjögren’s disease and RA the HPA axis is blunted and 
anti-inflammatory actions of GCs reduced (Sternberg, 2006). GCs influence various aspects of 
immune responses by inhibiting pro-inflammatory cytokine expression from innate immune cells 
like, macrophages and DCs but also influence the adaptive immune responses (Figure 1.7). GCs 
are able to inhibit the expression of IL-12 by DCs and macrophages resulting in decreased 
activation of Th1 cells and subsequently shifting activation towards Th2 cells (Agarwal & 
Marshall, 2001). Furthermore, GCs are able to suppress T cell activation via inhibiting the 
expression of MHC class II and co-stimulatory molecules (e.g. CD80, CD86) (Matyszak et al, 
2000). 
 
Figure 1.7 Effects of glucocorticoids on immune cells 
Glucocorticoids influence immune responses by inducing apoptosis of macrophages, dendritic cells, T 
and B cells or by inhibiting pro-inflammatory cytokine expression (Sternberg, 2006). 
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The classical theory for the mechanism of action of GCs is via the modulation of gene 
expression by binding to the intracellular GC receptor (GR) (Newton, 2000). Due to their 
lipophilic structure GCs are able to diffuse through the cell membrane into the target cells. 
Within the cytoplasm inactive GRs are found associated with a multi-protein complex formed by 
HSP90, HSP70 and other small proteins. Once bound by GCs, GRs dissociate from HSP90 and 
70, translocate into the nucleus and act as transcription factor by forming homodimers or 
heterodimers and binding to GC response elements (GREs) in the promotor region of different 
genes (Clark, 2007; Hayashi et al, 2004; Kassel & Herrlich, 2007). GRs have a ligand binding 
domain at the C-terminal and a DNA binding domain, which has two zinc finger motifs 
(Newton, 2000). Incorporated into the zinc finger motif is a dimerisation loop, which is essential 
for GR dimerisation and activation. The binding of GR to GRE motifs, leads to recruitment of 
RNA polymerase II and local chromatin remodelling by activation of histone acetyl-transferase. 
This can lead to increased transcription of target genes like metallothionein IIA and this process 
is called transactivation. Furthermore, activated GR can also interact with various transcription 
factors like the Th1 cell transcription factor T-bet, AP-1, and NFκB. Interaction of activated GR 
with T bet results in the inhibition of Th1 cell specific cytokine production, including IFNγ 
(Liberman et al, 2007). 
Anti-inflammatory genes that are transactivated by GCs binding to GREs include IL-10 and the 
type II IL-1 receptor antagonist (Barnes, 1998; Colotta et al, 1996; Mozo et al, 2004). Anti-
inflammatory actions of GCs are also transmitted via transactivation of genes encoding the 
transcription factors GC-induced leucin zipper (GILZ) or the DUSP1 (Abraham et al, 2006; 
Joanny et al, 2012). For some genes like osteocalcin binding of activated GRs to GREs can lead 
to suppression and are therefore called negative GREs (Meyer et al, 1997). However, only a few 
genes have been identified so far to be regulated via negative GREs. A point mutation in the GR 
protein (A458T) results in defective GR dimerisation in mice (GRdim) and therefore 
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compromises transactivation of target genes (Reichardt 1998). However, anti-inflammatory 
effects like IL-6, IL-1β and COX2 inhibition are unimpaired suggesting a mechanism 
independent of GR dimerisation (Reichardt 2001). The GC-induced inhibition of pro-
inflammatory cytokines and proteins like TNF, IL-1β, IL-6, IL-8, GM-CSF, iNOS and COX2 is 
mainly due to the interaction of activated GRs with other transcription factors like AP-1 or 
NFκB. This process is termed transrepression (Mukaida et al, 1994). 
Various studies investigated the activation of DUSP1 following GC treatment of macrophages in 
vitro and resulting inactivation of the MAPKs (Engelbrecht et al, 2003; Kassel et al, 2001; Lasa et 
al, 2002). GC treatment inhibits the expression of pro-inflammatory genes in macrophages and 
DUSP1 seems to play a role in this mechanism by inactivating MAPKs (Abraham et al, 2006). 
GREs have been identified in the promoter region of the Dusp1 gene, explaining the activation 
of DUSP1 expression following GC stimulation (Tchen et al, 2010). The anti-inflammatory 
effects of GCs lead to suppression of pro-inflammatory genes like TNF, IL-1 and COX2. 
However treatment of Dusp1-/- macrophage with dexamethasone showed impaired inhibition of 
these pro-inflammatory genes in vitro. Furthermore, in vivo dexamethasone treatment of Dusp1-/- 
mice challenged with zymosan showed decreases anti-inflammatory effects (Abraham et al, 
2006). 
These studies demonstrate a clear role of DUSP1 in the control of innate immune responses and 
in the anti-inflammatory effects of GCs. The expression of DUSP1 in both OBs and OCLs has 
been shown; however, the bone phenotype of mice lacking DUSP1 has not been well 
characterised to date and it is not clear if and how DUSP1 is involved in bone metabolism. 
Recent studies report a role of DUSP1 in regulating the MAPK signalling in OCLs and Dusp1-/- 
mice challenged with LPS displayed enhanced OCL activity (Carlson et al, 2009; Sartori et al, 
2009). 
Chapter One Introduction
 
47 
Synthetic GCs are used as anti-inflammatory drugs in the treatment of several chronic 
inflammatory diseases like RA. However, long term use of GCs is associated with several side 
effects like diabetes, skin and muscle atrophy, susceptibility to infections and osteoporosis. The 
side effects of GCs were believed to be largely caused by transactivation of genes as most of the 
anti-inflammatory effects are caused by transrepression (Schacke et al, 2002). However, there is 
now increasing evidence that GC-induced activation of genes like Dusp1 contribute to the anti-
inflammatory action of GCs (Clark et al, 2008). The possibility to separate the side effects caused 
by GR dimerisation-dependent transactivation from the beneficial, dimerisation-independent, 
anti-inflammatory effects caused by transrepression lead to the concept of developing 
“dissociated GCs”. The rational behind dissociated GCs are to selectively activate 
transrepression of pro-inflammatory genes without inducing transactivation. However as 
mentioned earlier, transactivation of genes such as Dusp1 is also involved in anti-inflammatory 
effects of GCs. 
 
1.8.1 Glucocorticoid-induced osteoporosis (GIO) 
Glucocorticoid-induced osteoporosis (GIO) is a common side effect of long term treatment with 
GCs. However, the wide variability in GC dosage used in patients and variations in susceptibility 
between individuals makes it difficult to define the epidemiology of GIO. GIO has an initial 
phase of rapid decreasing bone mineral density in the first 6-12 months, followed by a phase of 
more gradual bone loss (van Staa, 2006). The frequency of osteoporosis in patients with RA 
ranges from 4-24% and leads to an increased fracture risk. 
Multiple effects of GCs on OBs have been reported including impaired collagen synthesis, 
increased apoptosis, inhibition of osteogenic growth factors, and down-regulation of osteogenic 
gene expression (Delany et al, 1995; Weinstein et al, 1998). The Wnt/β-catening signalling 
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pathway is of particular importance in OB differentiation and the synthetic GC dexamethasone 
has been shown to act as an inhibitor of the β-catenin pathway. During OB differentiation β-
catenin translocates into the nucleus and activates transcription factors involved in gene 
expression. However, dexamethasone triggers degradation of β-catenin via glycogen-synthase 
kinase-3β (Smith & Frenkel, 2005). GCs binding to GRs also suppress the expression of 
osteocalcin by OBs via a negative GRE site at the 5’ promoter region of the osteocalcin gene. 
Binding of activated GRs to this GRE prevents the interaction of an enhancer, which is located 
upstream of the Runx2 binding site in the osteocalcin promoter (Leclerc et al, 2005). 
Furthermore, increased apoptosis of OBs as well as osteocytes was observed in prednisolone 
treated mice leading to decreased bone formation (Weinstein et al, 1998; Weinstein et al, 2000). 
Paradoxically, GCs are also known to promote differentiation of OBs in vitro from their 
mesenchymal progenitor cell. Although, how GCs induce differentiation  still remains unknown. 
Dexamethasone has also been shown to act in synergy with TGFβ to enhance OCL activity by 
promoting binding of transcription factors NFκB and AP-1 to target genes in OCLs following 
RANKL stimulation (Takuma et al, 2003). Moreover, GCs induce increased RANKL and M-
CSF expression and decreased expression of OPG by OBs, providing a strong proliferative 
environment for OCLs (Hofbauer et al, 1999). OCL activity is consequently higher in GIO and 
contributes to the rapid development of osteoporosis in the initial phase. Other indirect effects 
following long-term administration of exogenous GCs on bone may be mediated via reduction in 
levels of sex steroids or reduction in muscle mass. 
Implications of DUSP1 in the development of GIO have been reported. GC-induced inhibition 
of ERK affects proliferation and survival of OBs and expression of DUSP1 accounts for 
impaired OB responses to mitogens (Engelbrecht et al, 2003; Horsch et al, 2007). The up-
regulation of DUSP1 is controlled by GC:GR interaction that leads to transcriptional activation. 
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As different MAPKs play an important role in the proliferation and differentiation of OBs as 
well as OCLs, GCs might block proliferation and differentiation by inducing DUSP1 and hence 
inactivating MAPKs. A study on rats showed the prevention of GIO by the administration of a 
tyrosine phosphatases inhibitor, sodium orthovanadate (Hulley et al, 2002). These findings make 
it particularly interesting to investigate the role of DUSP1 in bone metabolism and GIO. 
 
1.9 Hypothesis and aims 
Regulation of the MAPK pathway is of crucial importance for most physiological processes in 
vertebrates and particularly in the responses to immune activation. Activation of the MAPK 
pathways leads to expression of pro-inflammatory cytokines in response to a variety of immune 
responses. Increased pro-inflammatory cytokine expression can lead to disease progression in a 
variety of chronic inflammatory diseases like RA. It is therefore crucial to dampen pro-
inflammatory cytokine production. Inactivation of the MAPK pathway by DUSP1 has been 
shown to partly mediate suppression of pro-inflammatory cytokines by GCs. However, long 
term GC treatment can also induce side effects like GIO. 
This project is based on two hypotheses. First, that DUSP1 expression – and the consequent 
inhibition of the different MAPK pathways – is a central mechanism in the development of GIO 
and that Dusp1-/- mice are protected from it. Second, that DUSP1 mediates anti-inflammatory 
effects of GCs in inflammatory autoimmune diseases like RA. 
 To investigate these hypotheses the specific aims of this project are: 
 To characterise the bone phenotype of Dusp1-/- mice in comparison with Dusp1+/+ mice. 
 To investigate responses of OCLs to dexamethasone and whether effects on 
proliferation and function are associated with induction of DUSP1 by dexamethasone 
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 To evaluate development of GIO in vivo and whether Dusp1-/- mice are protected. 
 To investigate if anti-inflammatory effects by GC are impaired in arthritic Dusp1-/- mice. 
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2 Materials & Methods 
2.1 Materials 
2.1.1 Recombinant mouse proteins 
Protein Catalogue No. Supplier 
Murine M-CSF 416-ML-050 R&D Systems, UK 
Murine GM-MCSF 315-03 PeproTech Inc., USA 
Murine RANKL 462-TR-010 R&D Systems, UK 
Murine TNF 410-MT-050 R&D Systems, UK 
Murine IL-1α 211-11A PeproTech Inc., USA 
Murine IL-4 214-14 PeproTech Inc., USA 
Murine IL-23 14-8231-63 eBioscience 
Table 2.1 Recombinant mouse proteins 
 
2.1.2 Conjugated flow cytometry antibodies 
Antibody Isotype Flourochrome Clone Catalogue No. Supplier 
CD4  FITC GK1.5 11-0041 eBioscience 
CD8  PE 53-6.7 12-0081 eBioscience 
IFNγ  eFlour 450 XMG1.2 48-7311 eBioscience 
IL-17a  APC eBio17B7 17-7177 BD Bioscience 
CD11c  FITC N418 11-0114 eBioscience 
Table 2.2 Conjugated flow cytometry antibodies 
 
2.1.3 Antibodies for Western blot analysis 
Antibody Specificity Molecular 
weight kDA 
Source Catalogue 
No.  
Supplier 
p38 MAPK p38α, -β, -γ 43 Rabbit 9212 Cell Signaling 
Technology Inc., USA 
Phospho-p38 
MAPK 
Thr180/Tyr182 43 Rabbit 9211 Cell Signaling 
Technology Inc., USA 
Phospho-
SAPK/JNK 
Thr183/Tyr185 46, 54 Rabbit 9251 Cell Signaling 
Technology Inc., USA 
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Phospho-p44/42 
MAPK (ERK) 
Thr202/Tyr204 42, 44 Rabbit 9101 Cell Signaling 
Technology Inc., USA 
Polyclonal Swine 
Anti-Rabbit/HRP 
Rabbit IgG - Swine 2014-12 DAKO Cytomation, 
Denmark 
Table 2.3 Western blot antibodies 
 
2.1.4 Reagents and consumables for Western blot analysis 
Reagent Catalogue No. Supplier 
BSATM Protein Assay Kit 23227 Thermo Fisher Scientific Ltd., UK 
Complete mini protease inhibitor 
cocktail tablets 
04693124001 Roche Diagnostic Ltd., UK 
NuPAGE 10% Bis-Tris Gel NP0301BOX Invitrogen, USA 
NuPAGE MOPS SDS Running 
buffer 20x 
NP0001 Invitrogen, USA 
Amersham full range Rainbow 
Molecular Weight Marker 
RPN800E GE Healthcare Ltd., UK 
Amersham HybondTM-P PVDF RPN303F GE Healthcare Ltd., UK 
Whatman Chromatography Paper 
3mm CHR 
3030-861 VWR International Ltd., USA 
Bovine Serum Albumin (BSA) A3294 Sigma-Aldrich Ltd., UK 
Amersham ECLTM Western 
Blotting Detection Reagent 
RPN2106 GE Healthcare Ltd., UK 
Fuji RX Medical X-Ray 18x24cm JTS010 Labtech International Ltd., UK 
Re-blot Plus Strong Antibody 
Strippin Solution 10x 
2504 Millipore Ltd., UK 
Table 2.4 Western blot reagents 
 
2.1.5 Commercial ELISA kits and antibodies 
Reagent Catalogue No. Supplier 
CTX RatLapsTM EIA kit AC-06F1 IDS plc. 
Mouse IFNγ ELISA set 555138 BD Bioscience 
Mouse IL-6 ELISA set 555240 BD Bioscience 
Anti-mouse IL-23p19 14-7232-81 eBioscience 
Anti-mouse IL12/IL-23p40 13-7123-81 eBIoscience 
Mouse IgG1 HRP 559626 BD Bioscience 
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Mouse IgG2a HRP 553391 BD Bioscience 
Table 2.5 Commercial ELISA kits 
 
2.1.6 Cell culture media and reagents 
Reagent Catalogue No. Supplier 
RPMI 22561021 Invitrogen, USA 
αMEM 22561021 Invitrogen, USA 
Penicillin/Streptomycin 100x P11-010 PAA Laboratories GmbH, Austria 
L-Glutamine 200mM M11-004 PAA Laboratories GmbH, Austria 
Phosphate Buffered Saline (PBS) 
10x 
4371 7K VWR International Ltd., UK 
Dexamethasone D2915 Sigma-Aldrich Ltd., UK 
LPS from E. coli, Serotype 
EH100 (Ra) (TLRTM grade) 
ALX-581-010-L002 Enzo Life Sciences Ltd., UK 
Table 2.6 Cell culture media and reagents 
 
2.1.7 Stains and buffers for histological staining 
Reagent Composition/Catalogue No. 
TRAP buffer 50mM Sodium Acetate Anhydrous (Sigma S7545), 40mM Potassium Sodium 
Tartrate (Sigma P0165), 400ml dH2O, adjust pH to 5.0 with glacial acetic acid 
TRAP stain 0.1mg/ml Naphtol AS-MX phosphate, 0.4mg/ml fast red violet LB salt, 1% 
dimethylformamide in TRAP buffer 
Toludine blue 
stain 
T3260 (Sigma-Aldrich Ltd., UK) 
Methyl Green 42585 (Raymond A. Lamb, UK) 
Table 2.7 Stains and buffers for histological staining 
 
2.2 Animals and experimental procedures 
The original Dusp1-/- mice were obtained from Bristol-Meyers Squib and were on a mixed 
background of approximately 75% C57BL/6 and 25% 129Sv. Mice were backcrossed onto the 
C57BL/6 background. Embryos were implanted into pseudo-pregnant C57BL/6 female mice to 
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rederive this strain. Heterozygote mice were then interbred and genotyped to identify Dusp1-/- 
and Dusp1+/+ littermates. After a further eight generations of backcrossing against C57BL/6, 
both the Dusp1-/- and Dusp1+/+ mice had an over 99.9% C57BL/6 genetic background and 
homozygous breeding colonies were established. All mice used were maintained in individual 
ventilated cages at 21 ± 2°C on a 12h light/dark cycle and ad libitum food and water. All 
experimental procedures were approved by a local ethical review committee and the UK Home 
Office. 
 
2.2.1 Glucocorticoid-induced osteoporosis (GIO) 
Glucocorticoid-induced osteoporosis (GIO) was induced in Dusp1+/+, Dusp1-/- and CD1 mice 
aged 12 weeks by slow release pellets containing either 2.5mg/60days placebo or prednisolone 
(Innovative Research of America, USA). Pellets were implanted subcutaneously at the lateral side 
of the neck. Mice were sacrificed after 28 days or 56 days. 
 
2.2.2 Collagen-induced arthritis (CIA) 
To induce arthritis, male mice aged between 10-15 weeks were immunised via subcutaneous 
injection at two sites at the base of the tail with chicken type II collagen (2mg/ml) in complete 
Freund’s adjuvant (CFA; 3.3mg/ml). The chicken type II collagen was prepared from sterna of 
chicken by Mr. Danny Perocheau (Inglis et al, 2008). Mice of different litters were kept in 
individual cages to prevent fighting, which might reduce the incidence of arthritis. After onset of 
arthritis paws were scored for clinical signs of inflammation and paw swelling with callipers 
(Kroeplin GMBH, Germany). Mice were treated, every day or every second day, either with PBS 
or dexamethasone (0.5mg/kg) via intraperitoneal injections. Ten days after disease onset, mice 
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were sacrificed, paws collected for histology and blood taken via cardiac puncture. Serum was 
used to measure cytokine and anti-collagen antibody levels. 
 
2.2.3 Clinical scoring and paw measurement 
In arthritic paws signs of inflammation were scored with a clinical score ranging from 0-4. Each 
limb was scored individually (0 = normal; 1 = mild inflammation with no joint damage; 2 = 
moderate inflammation with some joint erosions; 3 = severe inflammation and joint erosions; 4 
= severe inflammation and loss of joint architecture) (Inglis et al, 2008). Measurements were 
taken blinded to the genotype and treatment of the mouse. 
 
2.2.4 Histological scoring 
Hind paws of arthritic mice were assessed by hematoxilin and eosin (H&E) staining for 
inflammatory infiltration and joint damage. Histological scoring was performed on H&E 
sections blinded to the genotype of the mouse (0 = normal; 1 = mild inflammation with no joint 
damage; 2 = moderate inflammation with some joint erosions; 3 = severe inflammation and joint 
erosions; 4 = severe inflammation and loss of joint architecture). 3 serial sections were scored 
blinded towards genotype and treatment. 
 
2.3 Cell culture 
All cell culture procedures were performed under sterile conditions in a laminar flow cabinet 
(Class II microbiological safety, Gelair, Flow) and cell cultures were maintained in a humidified 
atmosphere of 5% CO2 at 37°C. 
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2.3.1 Isolation of mouse bone marrow cells 
Bone marrow cells were isolated from femurs and tibiae of Dusp1+/+ and Dusp1-/- mice. Skin and 
muscular tissue was removed from the bones which were then sterilised by dipping briefly in 
70% ethanol and kept in αMEM media containing FBS and P/S until processed. Briefly, both 
ends of the bones were cut with sterile scalpels to reveal the bone marrow and the bones were 
then placed in pierced 0.5ml eppendorf tubes, which in turn were placed in 1.5ml eppendorf 
tubes. Tubes were subsequently centrifuged at 3000rpm for 3min and resulting cell pellet was 
resuspended in complete αMEM media. 
 
2.3.2 In vitro osteoclast differentiation 
OCL differentiation was performed using bone marrow cells isolated from 10-13 week old male 
and female Dusp1+/+ and Dusp1-/- mice. To determine OCL formation cells were counted and 
plated at a density of 5x105 cells/well in flat-bottom 96-well plates (three wells/treatment) and 
incubated in αMEM supplemented with 10% FBS, 1% L-Glutamine, 1% P/S and 25ng/ml 
soluble recombinant murine M-CSF alone, as a control, or with various concentrations of 
RANKL and with or without various concentrations of TNFα. Cells were cultured for seven 
days with partial media changes every three days. Cells were then fixed with 4% 
formaldehyde/PBS and permeabilised with 1:1 (v/v) acetone:ethanol mix. OCL formation was 
measured by staining for TRAP for 15mins at 37°C with TRAP staining. Cells were then washed 
with water and the numbers of TRAP positive multinuclear cells, containing three or more nuclei 
were counted at 20x magnification on a light microscope. 
Resorptive activity of OCLs was determined by lacunar resorption assay on dentine slides. Cells 
were counted and plated at a density of 5x105 cells/well on top of sterile dentine slides in flat-
bottom 96-well plates (three wells/treatment). Cells were cultured in αMEM supplemented with 
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10% FBS, 1% L-Glutamine, 1% P/S and 25ng/ml soluble recombinant murine M-CSF alone, as 
a control, or with various concentrations of RANKL and with or without various concentrations 
of TNFα for 14 days with partial media changes every three days. OCLs were then lysed and 
dentine slides rinsed with dH20. Resorption pits were marked with ink and resorption area 
analysed using ImageJ software version 1.45d. 
 
2.3.3 Isolation of mouse lymph node cells 
Lymph node cells were isolated from inguinal lymph nodes of Dusp1+/+ and Dusp1-/- mice. 
Lymph nodes were mashed through a cell strainer (70μm, BD Bioscience, UK), washed with 
RPMI and isolated cells counted. Lymph node cells were used for T cell proliferation assays and 
flow cytometric analysis. 
 
2.3.4 In vitro T cell proliferation assay 
Cell proliferation was measured by incorporation of 3H-TdR. Lymph node cells were plated at a 
concentration of 1x106 cell/well in round-bottom 96 well plates in RPMI media supplemented 
with 10% FBS, 1% L-Glutamine, 1% P/S. 50μg/ml chicken type II collagen or 100ng/ml anti-
CD3 antibody was added as a proliferative stimulus. Cells were cultured for 48h and then pulsed 
with 0.5μCi/well tritiated thymidine (3H-TdR) for 12-16h. Cells were then harvested onto filter 
mats using a 96-well cell harvester. Scintillation fluid was added to the filter mat, which contains 
fluorophores that absorb radioactive energy and converts it into light that is then detected by a 
beta counter (Wallac) and data is expressed as counts per minute (cpm). 
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2.4 Histology 
Paws were fixed in 10% neutral buffered formalin for at least 24h and were then placed in 10% 
EDTA for 3-5weeks. Paws were then processed, embedded in paraffin wax and sectioned at 
4μm. The preparation of histological paw sections and H&E staining were performed by Ms 
Geethanjali Bahal and Ms Angela Seedhar. 
 
2.4.1 Histological TRAP staining 
Paraffin sections of paws were dewaxed in xylene with two changes each for 5min. Sections were 
then rehydrated with consecutive incubations in 100%, 90% and 75% ethanol for each 2min and 
finally in dH2O. Sections were then placed in TRAP buffer for 20min before staining with fresh 
TRAP solution for 1h at 37°C. Sections were viewed under a light microscope to verify staining. 
Methyl green was used to counterstain the sections for 3min. Sections were then washed in 
running tap water and left to air dry after which they were mounted with DPX mountant. 
 
2.4.2 Bone histomorphometry 
Tibiae and lumbar vertebrae were collected from mice, cleaned from attached muscle, fixed in 
4% v/v formalin/PBS at 4°C overnight or longer and dehydrated in graded concentrations of 
aceton (70%, 90% and 100%) for at least one hour at 4°C. Bones were then infiltrated in 
infiltration mix (90% destabilised methyl methacrylate (dMMA), 10% dibutylphtalate (DBP), 
0.05% benzyl peroxide (BPO)) for at least 4days at 4°C. Following infiltration bones were 
embedded in 8ml embedding solution (85%dMMA, 15%DBP, 3%BPO) at 37°C overnight or 
longer. Embedded bones were sectioned into 4µm sections and stained with toluidine blue stain 
to visualise bone structures. Histomorphometric analysis was performed using Osteomeasure 
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software (Osteometrics Inc., USA). Bone histomorphometric parameters were measured and 
expressed according to guidelines of the American Society of Bone and Mineral Research 
Histomorphometry Nomenclature Committee (Parfitt et al, 1987). 
 
2.5 Microcomputed tomography (micro CT) 
Hind paws of mice affect by spontaneous osteolysis and arthritic mice were harvested ten days 
after disease onset and scanned using SkyScan 1072 scanner (SkyScan, Belgium) at a resolution 
of 16 micron. MicroCT scanning was performed by Mr Kevin MacKenzie at the University of 
Aberdeen and scans were analysed using the SkyScan CT Analyser software version 1.9.3.0. Bone 
volume measurements of arthritic paws were performed by Dr. Andrew Freidin Kennedy 
Institute. A 1.5mm region including all five metacarpal joints of the paws was selected and a 
threshold of 115 density units was selected to distinguish mineralised from unmineralised tissue. 
 
2.6 Three-point bend testing 
The mechanical properties of bone are dependent on its composition (i.e. porosity and 
mineraliation) and organisation (i.e. trabecular and cortical bone architecture, collagen fibre 
orientation). A decrease in bone mineral mass and density leads to loss of bone stiffness and 
increases fracture risk. The three-point bending test of long bones has been used commonly to 
evaluate bone strength. Three-point bend testing was performed with the help of Dr. James 
Chan and using an Instron 5942 materials-testing load frame using custom-built mounts that 
incorporated rounded supports to minimise cutting and shear loads (Instron® Limited, USA). 
The right tibiae of mice treated with placebo or prednisolone were cleaned of soft tissues and 
fixed in 70% ethanol at 4°C. Prior to bend testing bones were rehydrated in PBS for two hours. 
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Tibiae were placed horizontally and centred on two support points and positioned with the 
anterior surface upward. Load was applied vertically downwards to the midshaft with a constant 
rate of displacement of 2mm/sec until failure. Based on the load-deformation curve, the 
maximum load and elastic modulus was determined. The load-deformation curves were plotted 
using Bluehill 3 software (Instron® Limited, USA). 
 
2.7 Flow cytometric analysis 
Expression of cell surface markers or intracellular cytokine expression of isolated lymph node or 
bone marrow cells was evaluated by flow cytometry using a BD-LSR II or BD-CANTO II flow 
cytometer (Becton-Dickinson Bioscience, USA) and data obtained using FACS Diva software. 
Cells were washed with PBS, blocked in FACS buffer (PBS, 1% FBS) and rat serum IgG, 
followed by incubation with appropriate concentrations (according to manufacturer’s 
instructions) of fluorochrome-conjugated monoclonal antibodies or isotype controls for 30mins 
at 4°C in the dark. Cells were then washed, resuspended in FACS buffer and analysed by flow 
cytometry. 10,000 events were recorded per sample and data were analysed using FlowJo 
software (Tree Star Inc., USA). 
 
2.7.1 Intracellular staining 
Intracellular cytokine staining was performed on stimulated lymph node cells. Cells were added 
at 1x106 cell/well in 96 round-bottom well plates in RPMI containing 50ng/ml phorbol myristate 
acetate (PMA) and 500ng/ml ionomycin. After two hours of incubation 10μg/ml brefeldin A 
was added and cells were incubated for another 2 hours. Cells were then washed, resuspended in 
FACS buffer and incubated with fluorochrome-conjugated antibodies for surface molecules as 
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described above. Cells were then washed with cold PBS, fixed with 4% formalin/PBS, incubated 
with permeabilisation buffer (eBioscience Ltd., UK), washed and incubated with fluorochrome-
conjugated antibodies for intracellular cytokines. Cells were then washed, resuspended in FACS 
buffer and analysed by flow cytometry. 
 
2.8 Enzyme linked immunosorbent assay (ELISA) 
Levels of secreted cytokines were quantified by ELISA. Commercially available ELISA kits were 
used according to manufacturer’s instructions to measure levels of IFNγ, IL-17 and IL-6. A 
sandwich ELISA was used for quantification of IL-23 in cell culture supernatants. In brief, high 
binding 96-well plates were coated over night with purified primary antibody specific for the 
individual antigen. Coated wells were blocked with 2% BSA for one hour at room temperature, 
washed with PBS-0.1%Tween20 solution and subsequently incubated with cell culture 
supernatants or standard solutions with known concentrations for one or two hours at room 
temperature. Plates were then washed with PBS-0.01%Tween20 solution and incubated with 
biotinylated secondary antibody specific for the individual antigen for one hour at room 
temperature. Wells were washed and incubated with streptavidin- horseradish peroxidase (HRP). 
Finally, wells were washed again prior to addition of 3,3’,5,5’-tetramethylbezidine (TMB) 
peroxidase substrate and the enzymatic reaction stopped by addition of 2N H2SO4. Plates were 
then read on a plate reader at 450nm. 
 
2.9 Western blot 
To investigate the activation of MAPKs in OCLs, whole cell protein lysates from bone marrow 
cells of Dusp1+/+ and Dusp1-/- mice were prepared and analysed by western blotting. 2x106 cells 
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were lysed in 50μl protein lysis buffer on ice for 30mins. Lysates were then centrifuged for 
15min at 4°C and stored at -20°C until analysis. The protein concentration was measured using a 
BCA protein assay kit (Thermo Fisher scientific). Serial dilutions of BSA were used as a standard. 
Standards or 2μl of protein lysate were added to the working solution in a 96-well ELISA plate 
and incubated for 30min at 37°C. Protein concentration was determined by absorbance values at 
540nm. 4x sample buffer (250mM Tris-HCl, 40% (v/v) glycerol, 5% (w/v) SDS, 1mM EDTA, 
50mM DTT, 0.05% (w/v) bromophenol blue) was added to samples and heat denatured for 
5min at 95°C prior to electorphoresis. 20μg of total protein per sample  were electrophoretically 
separated according to their molecular weight using 10% NUPAGE Bis-Tris gels (Invitrogen 
Corp., USA) and transferred onto Amersham Hybond-P polivinyldene fluoride (PVDF) 
membrane (GE Healthcare Ltd., UK) using a Novex X-Cell II Mini Cell (Biorad, UK). A marker 
to determine protein size was also included. Following transfer, membranes were blocked in 
blocking buffer (5% w/v fat-free milk in 0.1% TBS-Tween 20) for one hour at room 
temperature, washed and incubated with primary antibody specific for the protein of interest in 
blocking buffer over night at 4°C. Membranes were then washed and incubated with secondary 
peroxidase-conjugated antibody. Bound secondary antibody was detected using 
chemiluminescence reagents ECL (GE Healthcare Ltd., UK) and visualised on X-ray film (Fuji 
RX Medical X-ray, Labtech International Ltd.). Membranes were treated with stripping solution 
(Millipore Ltd., UK) for 15min at room temperature, re-blocked and probed with a different 
primary antibody. 
 
2.10 RNA isolation 
Total RNA was extracted from bone marrow cells or lymph node cells according to 
manufacturer’s instructions using QIAmp RNA Blood Mini kit (Qiagen Ltd., UK). RNA was 
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eluted in 30μl RNAse-free water and stored at -80°C. Quantification of RNA was done by 
spectrophotometry using a NanoDrop 1000 spectrometer (Thermo Fisher Scientific, USA). 
 
2.11 Quantitative real time PCR (QRT-PCR) 
mRNA expression levels were quantified by QRT-PCR using a Rotor-Gene 6000 (Corbett 
Research Ltd., UK). QRT-PCR reactions were set up with 100ng total RNA in 10μl using One-
step RT qPCR-MasterMix plus (Eurogentec, Belgium) and TaqMan probes for the gene of 
interest and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Table). Amplification 
conditions consist of an initial reverse transcription step to generate cDNA for 30min at 48°C, 
followed by denaturation step for 10min at 95°C, followed by 45 cycles of 3s at 95°C and 30s at 
60°C. mRNA levels were analysed using delta delta Ct analysis and were normalised against 
GAPDH. 
 
2.12 Statistical analysis 
Data is represented as mean ± standard error of mean (SEM). Statistical interpretation of the 
data was done using unpaired, two-tailed student’s t-test, one-way analysis of variance (ANOVA) 
and Boneferroni post hoc test or the chi squared test as indicated. Statistical significance was set 
for a P value less than 0.05. GraphPad Prism version 5 software (GraphPad Prism, San Diego, 
USA) was used for analysis. 
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3 The role of  dual specificity phosphatase 1 in bone 
homeostasis and glucocorticoid-induced osteoporosis 
3.1 Introduction 
The MAPK pathway is crucial in a variety of cell types for cell survival, differentiation, apoptosis 
and for inflammatory responses. MAPK activation by stress signals, growth factors or cytokines 
leads to expression of target genes via the activation of transcription factors. In osteoclasts 
(OCLs) activation of all three major MAPKs, p38 MAPK, JNK and ERK is crucial for 
differentiation and activation (Kobayashi et al, 2001; Lee et al, 2009; Li et al, 2002; Matsumoto et 
al, 2004a; Matsumoto et al, 2000a). p38 MAPK is also involved in post-transcriptional 
stabilisation of mRNA of TNF COX2, IL-1β, IL-6, GM-CSF and other cytokines but also 
metalloproteinases (Brook et al, 2000; Clark et al, 2003; Dean et al, 2004; Lasa et al, 2000). To 
limit the immune response and other MAPK driven cellular activities, it is critical to inactivate 
the MAPKs. DUSP1 dephosphorylates and inactivates MAPKs, particularly p38, and hence its 
role in bone turnover in normal homeostasis and in response to challenge is of interest for 
diseases associated with inflammation-induced bone loss such as rheumatoid arthritis (RA). 
Multiple studies have shown that when challenged with LPS, DUSP1 deficient mice have 
heightened inflammatory responses compared to wild type mice, due to lack of a negative 
regulation of the MAPK pathway (Abraham & Clark, 2006; Carlson et al, 2009; Yu et al, 2011). 
When challenged with LPS, enhanced activation of p38 MAPK in DUSP1 deficient 
macrophages leads to elevated expression of TNF and IL-6 (Chi et al, 2006; Hammer et al, 2005; 
Joanny et al, 2012; Salojin et al, 2006; Zhao et al, 2005). Furthermore, the anti-inflammatory 
action of glucocorticoids (GCs), such as dexamethasone, are reduced in Dusp1-/- mice as these 
effects are partly mediated by DUSP1 (Abraham et al, 2006). Expression of DUSP1 following 
GC stimulation subsequently inactivates the MAPK pathway and therefore limits the expression 
of pro-inflammatory cytokines like TNF and IL-6. 
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GCs can reduce inflammation by inhibiting the expression of pro-inflammatory genes and have 
long been used therapeutically in inflammatory diseases like RA, asthma and inflammatory bowel 
disease. Long term use, however, is associated with several side effects like susceptibility to 
infections, diabetes or development of glucocorticoid-induced osteoporosis (GIO) (Jilka, 2003). 
GIO is characterised by increased OCL activity and decreased OB activity leading to bone loss. 
Detrimental effects of GC on OBs include impaired collagen synthesis, inhibition of osteogenic 
growth factors and osteogenic gene expression and increased apoptosis (Delany et al, 1995; 
Weinstein et al, 1998). Furthermore, GC-induced increased M-CSF and RANKL expression by 
OBs provides a strong proliferative environment for OCLs (Hofbauer et al, 1999). 
The initial aim of this study was to establish whether increased activation of the MAPK in OCLs 
has implications on the bone phenotype of Dusp1-/- mice and whether these mice are protected 
from GIO. 
 
3.2 Characterisation of  Dusp1-/- mice 
Dusp1-/- mice were provided by Bristol-Meyers Squibb and were on a mixed genetic background 
of approximately 75% C57BL/6 and 25% 129Sv. The Dusp1 gene in these mice is disrupted by 
insertion of a neomycin cassette inserted into the second exon. Early studies of Dusp1-/- mice 
reported no apparent phenotype in these mice under unchallenged conditions (Dorfman et al, 
1996). Prior to commencing the characterisation of these mice, they were backcrossed onto the 
C57BL/6 background. Embryos from these mice were implanted into pseudo-pregnant 
C57BL/6 female mice to rederive this strain. Heterozygote mice were then interbred and 
genotyped to identify Dusp1-/- and Dusp1+/+ littermates. After a further eight generations of 
backcrossing against C57BL/6, both the Dusp1-/- and Dusp1+/+ mice had an over 99.9% 
C57BL/6 genetic background and homozygous breeding colonies were established. Mice of this 
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background were used in experiments throughout this project. The bone phenotype of these 
Dusp1-/- mice was then determined prior to establishing an experimental model of GIO. 
 
3.2.1 Spontaneous osteolysis in Dusp1-/- mice with mixed genetic 
background 
In the original Dusp1-/- mice with the mixed genetic background (C57BL/6 and 129Sv), a 
spontaneous phenotype developed that was characterised by swelling of the distal phalanges of 
front and hind paws. This swelling could affect from one to all 20 digits in the mouse. The 
phenotype was almost exclusive to female mice and the average age of onset was six months 
(Vattakuzhi et al, 2012). Further analysis of the affected paws of females aged 20 months were 
performed by micro-computed tomography (microCT). All microCT analyses in this chapter 
were performed by Kevin Mackenzie at the University of Aberdeen. The microCT scans 
revealed a star-like appearance of the distal phalangeal bones indicating extensive osteolysis and 
uncoordinated bone formation (Figure 3.1). 
 
Figure 3.1 Spontaneous osteolysis in Dusp1-/- mice 
Representative microCT image of normal (a) and affected (b) hind paws of female Dusp1-/- mice aged 20 
months. Paws were scanned at resolution of 16microns. 
 
Histological analysis of affected phalanges was previously performed by Dr. Sonya Abraham and 
revealed enhanced neutrophil infiltration, formation of collagen fibres within the tissue and 
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presence of multinuclear OCLs lining bone fragments (S. Abraham PhD Thesis 
2009;(Vattakuzhi et al, 2012). This spontaneous osteolytic phenotype was, however, not 
observed in Dusp1-/- mice backcrossed to the C57BL/6 background or by other researchers 
maintaining Dusp1-/- mouse strains on different genetic backgrounds (personal communications 
of Dr. Andy Clark with Dr. Andrew Cato, Dr. Anton Bennett), making it difficult to determine 
the exact contribution of missing DUSP1 activity to the osteolysis of the phalangeal bones. A 
role of DUSP1 in bone development or homeostasis could not be excluded as the different 
MAPKs have important roles in OB and OCLs differentiation and activity. It was therefore 
necessary to investigate the bone phenotype of the Dusp1-/- strain on a “pure” (> 99.9%) 
C57BL/6 background before establishing an experimental model of GIO in these mice. 
 
3.2.2 Bone Phenotyping: Tail length 
Weight and tail measurements were taken from female and male mice as an indication of growth 
differences arising from skeletal abnormalities in the Dusp1-/- mice. This is illustrated by the fact 
that in the HYP mouse strain, an experimental model of human X-linked hypophosphatemia, 
defective reabsorption of phosphate in the kidneys results in decreased trabecular bone 
formation and shorter tail length (Brownstein et al, 2010). 
The weight and tail lengths of 57 male Dusp1+/+ and 65 male Dusp1-/- mice as well as 46 female 
Dusp1+/+ and 60 female Dusp1-/- mice aged from 4 to 30 weeks of age were measured. The length 
of the tail was taken from the first caudal vertebra to the tip of the tail. No significant differences 
in the tail length of Dusp1+/+ and Dusp1-/- mice were observed in either sex (Figure 3.2a, b). The 
tail grows until the age of 12 weeks, when mice are considered to be skeletally mature. In 
addition, no differences were observed in juvenile mice at 4, 6, 8, and 10 weeks of age suggesting 
no early developmental abnormalities during the growth phase. 
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Figure 3.2 Tail length measurements in Dusp1+/+ and Dusp1-/- mice 
Tail length was measured from the first caudal vertebrae to the tip of the tail of male (a) and female (b) 
mice aged between 4 and 30 weeks. Graph shows mean ± SEM for at least 4 individuals per group. 
Statistical analysis was performed using one-way ANOVA and Bonferroni post hoc test (*p<0.05). 
 
3.2.3 Bone Phenotype: Body weight 
Abnormal OB activity could either result in increased bone formation and therefore increased 
bone mass or decreased bone formation and reduced bone mass. In both cases, it could be 
reflected in the body weight of the mouse. 
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Significant differences in body weight were apparent in mice of both sexes older than 12 weeks 
(Figure 3.3a, b). There was a mean decrease of 13% in weight in both male and female mice that 
was evident from 12-14 weeks of age. However, this observation might not arise from a 
difference in bone mass as it has been previously reported that total body fat is reduced in Dusp1-
/- mice (Wu et al, 2006). Observations made at dissection (Figure 3.3c) confirmed that Dusp1-/- 
mice had less subcutaneous and visceral adipose tissue compared to age and sex matched 
Dusp1+/+ mice. It is likely that this reduction in adipose tissue mass accounts for the differences 
seen in body weight. Based on these findings, a bone phenotype in the Dusp1-/- mice would not 
seem likely. However, more subtle differences in bone architecture cannot be eliminated without 
using more sophisticated measuring techniques like microCT analysis and bone 
histomorphometry. 
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Figure 3.3 Body weight differences observed between Dusp1+/+ and Dusp1-/- mice 
Body weight was measured of male (a) and female (b) mice aged between 4 and 30 weeks. Graphs show 
the mean ± SEM for at least 4 individuals per group. Statistical analysis was performed using one-way 
ANOVA and Bonferroni post hoc test (*p<0.05, **p<0.005, ***p<0.001). (c) Images of 24 week old male 
mice; arrows indicating subcutaneous fat. 
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3.2.4 Bone Phenotype: MicroCT and histomorphometry 
MicroCT analyses of tibiae of Dusp1+/+ and Dusp1-/- mice were performed in order to investigate 
any potential differences in bone homeostasis and whether the observed reduction in total body 
weight was solely due to alterations in fat metabolism without differences in bone mass. Bone 
volume of trabecular bone in the tibia was measured and expressed as percentage bone volume 
(bone volume/tissue volume; BV/TV). Trabecular bone, also known as cancellous bone, is 
found within vertebrae and at the ends of long bones like the tibia. In contrast to cortical or 
compact bone, trabecular bone is less dense and has a higher surface area. It forms an 
interconnected meshwork of bone that provides structural integrity. The connectivity of 
trabecular bone can also be measured by microCT and is expressed as trabecular pattern factor 
(Tb. Pf.). Greater spaces between trabeculae is expressed in higher Tb. Pf. values and indicates 
reduced bone formation or an increased bone turnover. Like Tb. Pf. trabecular thickness (Tb. 
Th.) also gives an indication of bone formation and bone turnover. 
Both male and female skeletally mature mice aged 12 weeks and 30 weeks were sacrificed and 
tibiae and lumbar vertebrae kept in 10% formaldehyde at 4°C overnight and then left in 70% 
ethanol until microCT analysis. As expected the bone volume of female mice was lower than that 
of male mice, both in Dusp1+/+ and Dusp1-/- mice (Figure 3.4). Furthermore, bone volume of 30 
week old mice was reduced compared to 12 week old mice. This was evident in both male and 
female Dusp1+/+ and Dusp1-/- mice. The bone volume decreased in male Dusp1+/+ mice by 
16.41% and similarly in male Dusp1-/- mice by 18.1%. The age related reduction in bone volume 
was more pronounced in female mice of both genotypes with a reduction of 31.38% in female 
Dusp1+/+ mice and 29.22% in female Dusp1-/- mice. An age related decrease in bone volume in 
C57BL/6 mice and that female mice tend to undergo more rapid decline in bone volume than 
male mice has been reported previously (Glatt et al, 2007). Age related changes in gonadal 
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steroid production, like estradiol, testosterone and androgen but also an increase in RANKL and 
a decrease in osteoprotegerin (OPG) expression from OBs in older mice contribute to these 
changes in bone volume (Cao et al, 2003; Glatt et al, 2007). 
No significant differences were observed in bone volume between age and sex matched Dusp1+/+ 
and Dusp1-/- mice (Figure 3.4). Other parameters derived from microCT analysis were bone 
surface density, trabecular pattern factor, separation and number (Table 3.1 and Table 3.2), none 
of which showed statistically significant differences between the two genotypes. Also bone 
histomorphometric analysis of tibiae of 12 week old mice showed no differences in OB and 
OCL number between Dusp1+/+ and Dusp1-/- mice (Figure 3.5, Table 3.3). 
 
Figure 3.4 Bone volumes of Dusp1+/+ and Dusp1-/- mice 
Tibiae of 12 week and 30 week old male (a) and female (b) Dusp1+/+ and Dusp1-/- mice were analysed by 
microCT. Graphs show percentage bone volume (BV/TV) ± SEM of 4 individual mice per group. 
Statistical analysis was performed using one-way ANOVA and Bonferroni post hoc test. 
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♂ 
Dusp1+/+ 
12wk 
Dusp1-/- 
12wk 
Dusp1+/+ 
30wk 
Dusp1-/- 
30wk 
Bone surface density (1/µm) 
0.0129925 
±0.0003 
0.0116025 
±0.0007 
0.010445 
±0.001 
0.008335 
±0.003 
Trabecular thickness (µm) 
52.7778  
±0.98 
56.13938 
±3.21 
57.86316 
±0.95 
60.0633  
±3.45 
Trabecular separation (µm) 
171.9373 
±4.19 
189.4398 
±5.73 
204.9539 
±22.56 
268.5184 
±68.77 
Trabecular number (1/µm) 
0.003425 
±0.0001 
0.0029825 
±0.0002 
0.002925 
±0.0004 
0.002305 
±0.001 
Trabecular pattern factor(1/µm) 
0.0193775 
±0.001 
0.0202975 
±0.002 
0.0163    
±0.001 
0.01783  
±0.004 
Table 3.1 Bone microCT parameters males Dusp1+/+ and Dusp1-/- mice 
Tibiae of 12 week and 30 week old male Dusp1+/+ and Dusp1-/- mice were analysed by microCT. Table 
shows mean ± SEM of 4 individual mice per group. Statistical analysis was performed using one-way 
ANOVA and Bonferroni post hoc test. 
 
♀ 
Dusp1+/+ 
12wk 
Dusp1-/- 
12wk 
Dusp1+/+ 
30wk 
Dusp1-/- 
30wk 
Bone surface density (1/µm) 
0.007105 
±0.0001 
0.006575 
±0.0001 
0.004380 
±0.0002 
0.004745 
±0.0003 
Trabecular thickness (µm) 
46.925790 
±1.7 
47.478150 
±0.25 
51.800000 
±2.1 
48.350000 
±1.8 
Trabecular separation (µm) 
253.42140 
±3.65 
278.93820 
±11.43 
373.50000 
±13.67 
398.00000 
±9.45 
Trabecular number (1/ µm) 
0.0017425 
±0.00004 
0.001580 
±0.00003 
0.0009885 
±0.00002 
0.001185 
±0.00001 
Trabecular pattern factor(1/ µm) 
0.0309175 
±0.001 
0.0311525 
±0.0003 
0.032050 
±0.0004 
0.027550 
±0.0003 
Table 3.2 Bone microCT parameters of female Dusp1+/+ and Dusp1-/- mice 
Tibiae of 12 week and 30 week old female Dusp1+/+ and Dusp1-/- mice were analysed by microCT. Table 
shows mean ± SEM of 4 individual mice per group. Statistical analysis was performed using one-way 
ANOVA and Bonferroni post hoc test. 
 
Chapter Three The role of DUSP1 in bone homeostasis and GIO
 
76 
 
Figure 3.5 Histomorphometric analysis of tibia from 12 week old Dusp1+/+ and Dusp1-/- mice 
Tibiae of 12 week old male and female Dusp1+/+ and Dusp1-/- mice were analysed by histomorphometry. 
 
 Dusp1+/+ 
12wk ♂ 
Dusp1-/- 
12wk ♂ 
Dusp1+/+ 
12wk ♀ 
Dusp1-/- 
12wk ♀ 
Osteoclast number 19.2 ± 3.0 29 ± 5.7 19.3 ± 5.3 21.1 ± 6.2 
Osteoblast number 121 ± 12.5 106.1 ± 4.2 108 ± 8.6 96.4 ± 8.3 
Table 3.3 Histomorphometric analysis of tibia from 12 week old Dusp1+/+ and Dusp1-/- mice 
Tibiae of 12 week old male and female Dusp1+/+ and Dusp1-/- mice were analysed by histomorphometry. 
Table shows mean ± SEM of 5 individual mice per group. Statistical analysis was performed using one-
way ANOVA and Bonferroni post hoc test. 
 
A study by Carlson et al. on DUSP1 deficient mice of the mixed background showed a small 
reduction in trabecular bone density in 8 week old female Dusp1-/- mice (Carlson et al, 2009). To 
confirm that skeletally immature mice have a reduced bone density in absence of DUSP1 
compared to wild type mice, tibiae of 6 week old mice were subjected to microCT analysis. 
However, none of the parameters measured reached significance below p<0.01 (Figure 3.6).  
MicroCT as well as bone histomorphometry analysis confirmed a normal bone phenotype in 
DUSP1 deficient mice. Bone volume and trabecular integrity of the tibia of Dusp1-/- mice did not 
differ from Dusp1+/+ mice in skeletally immature mice (6 weeks), skeletally mature mice (12 
weeks) and in aged mice (30 weeks) under physiological conditions. 
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Figure 3.6 Bone volumes of 6 week old Dusp1+/+ and Dusp1-/- mice 
Tibiae of 6 week old male and female Dusp1+/+ and Dusp1-/- mice were analysed by microCT. Graphs 
show percentage bone volume (BV/TV) with 4 individual mice per group ± SEM. Statistical analysis was 
performed using one-way ANOVA and Bonferroni post hoc test. 
 
3.2.5 Bone Phenotype: Serum markers of bone turnover 
Bone is a dynamic tissue that undergoes constant remodelling processes. In a tightly regulated 
and coupled manner OBs form new bone while OCLs resorb bone. OCLs are characterised by 
the expression of tartrate-resistant acid phosphatase (TRAP) enzyme, more specifically the 
isoenzyme form 5b (Teitelbaum, 2000). Serum levels of TRAP 5b can be used as an indicator for 
bone resorption by OCLs. An increase in bone turnover therefore leads to an increase in serum 
levels of TRAP 5b. 
There was no difference in bone volume in skeletally mature Dusp1-/- mice compared to Dusp1+/+ 
according to microCT measurements. To comprehensively confirm that there were no 
alterations in basal bone turnover, serum was collected from 12 week old female mice by cardiac 
puncture and TRAP 5b levels determined by solid-phase enzyme immunoassay (EIA). Serum 
TRAP 5b levels showed no statistical difference between Dusp1-/- mice compared to age and sex 
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matched Dusp1+/+ mice (Figure 3.7). These observations validate that DUSP1 deficiency does 
not affect bone formation nor bone turnover in healthy mice. 
 
Figure 3.7 Serum TRAP 5b levels in Dusp1+/+ and Dusp1-/- mice 
Serum was collected from 12 week old female mice and tested for TARP 5b levels. Graph shows mean ± 
SEM for 4 individual serum samples per group. Statistical analysis was performed using Student’s t-test. 
 
3.3 MAPK activation by RANKL in osteoclasts 
Activation of the MAPK pathway is important for OCL differentiation and activation (Ikeda et 
al, 2004; Lee et al, 2009). In particular, p38 MAPK is involved in OCL differentiation and is 
crucial for gene expression of cathepsin K and other OCL-associated genes (Matsumoto et al, 
2004a). It has previously been reported that RANKL is an inducer of Dusp1 gene expression in 
murine OCLs (Carlson et al, 2009). In order to examine how the activation of Dusp1 impacts on 
the inactivation of MAPKs, bone marrow cells from Dusp1+/+ and Dusp1-/- mice were isolated 
and cultured in the presence of 25ng/ml M-CSF and 50ng/ml RANKL for increasing times. The 
activation of MAPKs was examined by western blot analysis with phospho-specific antibodies 
against p38 MAPK, JNK and ERK1/2. 
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The activation of p38 MAPK following RANKL stimulation was enhanced and prolonged in 
Dusp1-/- compared to Dusp1+/+ OCLs (Figure 3.8). The expression of ERK is more rapid in the 
Dusp1-/- OCL at 5min compared to a delayed activation in Dusp1+/+ OCL. However, there was no 
clear difference in the activation of JNK. Similarly a previous report by Carlson has also shown 
enhanced p38 MAPK activation in OCLs of DUSP1 deficient mice (Carlson et al, 2009) 
confirming DUSP1 as a negative regulator of RANKL-induced p38 MAPK activation in OCLs. 
 
Figure 3.8 MAPK activation in Dusp1+/+ and Dusp1-/- OCL 
Bone marrow cells of 12 week old Dusp1-/- and Dusp1+/+ mice were isolated and cultured in 25ng/ml M-
CSF and 50ng/ml RANKL for increasing time or 10ng/ml LPS for 60mins. Cells were lysed and 20ug of 
protein per condition was subjected to western blot analysis for the detection of phosphorylated p38 
MAPK, JNK and ERK1/2. Total p38 MAPK was used as a loading control. 
 
3.4 DUSP1 mediates p38 MAPK inactivation by GCs in OCLs 
GCs are potent inhibitors of pro-inflammatory cytokine expression. Previous work in the lab has 
shown that dexamethasone treatment of mouse macrophages resulted to increased expression of 
Dusp1, and thus dephosphorylation of MAPKs, resulting in reduced MAPK-induced pro-
inflammatory cytokine expression (Abraham et al, 2006). Dephosphorylation of MAPKs by 
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DUSP1 has been proposed as one of the regulatory mechanisms for the anti-inflammatory effect 
of GCs (Clark, 2003). However, increased bone resorption leading to osteoporosis is one of the 
side effects of long-term GC treatment. On the one hand, GCs induce RANKL production by 
OBs and therefore, increase OCL activity, and on the other hand GCs decrease OB anabolic 
activity. Both of these result in a disruption of the balance between OB and OCL activity leading 
to bone loss. Furthermore, MAPKs are activated in OCLs during differentiation and bone 
resorption. To assess the effects of GCs, such as dexamethasone, on MAPK activation in OCLs, 
bone marrow cells from Dusp1+/+ and Dusp1-/- mice were isolated and cultured in the presence of 
25ng/ml M-CSF, 50ng/ml RANKL and 100nM dexamethasone for increasing time. The 
activation of the MAPKs was examined by western blot analysis with phospho-specific 
antibodies against p38 MAPK, JNK and ERK1/2. 
RANKL-induced activation of p38 MAPK peaked at 15mins without the addition of 
dexamethasone but was still detectable at 30mins in Dusp1+/+ OCLs at low levels (Figure 3.8). 
The addition of dexamethasone reduced phosphorylation of p38 MAPK after 15mins in 
Dusp1+/+ OCLs and no phosphorylated p38 MAPK was detectable at 30mins (Figure 3.9). 
However in Dusp1-/- OCLs, p38 MAPK showed prolonged activity in the presence of 
dexamethasone. Activated p38 MAPK was detectable in Dusp1-/- OCLs after incubation for 
90min in the presence of M-CSF, RANKL and dexamethasone (Figure 3.9). No difference in 
activation of JNK and ERK between Dusp1+/+ and Dusp1-/- cells was observed. This observation 
indicates a role of DUSP1 in dexamethasone-induced inhibition of p38 MAPK activation 
following RANKL stimulation in OCLs as p38 MAPK activation is prolonged in the Dusp1-/- 
cells. 
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Figure 3.9 MAPK inactivation by dexamethasone in Dusp1+/+ and Dusp1-/- OCL 
Bone marrow cells of 12 week old Dusp1-/- and Dusp1+/+ mice were isolated and cultured in the presence 
of 25ng/ml M-CSF, 50ng/ml RANKL and 100nM Dex for increasing time or 10ng/ml LPS for 60mins. 
Cells were lysed and 20ug of protein per condition was subjected to western blot analysis for the 
detection of phosphorylated p38 MAPK, JNK and ERK1/2. Total p38 MAPK was used as a loading 
control. 
 
3.5 Dusp1 gene expression in OCLs 
OCLs can be differentiated in vitro from bone marrow precursor cells in the presence of M-CSF 
and RANKL. The RANK:RANKL interaction leads to binding of TRAF6 to RANK 
intracellular domain which in turn leads to activation of the NF B and MAPK pathways 
(Kobayashi et al, 2001). As DUSP1 is an inducible nuclear phosphatase that regulates the 
inactivation of MAPKs, we investigated the expression of Dusp1 gene following RANKL 
stimulation. Bone marrow cells of Dusp1+/+ mice were isolated and cultured in the presence of 
M-CSF and 50ng/ml RANKL and Dusp1 expression was determined by RT-PCR. 
In vitro Dusp1 gene expression was up-regulated after exposure to RANKL, and reached a peak 
of five-fold increase at 60mins. Expression levels returned back to baseline and increased again 
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after 96hours of RANKL exposure (Figure 3.10). Together with the previous result this 
demonstrates RANKL as an inducer of Dusp1 expression, which subsequently regulates p38 
MAPK activation in OCL formation. 
 
Figure 3.10 Dusp1 gene expression in bone marrow cells of Dusp1+/+ mice 
Bone marrow cells of 12 week old Dusp1+/+ mice were isolated and cultured in the presence of 25ng/ml 
M-CSF, 50ng/ml RANKL. Cells were lysed, RNA extracted and levels of Dusp1 mRNA was measured by 
RT-PCR. mRNA levels were normalised against GAPDH and expressed a relative fold change compared 
to bone marrow cells without exposure to RANKL. Means ± SEM of 6 independent experiments are 
shown. Statistical analysis was performed using one way ANOVA followed by Dunnett’s post hoc test. 
 
3.6 Osteoclast gene expression 
Different genes expressed by OCLs are dependent on activation of MAPKs, like catheptin K, 
TRAP and αvβ3 integrin. OCLs adhere to bone surfaces via αvβ3-integrins. αvβ3 integrins bind to a 
variety of extracellular matrix proteins like osteopontin and proteolysed collagen. Binding of αvβ3 
integrins to osteopontin leads to formation of the sealing zone and podosomes in OCLs. 
Inhibition of αvβ3 integrins leads to decreased bone resorption in vitro (Engleman et al, 1997). 
Furthermore, mice lacking β3 integrins show normal OCL differentiation and contain increased 
number of OCL but develop osteosclerosis (McHugh et al, 2000). Following RANK:RANKL 
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interaction in OCLs, NFATc1 and PU.1 regulate transcription of mouse αvβ3 integrin gene 
(Crotti et al, 2008). The metalloenzyme TRAP is predominantly expressed in OCLs, 
macrophages, and dendritic cells (DCs). However, in differentiating OCLs its expression is 
highly up-regulated making it a good marker to identify OCLs (Walsh et al, 2003). Mice lacking 
TRAP present with deformed long bones and mild osteopetrosis (Hayman & Cox, 2003). Like 
αvβ3 integrin, the promoter region of TRAP also has binding sites for PU.1 and NFATc1. In 
addition, interactions between MITF and PU.1 can enhance TRAP gene expression (Luchin et 
al, 2000; Partington et al, 2004). The lysosomal protease Cathepsin K is also predominantly 
expressed in OCLs and its expression is dependent on interactions of p38 MAPK, NFATc1 and 
PU.1 following RANK activation. 
To investigate whether DUSP1 deficiency results in altered expression of OCL-specific genes, 
bone marrow cells were isolated from Dusp1+/+ and Dusp1-/- mice and plated in the presence of 
25ng/ml M-CSF and 50ng/ml RANKL for up to 72 hours. Cells were lysed at various time 
points and total RNA extracted. RNA was then subjected to qRT-PCR analysis. As expected, the 
gene expression levels of all three OCL specific genes, cathepsin K, αvβ3 integrin and TRAP 
increased following RANKL exposure (Figure 3.11). The strongest up-regulation was observed 
in TRAP mRNA levels, with a 20 to 30 fold increase after 72 hours. However, with all three 
genes there were no significant differences in expression observed between Dusp1+/+ and Dusp1-/- 
cells. RANKL-mediated Dusp1 expression might therefore not affect the expression pattern of 
these genes despite their involvement of MAPK associated transcription factors like MITF. This 
is in accordance with the observed normal bone phenotype in Dusp1-/- mice as a defective 
activation of these genes would most likely result in defective OCL formation or activation and 
consequently abnormal bone remodelling. 
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Figure 3.11 Expression of OCL-associated genes in Dusp1+/+ and Dusp1-/- OCL 
Bone marrow cells of 12 week old Dusp1+/+ and Dusp1-/- mice were isolated and cultured in the presence 
of 25ng/ml M-CSF, 50ng/ml RANKL. Cells were lysed, RNA extracted and levels of (a) cathepsin K, (b) 
TRAP, (c) αvβ3 integrin mRNA was measured by RT-PCR. mRNA levels were normalised against 
GAPDH and expressed as relative fold change compared to bone marrow cells without exposure to 
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RANKL. Graph represents 4 individual experiments ± SEM. Statistical analysis was performed using 
one-way ANOVA and Bonferroni post hoc test. 
 
3.7 Osteoclast differentiation and activity 
RANK:RANKL interactions trigger the activation of MAPKs (Figure 3.8) amongst other 
signalling pathways. Deregulation of MAPK signalling can lead to altered OCL formation and 
activity. Mice lacking c-Jun in OCLs develop severe osteopetrosis due to reduced OCL activity 
(Ikeda et al, 2004) whilst inhibition of p38 MAPK prevents RANKL-induced OCL 
differentiation (Matsumoto et al, 2000b). To test whether delayed MAPK dephosphorylation in 
the absence of DUSP1 results in enhanced OCL differentiation, bone marrow cells from 
Dusp1+/+ and Dusp1-/- mice were cultured in presence of M-CSF and increasing concentrations of 
RANKL. Furthermore, previous studies have reported GC-induced Dusp1 expression in bone 
marrow macrophages (Abraham et al, 2006). To investigate potential implications of GC 
treatment on OCL differentiation, 100nM dexamethasone was added to the culture media. Cells 
were cultured for one week with media changes every 3 days. After 7 days cells were fixed, 
permeabilised and stained for TRAP. 
Bone marrow cells cultured in the presence of M-CSF alone were viable but unable to form 
OCLs and did not stain positive for TRAP, as RANKL is essential for OCL differentiation. A 
dose dependent increase in OCL formation was observed in Dusp1+/+ and Dusp1-/- cells (Figure 
3.12). At low RANKL concentrations of 5ng/ml bone marrow cells from Dusp1-/- mice showed 
increased TRAP positive OCL formation compared to Dusp1+/+ cells, however, this observation 
is not statistically significant. At higher RANKL concentrations this increase was not evident. 
This was also consistent in cultures treated with dexamethasone. Addition of dexamethasone to 
the culture media showed no effect at RANKL concentrations of 5ng/ml and 25ng/ml. A 
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decrease in OCL formation in Dusp1+/+ cells at high RANKL concentrations (50ng/ml) was 
observed, although not significant (Figure 3.12). 
 
 
Figure 3.12 In vitro osteoclast formation of Dusp1+/+ and Dusp1-/- bone marrow cells 
Bone marrow cells of Dusp1+/+ and Dusp1-/- mice aged 11-13 weeks were harvested and plated in 96-well 
plates at a density of 5x105 cells/per well in triplicate and treated with M-CSF 25ng/ml alone as a control 
or with increasing doses of RANKL (5, 25, 50ng/ml) in the presence or absence of 100nM 
dexamethasone (Dex). Cells were stained for TRAP activity after 7 days. Number of TRAP positive 
multinucleated cells (mnc) per well are shown. Result are represented as mean of 6 independent 
experiments ± SEM. Statistical analysis was performed using one-way ANOVA and Bonferroni post hoc 
test (*p<0.05). (b-d) Dusp1+/+ cells, (e-g) Dusp1+/+ cells in the presence of Dex, (h-j) Dusp1-/- cells, (k-m) 
Dusp1-/- cells in the presence of Dex. 20x magnification 
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The ultimate test of OCL activity is their ability to resorb calcified matrices like dentine surfaces. 
Dentine serves as a resorption substrate for activated OCLs, which adhere to the dentine surface 
and form resorption lacunae. The area of resorption lacunae formed gives a quantitative measure 
of OCL activity. Bone marrow cell cultures were set up as previously described for the TRAP 
assay except that the cells were placed on top of dentine slices. After 14 days cells were lysed and 
the dentines rinsed with dH2O. Resorption lacunae were marked with a marker pen and 
resorption area quantified with ImageJ software. 
As expected, no resorption lacunae were detected in cultures without RANKL. Like OCL 
formation also the area of resorption increased with higher RANKL concentrations in both 
Dusp1+/+ and Dusp1-/- cells (Figure 3.13). This was also observed in cultures containing 
dexamethasone. However, there were no significant differences of resorptive activity between 
Dusp1+/+ and Dusp1-/- cells. 
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Figure 3.13 Osteoclast resorptive activity of Dusp1+/+ and Dusp1-/- OCL 
Bone marrow cells of Dusp1+/+ and Dusp1-/- mice aged 11-13 weeks were harvested and plated in 96-well 
plates at a density of 5x105 cells/per well in triplicate and treated with M-CSF 25ng/ml alone as a control 
or with increasing doses of RANKL (5, 25, 50ng/ml) in the presence or absence of 100nM 
dexamethasone (Dex). (a) Resorption area per dentine is shown. Result are represented as mean of 4 
independent experiments ± SEM. Statistical analysis was performed using one-way ANOVA and 
Bonferroni post hoc test. Dentines were marked for resorption area seen in black. (b-d) Dusp1+/+ cells, (e-g) 
Dusp1+/+ cells in the presence of Dex, (h-j) Dusp1-/- cells, (k-m) Dusp1-/- cells in the presence of Dex. 20x 
magnification. 
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DUSP1 deficient bone marrow cells show an increased ability to differentiate into OCLs at low 
RANKL concentrations. This was however, not reflected in their resorptive activity. The 
addition of dexamethasone to the culture medium did not influence OCL differentiation or 
activity in Dusp1+/+ and Dusp1-/- cells at low or medium RANKL concentrations. However, at 
high RANKL concentrations dexamethasone triggered a decrease in OCL resorptive activity in 
Dusp1+/+ and Dusp1-/- cells. This effect was more pronounced in Dusp1+/+ cells and might 
indicate involvement of DUSP1. A similar effect of reduced osteoclastogenesis in the presence 
of dexamethasone was observed by Kim et al., where bone marrow monocytes/macrophages 
were co-cultured with primary OBs which express RANKL to induce osteoclastogenesis. In the 
presence of dexamethasone RANKL and OPG expression from the OBs showed no difference 
while β3-integrin expression in OCLs was reduced subsequently reducing OCL numbers (Kim et 
al, 2006). In cultures of OCLs alone dexamethasone has been shown to decrease expression of β3 
integrin via Calpain-6, a molecule associated with cytoskeletal organisation (Hong et al). A 
decrease in β3 integrin would explain the observed decrease in resorptive activity in OCLs, as the 
expression of αVβ3 integrins in OCL are involved in cell contact, mediating fusion and are 
particularly important in formation of the sealing zone to resorb bone. 
 
3.8 TNF enhances osteoclast formation and activity 
No strong phenotypical differences of bone turnover were observed in Dusp1+/+ and Dusp1-/- 
mice, however, previous reports demonstrated that Dusp1-/- mice challenged with LPS have 
enhanced osteoclastogenesis and resorption (Carlson et al, 2009; Sartori et al, 2009; Yu et al, 
2011). Furthermore, in vitro Dusp1-/- macrophages express high levels of TNF after LPS challenge 
(Joanny et al, 2012). TNF has been reported to enhance OCL activity in various animal models, 
including CIA (Brennan et al, 1992). Since TNF also activates both p38 MAPK and NF B, in 
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vitro OCL differentiation and activity was examined in cultures containing 2pg/ml TNF. Low 
concentrations of TNF (1-100pg/ml) added to human OCL cultures has previously been shown 
to significantly increase OCL formation in vitro (Danks et al, 2011). TRAP and resorption assays 
were performed as previously described in section 1.7. 
Addition of TNF at low concentrations (2pg/ml) to M-CSF and RANKL strongly increased 
differentiation and resorptive activity of OCL in Dusp1-/- cultures (Figure 3.14). Similar synergy 
was not observed in Dusp1+/+ cells. DUSP1 might therefore play a more important role in the 
regulation of OCL activity in an inflammatory environment. 
 
 
Figure 3.14 Osteoclast differentiation and activity in the presence of TNF 
Bone marrow cells of Dusp1+/+ and Dusp1-/- mice aged 11-13 weeks were harvested and plated in 96-well 
plates at a density of 5x105 cells/per well in triplicate and treated with 25ng/ml M-CSF alone as a control 
or with 5ng/ml RANKL (in the presence or absence of 2pg/ml TNF. (a) Number of TRAP positive 
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multinucleated cells (mnc) per well. (b) Resorption area per dentine. Result are represented as mean of 4 
independent experiments ± SEM. Statistical analysis was performed using one-way ANOVA and 
Bonferroni post hoc test (*p<0.05, **p<0.005, ***p<0.001). (c-f) Cells were fixed after 7 days, stained for 
TRAP and photographed at 20x magnification. (g-j) Resorption lacunae. 
 
3.9 Experimental GIO in Dusp1-/- mice 
Expression of Dusp1 has previously been shown to be induced by GCs in a variety of cells 
including bone marrow macrophages and OBs (Abraham et al, 2006; Horsch et al, 2007). GCs 
are used therapeutically as potent anti-inflammatory drugs; however, long term exposure can lead 
to GIO due to elevated M-CSF and RANKL production by OBs and fibroblastic cells resulting 
in increased OCL activity. Previous studies have suggested that an inhibition of tyrosine 
phosphatases can prevent GC-induced bone loss in rats (Hulley et al, 2002). Based on these 
findings, the response of Dusp1-/- mice to prolonged exposure to GCs was investigated.  
Long term exposure to the GC prednisolone has been shown to induce trabecular bone loss in 
Swiss Webster mice (Balooch et al, 2007; Weinstein et al, 2004; Yao et al, 2008). Slow release 
pellets containing prednisolone or placebo were implanted subcutaneously in 12 week old 
Dusp1+/+ and Dusp1-/- female mice to induce GIO. The pellets released 3.2mg/kg/day. After 28 
days tibiae were collected and subjected to microCT analysis. Initial microCT analysis of tibia of 
prednisolone treated mice showed no difference in bone volume compared to placebo treated 
mice, both in Dusp1+/+ as well as in Dusp1-/- mice (Figure 3.15). 
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Figure 3.15 Bone volume of mice treated with prednisolone 
Tibia from female mice treated with placebo or prednisolone (3.2mg/kg/day) were harvested after 28days 
and analysed by microCT. Trabecular bone volume is represented as percentage of bone volume/tissue 
volume (BV/TV). Graphs represent ±SEM of two tibiae per group. Statistical analysis was performed 
using one-way ANOVA and Bonferroni post hoc test. 
 
To test whether mice were exposed to appropriate dosage of GC to induce GIO, increased 
exposure to prednisolone was tested by treating mice for 56 days with 3.2mg/kg/day. microCT 
analysis was performed on lumbar vertebrae (LV), as there is more trabecular bone present and 
hence it is more prone to osteoporosis. LVs were also analysed by histomorphometric analysis. 
No evidence of bone loss was obtained by either microCT analysis (Figure 3.16a) or bone 
histomorphometry (Figure 3.16b). 
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Figure 3.16 Lumbar bone volume analysis of Dusp1+/+ and Dusp1-/- mice treated with 
prednisolone or placebo 
Lumbar vertebrae from female mice treated with placebo or prednisolone (3.2mg/kg/day) were harvested 
after 56 days and analysed by microCT and bone histomorphometry. (a) Trabecular bone volume is 
represented asBV/TV. Graphs represent ±SEM of tibiae of three individual mice in the placebo groups 
and 5 tibiae of individual mice in the prednisolone group. Statistical analysis was performed using one-
way ANOVA and Bonferroni post hoc test. (b) Lumbar vertebra of mice treated with either prednisolone 
or placebo. 
 
In GIO increased bone resorption by OCLs and decreased bone formation by OBs leads to 
bone loss. Increased bone resorption can be measured by levels of C-terminal telopeptide of type 
I collagen (CTX) in the serum. Activated OCLs cleave type I collagen in the bone substrate and 
release it as CTX. Levels of CTX act as a marker of OCL activation and are elevated in 
osteoporosis. To determine bone turnover in mice treated with prednisolone serum was taken 
and tested for CTX. Serum CTX levels in Dusp1+/+ and Dusp1-/- mice showed no significant 
difference in prednisolone treated compared to placebo treated or naïve mice (Figure 3.17). 
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Figure 3.17 Serum CTX levels of Dusp1+/+ and Dusp1-/- mice 
Serum CTX levels of female mice treated with placebo or prednisolone (3.2mg/kg/day) for 56 days 
Graphs represent ±SEM of serum samples of three individual mice in the placebo groups and five in the 
prednisolone group. Statistical analysis was performed using one-way ANOVA and Bonferroni post hoc 
test. 
 
3.10 Experimental GIO: differences between mouse strains 
Experimental models of GIO are well established in outbred Swiss Webster mice, in which loss 
of bone volume and trabecular connectivity is observed (Balooch et al, 2007; Weinstein et al, 
2004; Yao et al, 2008). However, most genetically modified mice are on a C57BL/6 background. 
To investigate whether C57BL/6 mice are less responsive to GIO, slow release pellets 
containing prednisolone (3.2mg/kg/day) were implanted in female C57BL/6 and CD1 mice for 
56 days. CD1 mice are an outbred mouse strain similarly derived from the original Swiss mice. 
Serum of mice was collected and analysed for CTX by ELISA. 
MicroCT analysis of LVs showed that long term prednisolone treatment significantly reduced 
trabecular bone volume in female CD1 mice but had no effect on female C57BL/6 mice (Figure 
3.18a). Furthermore, serum CTX levels were elevated in prednisolone treated CD1 mice 
compared to placebo treated mice. In C57BL/6 mice no difference in serum CTX levels was 
detected whilst there was an increase in CTX in the prednisolone treated CD1 mice (Figure 
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3.18b). These findings show that the C57BL/6 mice are much more resistant to GC-induced 
osteoporosis compared to other mouse strains. 
 
Figure 3.18 Bone volume and CTX levels in CD1 mice following induction of GIO 
Lumbar vertebrae from female C57BL/6 and CD1 mice treated with placebo or prednisolone 
(3.2mg/kg/day) were harvested after 56days and analysed by (a) microCT. Trabecular bone volume is 
represented asBV/TV. Graphs represent ±SEM of tibiae of three individual mice in the placebo 
prednisolone group. (b) Serum CTX levels. Graphs represent ±SEM of three serum samples per group. 
Statistical analysis was performed using one-way ANOVA and Bonferroni post hoc test (*p<0.05). 
 
Increased bone turnover and reduced trabecular bone volume affect the biomechanical 
properties of bone. These biomechanical properties can be tested in long bones, like tibia or 
femur, by three-point bend testing. Tibiae of mice treated with placebo or prednisolone were 
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cleaned and fixed in 70% ethanol at 4°C. Prior to bend testing bones were rehydrated in PBS for 
two hours. Based on the load-deformation curve, the maximum load and elastic modulus was 
determined. The elastic modulus depends on the amount of hydroxyapatite crystals and collagen 
fibres within the bone. In accordance with the previous results obtained for decreased bone 
volume, the strength of tibiae from CD1 mice treated with prednisolone was significantly 
reduced compared to placebo treated animals (Figure 3.19a). Also, their tibiae were less elastic 
than those from placebo-treated controls (Figure 3.19b). In C57BL/6 mice, however, strength 
and elasticity of tibiae in prednisolone treated mice and placebo treated mice were not different. 
Therefore, unlike other mouse strains, treatment with subcutaneous prednisolone pellets at 
3.2/mg/kg/day is not sufficient to induce GIO in C57BL/6 mice. Strain dependent differences 
in sensitivity to GCs has been shown previously with C57BL/6 mice being less sensitive to 
prednisolone-induced accelerated calcium loss (Ambrus et al, 1978) 
 
Figure 3.19 Long term prednisolone treatment decreases elasticity and strength of tibiae of CD1 
mice 
Tibiae of female C57BL/6 and CD1 mice treated with placebo or prednisolone (3.2mg/kg/day) were 
harvested after 56 days, cleaned and fixed in 70% ethanol. Three-point bend testing was performed to test 
(a) elastic modulus and (b) maximum load. Graphs represent ±SEM of tibiae of three individual mice in 
the placebo and prednisolone group. Statistical analysis was performed using one-way ANOVA and 
Bonferroni post hoc test (*p<0.05). 
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3.11 Discussion 
3.11.1 Healthy Dusp1+/+ and Dusp1-/- mice have similar bone phenotype 
The MAPK pathway has an important role in the formation and maintenance of bone. This has 
been evident by multiple inhibition or knockout experiments. Inhibition of JNK leads to 
decreased matrix mineralisation via the OBs (Matsuguchi et al, 2009), while inhibition of p38 
MAPK prevents RANKL-induced OCL differentiation (Matsumoto et al, 2000b). Furthermore, 
mice with OCL deficient of c-Jun, which is activated by JNK, have a severe osteopetrotic bone 
phenotype due to reduced OCL activation (Ikeda et al, 2004). The first aim of this chapter was to 
determine whether ineffective inactivation of the MAPKs, due to the lack of DUSP1, would 
result in an altered bone phenotype of Dusp1-/- mice. 
Potential differences in bone phenotype were not evident from the tail length. This was verified 
by microCT and bone histomorphometric analysis of tibiae of young, adult and aged mice 
(Figure 3.4). However, a difference in body weight was observed in older mice which may be 
related to increased activation of the MAPK pathway in white adipose tissue and results in 
reduced adipose tissue in DUSP1 deficient mice (Wu et al, 2006). It has been reported that 
DUSP1 plays role in adipocyte differentiation in vitro by regulating ERK1/ERK2 
dephosphorylation (Datta et al, 2010; Sakaue et al, 2004). However, Dusp1-/- mice have reduced 
visceral and subcutaneous adipose tissue (Figure 3.3) and Wu et al. demonstrated that adipocyte 
differentiation was not affected by DUSP1 deficiency (Wu et al, 2006). 
Reports on Dusp1-/- mice on the mixed background (C57BL/6 129Sv) have demonstrated a 
sexual dimorphism in bone mass. While male Dusp1-/- mice showed no difference in bone mass, 
8-12 week old female Dusp1-/- mice had reduced bone mass, trabecular thickness and increased 
bone turn over measured by serum TRAP levels compared to Dusp1+/+ mice (Carlson et al, 2009; 
Datta et al, 2010; Mahalingam et al, 2011). Furthermore, Carlson et al. reported that differences 
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in bone development can be overcome as the mice develop further, so that by 12 weeks when 
mice are completely grown differences are no longer apparent. Results obtained here confirm a 
normal bone phenotype in DUSP1 deficient mice on a C57BL/6 background. In our study mice 
aged 12 weeks were used for OCL assays and experimental GIO as the skeletal system is 
completely developed by that age. No significant differences in the basal bone phenotype and 
homeostasis between Dusp1+/+ and Dusp1-/- mice were observed (Figure 3.4, Figure 3.6, Figure 
3.11, Figure 3.12), suggesting that DUSP1 although activated by RANKL, plays a little role in 
normal bone development. 
 
3.11.2 DUSP1 limits in vitro osteoclast activity in inflammatory conditions 
The spontaneous osteolytic phenotype in female Dusp1-/- mice of the mixed genetic background 
(Figure 3.1) revealed increased OCL activity, which lead to extensively resorbed proximal 
phalangeal bones in the affected toes. Osteolysis of the bone was associated with infiltration of 
neutrophils, which indicates inflammation (Vattakuzhi et al, 2012)(Ph.D. thesis S. Abraham 
2009). Furthermore, various studies have demonstrated an important role of DUSP1 in limiting 
inflammation (Abraham et al, 2006; Carlson et al, 2009; Hammer et al, 2006; Sartori et al, 2009; 
Yu et al, 2011). Innate immune challenge by LPS or zymosan, results in increased pro-
inflammatory cell infiltrate and increased pro-inflammatory cytokine production (Abraham et al, 
2006; Hammer et al, 2006; Joanny et al, 2012). Different pro-inflammatory cytokines like IL-1 
and TNF are known to promote OCL activity both in vitro but also diseases like periodontal 
disease or RA (Assuma et al, 1998; Bertolini et al, 1986; Danks et al, 2011; Zhang et al, 2001). 
Furthermore, TNF is known to activate p38α isoform in OCLs (Bohm et al, 2009). Also 
RANKL stimulation leads to expression of p38 MAPK and DUSP1 in OCLs (Figure 3.7, Figure 
3.9) (Carlson et al, 2009). Subsequently due to ineffective dephosphorylation in the absence of 
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DUSP1, prolonged p38 MAPK activation was observed in Dusp1-/- OCL cultures (Figure 3.7). 
The increased resorptive activity of Dusp1-/- OCL in the presence of TNF (Figure 3.13) is 
therefore most likely due to ineffective inactivation of p38 MAPK and enhanced sensitivity to 
TNF-induced resorption. A role of DUSP1 in limiting inflammatory bone resorption in diseases 
like RA can be anticipated. Experimental arthritis models in mice like CIA or AIA can be used to 
test this hypothesis. 
 
3.11.3 Susceptibility to experimental GIO is strain dependent 
After establishing that there are little differences in the bone phenotype of healthy Dusp1+/+ and 
Dusp1-/- mice, the aim was to establish GIO in these mice to investigate the hypothesis that 
Dusp1-/- mice are protected from GIO. Previously inhibition of tyrosine phosphatases has been 
shown to prevent GC-induced bone loss in rats (Hulley et al, 2002). However, administration of 
prednisolone by slow release pellets did not reduce bone volume in Dusp1+/+ and Dusp1-/- mice. 
The method and dosage used has been shown to successfully induce GIO in other mouse strains 
like Swiss Webster mice and is considered a good experimental model as it shares many features 
with the clinical condition (Balooch et al, 2007; Yao et al, 2008). In Dusp1+/+ and Dusp1-/- mice, 
which are on the C57BL/6 background, bone volume and serum CTX levels were not affected 
by treatment with prednisolone for either 28 or 56 days (Figure 3.14, Figure 3.15, Figure 3.16). 
However, treating female CD1 mice, which are an outbred mouse strain of the Swiss mice, with 
prednisolone for 56 days significantly reduced bone volume and increased serum CTX levels 
(Figure 3.17). Furthermore, it has been known from previous studies of GC treated patients and 
from animal models that reduced OB activities not only leads to reduced mineralisation, and 
therefore bone volume, but also to reduced elasticity. In accordance with that, three-point bend 
testing of tibiae displayed reduced elasticity and strength in prednisolone treated CD1 mice 
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(Figure 3.18). These observations confirm the effectiveness of prednisolone release from the 
slow release pellets inducing loss of bone volume. However, it also raises the question whether 
sensitivity to GCs is strain dependent. Strain differences in stress-induced corticosterone levels 
have been reported between Fischer 344 and Lewis rats and between female C57BL/6 and 
DBA/2 mice (Dhabhar et al, 1993; Jones et al, 1998). It is not clear at this stage why bone loss 
was not detected in Dusp1+/+ mice as the use of prednisolone in C57BL/6 mice has been shown 
to reduce bone mineral density in LV (Yamada et al, 2004). It has been reported previously that 
exogenous GCs interfere with the HPA axis by competing with endogenous GCs like 
corticosterone resulting in its suppressed secretion from the adrenal cortex. Furthermore, daily 
administration of GCs has been shown to have an inverse relation with serum corticosterone 
levels in mice (Rauchhaus et al, 2009). It is possible that predinisolone, an exogenous GCs, may 
have served as a hypothalamic negative feedback signal in our study and the total effect of 
endogenous and exogenous GC for this matter did not produce the expected results. Also, to 
test whether release of prednisolone from the pellet was dysfunctional, serum corticosterone 
levels can be measured. 
 
In conclusion the results obtained demonstrated no apparent differences in bone homeostasis in 
healthy Dusp1+/+ and Dusp1-/- mice on a C57BL/6 background. Furthermore, the genetic 
background seems to affect sensitivity to GC-induced bone loss with C57BL/6 mice being less 
susceptible than CD1 mice. DUSP1 seems, however, to regulate OCL activity in the presence of 
pro-inflammatory TNF. TNF is of particular importance in the pathogenesis and bone loss 
associated with RA. Several previous publications have reported a role of DUSP1 in limiting 
inflammation. The effects of CIA in Dusp1-/- mice are investigated next to determine a role of 
DUSP1 in inflammatory-induced bone loss. 
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4 DUSP1 limits osteolysis and mediates therapeutic 
effects of  dexamethasone in collagen-induced arthritis 
4.1 Introduction 
Human RA is a multifactorial autoimmune disease characterised by chronic inflammation of the 
joint. Multiple animal models of RA have been developed by gene mutations or by challenging 
animals with adjuvants or cartilage specific proteins. As one of the animal models of RA, CIA in 
mice or rats, has been used extensively to investigate disease pathogenesis and to validate 
therapeutic targets. Arthritic joints of CIA in mice and human RA show similar symptoms of 
synovitis, pannus formation, cartilage damage and bone erosions (Trentham, 1982; Williams, 
2007). Cytokines like TNF, IL-1 and IL-17 are highly expressed by macrophages and 
lymphocytes in arthritic joints and drive inflammation but also promote bone destruction by 
OCLs (Gravallese et al, 2000; Lam et al, 2000; Schett & Teitelbaum, 2009). 
Experiments described in the previous chapter and several other studies indicate that DUSP1 
might have a regulatory role in OCL activity during inflammation (Carlson et al, 2009; 
Vattakuzhi et al, 2012; Yu et al, 2011). Furthermore, anti-inflammatory effects of GCs are 
mediated partly through up-regulation of DUSP1 and the inactivation of the MAPK signalling 
pathway (Abraham et al, 2006; Clark, 2003; Clark, 2007; Quante et al, 2008; Schett, 2007). GCs 
are used as anti-inflammatory drugs in various acute and chronic inflammatory diseases including 
Crohn’s disease, asthma, cystic fibrosis, or RA. Moreover, dexamethasone treatment of arthritic 
C57BL/6 mice has been shown to reduce joint swelling (Inglis et al, 2007). 
The aim of this chapter was to investigate the role of DUSP1 in bone erosions following CIA 
induction in mice and its role in mediating the therapeutic effects of dexamethasone treatment. 
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4.2 Increased incidence and earlier onset of  CIA in Dusp1-/- 
mice 
Similar to human RA, susceptibility to CIA in mice correlates with MHC haplotypes. The highest 
susceptibility is associated with H-2q or H-2r. Most CIA experiments are therefore performed by 
immunising susceptible Dilute, Brown and non-Agouti (DBA) mice, which express H-2q 
haplotype, with bovine collagen type II in complete Freund’s adjuvant (CFA) (Williams, 2007). 
While mice bearing the H-2q haplotype are the most susceptible, CIA can also be established in 
C57B/6 mice bearing the H-2b haplotype by immunising with chicken collagen type II in CFA 
(Inglis et al, 2008). However, the incidence of developing arthritis in C57BL/6 mice can vary 
between 50 and 70% (Campbell et al, 2000; Inglis et al, 2008), and is lower compared to DBA 
mice (80-100% incidence)(Brand et al, 2007). Also disease onset is delayed in C57BL/6 mice (21-
42 days after immunisation) compared to DBA mice (21-28 days after immunisation). 
Male Dusp1+/+ and Dusp1-/- mice on a C57BL/6 background (H-2b) aged between 10-15 weeks 
were immunised with 200 µg chicken type II collagen emulsified in CFA by subcutaneous 
injections at two sites at the base of the tail. Mice were monitored for signs of arthritis. 
Incidence of disease was significantly higher in Dusp1-/- mice (Figure 4.1a) as previously reported 
for Dusp1-/- mice on a mixed 129Sv/C57BL/6 background (Salojin et al, 2006). In a total of six 
independent experiments 75% (42 of 56) of immunised Dusp1-/- mice developed CIA, compared 
to just 35% (24 of 69) of Dusp1+/+ mice (Figure 4.1a). Also, consistent with the study by Salojin 
in the mixed background, onset of disease was significantly earlier in Dusp1-/- mice with an 
average of 23 days after immunisation. Dusp1+/+ mice developed disease on average after 34 days 
(Figure 4.1b). Male Dusp1-/- mice therefore appear to have a higher susceptibility to develop CIA 
and the disease incidence is comparable to other mouse strains containing the H-2q or H-2r 
haplotype. 
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Figure 4.1 Incidence and onset of CIA in Dusp1-/- mice 
Male Dusp1+/+ and Dusp1-/- mice aged 10-15 weeks were immunised with chicken collagen type II 
emulsified in CFA. (a) The mean percentage ± SEM of immunised mice developing arthritis in six 
independent experiments was calculated. Statistical analysis was performed using chi-squared test. (b) The 
mean time ± SEM from immunisation to onset of arthritis was recorded in six independent experiments. 
Statistical analysis was performed using unpaired two-tailed student’s t-test (***p<0.001). 
 
4.3 Decreased effects of  dexamethasone treatment in Dusp1-/- 
mice 
Anti-inflammatory actions of dexamethasone are partly mediated through inactivation of MAPK 
signalling via DUSP1 in macrophages. Therapeutic effects of dexamethasone have been shown 
to be impaired in DUSP1 deficient mice in a model of localised acute inflammation by injecting 
LPS into an air pouch (Abraham et al, 2006). Similarly, administration of dexamethasone does 
not protect Dusp1-/- mice from lethal endotoxic shock (Zhao et al, 2006). These reports highlight 
the role of DUSP1 in mediating the effects of GCs in innate immune responses. However, the 
involvement of GC-induced DUSP1 expression in complex inflammatory models involving the 
adaptive immune system, like CIA, has not been tested to date. To investigate whether DUSP1 
also mediates anti-inflammatory effects of GCs in CIA, mice were treated with either PBS or 
dexamethasone (0.5mg/kg) via intra-peritoneal injection every second day after disease onset. In 
total 12 Dusp1+/+ mice were treated with PBS, 9 Dusp1+/+ mice with dexamethasone, 21 Dusp1-/- 
mice with PBS and 17 Dusp1-/- mice with dexamethasone. Swelling of the joints in the front and 
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back paws was scored with clinical scores ranging from 0-3 (0 = no swelling, 1 = redness and 
swelling of at least one digit, 2 = pronounced swelling, 3 = severe swelling of the paw, joint 
rigidity) until day 10 after disease onset after which the mice were sacrificed. Paw swelling was 
also measured using callipers. 
The combined clinical score (i.e. sum of scores for all four paws) can reach a maximum of 12. 
The combined clinical scores of arthritic paws did not show significant differences between PBS 
treated Dusp1+/+ and Dusp1-/- mice until day 10 after disease onset. At day 10 clinical scores 
reached a mean of 9.5 in Dusp1-/- mice compared to 8 in Dusp1+/+ mice (Figure 4.2a). Although 
the combined clinical score is an established scoring system in CIA experiments, it does not take 
into account that disease onset and progression varies between individual paws. As such Figure 
4.2b shows the individual clinical score of the first affected paw in each mouse. These data 
demonstrate more rapid disease progression in Dusp1-/- mice. Dusp1-/- mice reached a maximum 
clinical score by day 3 after disease onset, compared to day 7 in Dusp1+/+ mice. 
 
Figure 4.2 Accelerated disease progression in Dusp1-/- mice 
Swelling of the joints of the front and back paws was scored for 10 days after disease onset with a clinical 
score for each paw (0 = no swelling, 1 = redness and swelling of at least one digit, 2 = pronounced 
swelling, 3 = severe swelling of the paw, joint rigidity). Data for 12 Dusp1+/+ and 21 Dusp1-/- mice are 
shown. Combined score of all four paws (a). Score for first affected individual paw (b). Values are shown 
as mean score ± SEM. Statistical analysis was performed using one-way ANOVA and Bonferroni post hoc 
test (*p<0.05, ***p<0.001). 
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Treatment of arthritic mice with dexamethasone showed a significant reduction of clinical scores 
in Dusp1+/+ mice from day 7 onwards (43% reduction on day 10) (Figure 4.3a). A therapeutic 
effect of dexamethasone was also observed in Dusp1-/- mice (Figure 4.3b). This was however, not 
as marked as in the Dusp1-/- mice (17% reduction on day 10). These data indicate that the 
therapeutic effects of dexamethasone in CIA are only partly mediated via DUSP1. Severe 
swelling of all digits, the foot and the ankle region was observed in most arthritic Dusp1-/- mice 
treated with PBS by day 6 after disease onset (Figure 4.3c top pictures). Affected paws of PBS 
treated Dusp1+/+ mice presented with less severe swelling in both PBS and dexamethasone 
treated groups compared to Dusp1-/- mice (Figure 4.3c). 
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Figure 4.3 Clinical score of PBS and dexamethasone treated mice 
Swelling of the joints of the front and back paws was scored for 10 days after disease onset with a clinical 
score for each paw (0 = no swelling, 1 = redness and swelling of at least one digit, 2 = pronounced 
swelling, 3 = severe swelling of the paw, joint rigidity). Mice were treated with either PBS or 
dexamethasone (Dex, 0.5mg/kg) every second day. (a) 12 Dusp1+/+ mice were treated with PBS, 9 
Dusp1+/+ mice were treated with dexamethasone. (b) 21 Dusp1-/- mice were treated with PBS, 17 Dusp1-/- 
mice were treated with dexamethasone. Values are shown as mean score ± SEM. Statistical analysis was 
performed using one-way ANOVA and Bonferroni post hoc test (*p<0.05, **p<0.005, ***p<0.001). (c) 
Affected hind paws of Dusp1+/+ and Dusp1-/- mice, treated either with PBS or Dex were photographed 6 
days after disease onset. 
 
At day five after disease onset Dusp1-/- mice reached a mean paw diameter of 3.6mm whereas 
Dusp1+/+ mice reached a mean of 3.2mm. The mean paw diameter in Dusp1-/- mice reached a 
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peak of 3.9mm on day seven and did not change significantly for the remainder of the 
experiment (Figure 4.4b). The mean paw diameter in Dusp1+/+ mice treated with PBS peaked at 
3.7mm on day 10 (Figure 4.4a). However, as the paw measurement is taken at the region of the 
metatarsal joints, it does not reflect the swelling of the digits or the ankle region. In arthritic 
Dusp1-/- mice swelling of the entire paw including the ankle region was observed, as can be seen 
in Figure 4.3c. Corresponding with the clinical score, dexamethasone treatment showed a 
significant reduction of 25% in paw diameter in Dusp1+/+ mice after day 7 (Figure 4.4a). This was 
also observed in dexamethasone treated Dusp1-/- mice however to a lesser degree, reducing the 
paw diameter by 11% by day 10 after disease onset (Figure 4.4b). A therapeutic effect of 
dexamethasone treatment was reflected both in clinical scores and paw diameter of Dusp1+/+ and 
Dusp1-/- mice, suggesting that GC-induced activation of DUSP1 and subsequent MAPK 
inactivation is only partly responsible for the therapeutic effect. 
 
Figure 4.4 Paw swelling in arthritic Dusp1+/+ and Dusp1-/- mice 
The paw diameter of the back paws was measured for 10 days after disease onset. Mice were treated with 
either PBS or dexamethasone (Dex, 0.5mg/kg) every second day. (a) 12 Dusp1+/+ mice were treated with 
PBS, 9 Dusp1+/+ mice were treated with dexamethasone. (b) 21 Dusp1-/- mice were treated with PBS, 17 
Dusp1-/- mice were treated with dexamethasone. Values are shown as mean ± SEM. Statistical analysis was 
performed using one-way ANOVA and Bonferroni post hoc test (*p<0.05, **p<0.005). 
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4.4 Enhanced inflammation in Dusp1-/- mice 
Mice were sacrificed 10 days after disease onset and hind paws were collected, fixed in formalin, 
decalcified in EDTA and analysed by histology. Hematoxilin and eosin (H&E) stained sections 
of the proximal interphalangeal joints were scored blinded to the mouse genotype and treatment. 
Scores between 0-4 were given (0 = normal; 1 = mild inflammation with no joint damage; 2 = 
moderate inflammation with some joint erosions; 3 = severe inflammation and joint erosions; 4 
= severe inflammation and loss of joint architecture). Histological sections showed increased 
inflammatory infiltrate in both PBS treated and dexamethasone treated Dusp1-/- mice compared 
to Dusp1+/+ mice (Figure 4.5a 10x). Synovial hyperplasia and periarticular bone erosions were 
evident in arthritic joints of PBS treated mice and were increased in Dusp1-/- mice. Enhanced 
inflammatory infiltrate in the joint space was apparent in PBS treated Dusp1-/- mice and also 
cartilage erosions were augmented compared to Dusp1+/+ mice (Figure 4.5a 20x). The histological 
score was therefore significantly higher in PBS treated Dusp1-/- mice (Figure 4.5b). 
Dexamethasone treatment reduced inflammatory infiltrates and histological scores in Dusp1+/+ 
mice but was ineffective in Dusp1-/- mice (Figure 4.5a, b). These findings verify the enhanced 
disease progression observed in Dusp1-/- mice and confirm that the ability of dexamethasone to 
reduce inflammation was diminished in Dusp1-/- mice. The data therefore highlight a role of 
DUSP1 in reducing inflammation driven joint destruction. 
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Figure 4.5 Increased joint damage and inflammation in arthritic joint of Dusp1-/- mice 
Affected hind paws of Dusp1+/+ and Dusp1-/- mice, treated either with PBS or dexamethasone (Dex, 
0.5mg/kg) every second day, were photographed 6 days after disease onset (a). H&E stained sections of 
proximal interphalangeal joints were prepared 10 days after disease onset (b) Images were taken at 10x 
and 20x magnification. Blue arrow indicated synovial hyperplasia, green bone erosions, yellow 
inflammatory infiltrate, and red cartilage degradation. (c)Histological scoring was performed on H&E 
sections of nine individual paws per group and represented as mean ± SEM. Statistical analysis was 
performed using one-way ANOVA and Bonferroni post hoc test (*p<0.05, ***p<0.001; n.s. not 
significant). 
 
4.5 Increased osteolysis in Dusp1-/- mice 
In RA, as well as in CIA, the formation of OCL at the sites of contact of pannus and the 
periarticular bone surface has been well described (Frazier et al, 2009; Gravallese et al, 1998). 
Enhanced OCL formation and activity, which can be triggered by pro-inflammatory cytokines 
like TNF, causes bone erosions in arthritic joints. To investigate OCL formation, sections of 
arthritic hind paws were stained for TRAP. In Dusp1-/- mice a significantly higher number of 
TRAP positive OCLs were present in the affected joints and the majority of OCLs were found at 
the interface between pannus and periosteal bone surface (Figure 4.6a). In both PBS and 
dexamethasone treated mice, numbers of OCLs in the joint were significantly higher in Dusp1-/- 
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mice compared to Dusp1+/+ mice (Figure 4.6b). Dexamethasone did not have a significant effect 
on numbers of OCLs present in arthritic joints of Dusp1+/+ and Dusp1-/- mice. 
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Figure 4.6 Increased osteoclasts present in arthritic joints of Dusp1-/- mice 
Affected hind paws of Dusp1+/+ and Dusp1-/- mice, treated either with PBS or dexamethasone (Dex, 
0.5mg/kg) every second day, were collected 10 days after disease onset, sectioned and stained for TRAP 
(red) (a). Images were taken at 10x and 40x magnification. (b) TRAP positive cells per field of view at 10x 
magnification were counted. Graph represents mean ± SEM for 9 PBS or dexamethasone treated 
Dusp1+/+ mice and 10 PBS or dexamethasone treated Dusp1-/- mice. Statistical analysis was performed 
using one-way ANOVA and Bonferroni post hoc test (**p<0.005; n.s. not significant). 
 
Affected paws of naïve and PBS or dexamethasone treated Dusp1+/+ and Dusp1-/- mice were 
collected 10 days after disease onset and also analysed by microCT to investigate bone volume 
and the effects of OCL activity in the arthritic joints. Bone erosions could be seen at the 
proximal interphalangeal (PIP) joints, metatarsophalangeal (MTP) joints and the tarsal joint of 
the affected hind paws. As indicated by the number of OCL in the joints, bone erosions were 
greater in Dusp1-/- compared to Dusp1+/+ mice (Figure 4.7a). Further, bone erosions appear to be 
reduced in dexamethasone treated Dusp1-/- mice. In arthritic Dusp1+/+ and Dusp1-/- mice bone 
erosions were most prominent at the MTP joints. MTP joints were then selected to calculate 
bone volume. As expected, no significant differences of bone volume was observed between 
naïve Dusp1+/+ and Dusp1-/- mice. In comparison to age matched naïve mice, CIA-induced 
significant loss of bone volume in PBS treated Dusp1-/- but not Dusp1+/+ mice (Figure 4.7b). 
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Bone erosions were still observed in dexamethasone treated arthritic mice of both genotypes. 
Although loss of bone volume was reduced, it did not reach statistical significance. 
 
Figure 4.7 Increased bone resorption in arthritic Dusp1-/- mice 
10 days after disease onset affected hind paws of Dusp1+/+ and Dusp1-/- mice, treated either with PBS or 
dexamethasone (Dex) were collected and analysed by microCT. Reconstructed microCT images of naïve 
and immunised mice (CIA) are shown (a). Bone volume was measured within a 1.5mm region of interest 
(roi) centred at the MTP joints (b). Graph represents mean ± SEM for 3 age matched naïve control mice 
and 6 arthritic animals treated with PBS or Dex of each genotype. Statistical analysis was performed using 
one-way ANOVA and Bonferroni post hoc test (**p<0.005; n.s. not significant). 
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These microCT images clearly illustrate the extensive bone damage caused by severe 
inflammation in arthritic Dusp1-/- mice. To quantify bone loss, joint damage and deformation 
Richard M. Siegel and colleagues devised a scoring method based on microCT scans (Figure 4.8a 
Song et al., unpublished). Scores are given to 3 different regions of the hind paw (the tarsal, MTP 
and PIP joints) according to resorption and deformation (Figure 4.8a). For the ankle region 
scores between 0 and 2 in 0.5 increments are assigned (0= normal, 0.5-1= mild, 1-1.5= 
moderate, 2= severe) and multiplied by 5 giving a maximum of 10. Next each of the MTP joints 
is assigned a score from 0 to 2 (0= normal, 1= periosteal changes or mild erosions but joint 
space maintained, 2= severe erosions, especially on both sides of the joint, deformation). Finally 
each PIP joint is assigned either a score of 0 or 1 (0= normal, 1= periosteal changes or erosions). 
Paws of naïve animal are therefore scored 0 and a maximum score of 25 can be assigned to each 
affected paw. The assigned score was higher in in PBS treated arthritic Dusp1-/- mice compared to 
PBS treated Dusp1+/+ mice reflecting the extensive erosions observed. In arthritic Dusp1+/+ as 
well as Dusp1-/- mice dexamethasone treatment reduced the mean score although this did not 
reach statistical significance (Figure 4.8b). In accordance with data obtained from OCL specific 
TRAP staining of paw sections (Figure 4.6b) and bone volume measurement (Figure 4.7b), these 
microCT scores show that dexamethasone treatment does not significantly reduce bone erosions 
in arthritic Dusp1+/+ as well as Dusp1-/- mice. 
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Figure 4.8 Increased microCT scores in arthritic Dusp1-/- mice 
Bone resorption was analysed on microCT scans of affected hind paws of Dusp1+/+ and Dusp1-/- mice, 
treated either with PBS or dexamethasone (Dex). (a) Diagram depicting joints and scoring given 
according to bone erosions seen (kindly provided by Richard M. Siegel). (b) Graph representing mean ± 
SEM for 6 mice per group. Statistical analysis was performed using one-way ANOVA and Bonferroni post 
hoc test (**p<0.005; n.s. not significant). 
 
In order to establish whether bone turnover was affected in arthritic mice, serum was also 
collected 10 days after disease onset and assayed for CTX. As expected levels of serum CTX 
were significantly higher in arthritic Dusp1+/+ and Dusp1-/- mice compared to age matched naïve 
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mice (Figure 4.9). Furthermore, dexamethasone treatment did not significantly change CTX 
levels compared to PBS treatment in Dusp1+/+ and Dusp1-/- mice indicating OCL activity was not 
affected by GC treatment. Surprisingly however, CTX levels showed no difference in PBS 
treated arthritic Dusp1+/+ mice compared to arthritic Dusp1-/- mice, despite increased bone 
erosions present in arthritic Dusp1-/- mice. Different experimental arthritis models in mice 
suggest cartilage and bone damage are detectable in collagen immunised animals soon after 
disease onset (Chu et al, 2003; Lubberts et al, 2001). Measuring serum CTX levels at earlier time 
points during disease might therefore better reflect the increased bone erosions observed in 
arthritic Dusp1-/- mice with higher serum CTX levels. 
 
Figure 4.9 Increased serum CTX in arthritic Dusp1+/+ and Dusp1-/- mice 
Sera from naïve and arthritic Dusp1+/+ and Dusp1-/- mice, treated either with PBS or dexamethasone (Dex) 
were collected 10 days after disease onset and assayed for CTX levels. Data represent the mean ± SEM of 
6 naïve mice per group, 9 Dusp1+/+ mice treated with PBS or dexamethasone and 15 Dusp1-/- mice treated 
with PBS or dexamethasone. Statistical analysis was performed using one-way ANOVA and Bonferroni 
post hoc test (**p<0.005; n.s. not significant). 
 
The data in Figure 4.1 and Figure 4.5 showing earlier disease onset and enhanced inflammation 
in Dusp1-/- mice support that of previous studies (Salojin et al, 2006). Furthermore, the incidence 
of disease development was higher in Dusp1-/- mice compared to Dusp1+/+ mice and reached 
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similar percentage to CIA susceptible mouse strains like DBA mice. Together these data support 
the notion that DUSP1 is a crucial regulator of both innate and adaptive immune responses. 
Dexamethasone treatment reduced clinical signs of inflammation like paw swelling in arthritic 
Dusp1+/+ mice and to a lesser extent also in arthritic Dusp1-/- mice, suggesting DUSP1 only partly 
mediates anti-inflammatory mechanisms of GCs. However, dexamethasone-mediated reduction 
in joint inflammation did not significantly reduce bone erosions and bone loss. 
 
4.6 Daily dexamethasone treatment reduces joint inflammation 
effectively 
Dexamethasone treatment of arthritic Dusp1-/- mice every second day showed a minimal 
reduction in disease severity and paw swelling, indicating that DUSP1 independent mechanisms 
are involved in anti-inflammatory actions of GCs. To determine whether increased inflammation 
seen in arthritic Dusp1-/- mice can be treated as effectively as in Dusp1+/+ mice with more frequent 
injections of dexamethasone, arthritic Dusp1+/+ and Dusp1-/-mice were given daily injections of 
0.5mg/kg dexamethasone after disease onset. In arthritic Dusp1+/+ mice treated with daily 
dexamethasone injections, significant reduction of clinical score and paw swelling was reached 
earlier than compared to Dusp1-/-mice. In Dusp1+/+ mice the treatment effectively reduced clinical 
score from day 5 after disease onset onwards. By day 10 a 71% reduction in clinical score can be 
seen (Figure 4.10a). In contrast, dexamethasone treatment of Dusp1-/- mice resulted in a 
significant reduction in both clinical score and paw diameter only after day 8. By day 10, clinical 
score was reduced by 43% (Figure 4.10b). In dexamethasone treated Dusp1+/+ mice, paw 
diameter was reduced by 37% (Figure 4.10c). This effect was reduced in Dusp1-/- mice. Daily 
dexamethasone treatment also significantly reduced paw swelling compared to PBS treated 
Dusp1-/- mice by 28% 10 days after disease onset (Figure 4.10d, Table 4.1). Reduction in clinical 
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score and paw swelling following daily dexamethasone treatment remained significantly stronger 
in arthritic Dusp1+/+ mice compared to Dusp1-/- mice, suggesting dexamethasone was more 
efficacious in Dusp1+/+ mice. 
 
Figure 4.10 Frequent dexamethasone treatment reduces paw swelling 
Swelling of the joints of the front and back paws was scored for 10 days after disease onset with a clinical 
score for each paw (0 = no swelling, 1 = redness and swelling of at least one digit, 2 = pronounced 
swelling, 3 = severe swelling of the paw, joint rigidity). Mice were treated with either PBS or 
dexamethasone (Dex, 0.5mg/kg) every day. (a) 3 Dusp1+/+ mice were treated with PBS, 3 Dusp1+/+ mice 
were treated with dexamethasone. (b) 3 Dusp1-/- mice were treated with PBS, 4 Dusp1-/- mice were treated 
with dexamethasone. The paw diameter of the back paws was measured for 10 days after disease onset (c, 
d). Values are shown as mean ± SEM. Statistical analysis was performed using one-way ANOVA and 
Bonferroni post hoc test (*p<0.05, **p<0.005, ***p<0.001). 
 
 Treatment Clinical score Paw diameter [mm] 
Dusp1+/+ PBS 8.5 ± 0.5 3.8 ± 0.1 
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Dex (0.5mg/kg/day) 2.5 ± 0.3 2.4 ± 0.1 
Dusp1-/- 
PBS 9.2 ± 0.6 3.9 ± 0.1 
Dex (0.5mg/kg/day) 5.3 ± 0.5 2.8 ± 0.2 
Table 4.1 Measurements at day 10 after disease onset 
Clinical score and paw diameter of arthritic Dusp1+/+ and Dusp1-/- mice at day 10 after disease onset is 
shown ± SEM. Mice were treated daily with either PBS or dexamethasone (Dex, 0.5mg/kg). 
 
Compared to dexamethasone treatment of arthritic mice every second day, daily treatment 
reduced clinical signs of inflammation more strongly in arthritic Dusp1+/+ mice and was 
comparable to previous reports of CIA in C57BL/6 mice (Inglis et al, 2007). Therapeutic effects 
of dexamethasone were observed in arthritic Dusp1-/- mice but were decreased compared to 
Dusp1+/+ mice. A decrease in clinical score was apparent at both treatment regimes, indicating 
that therapeutic effects of dexamethasone are only partly dependent on DUSP1. However, 
frequent treatment showed an earlier therapeutic effect in Dusp1-/- mice. Therefore, DUSP1 
dependence of therapeutic responses is less evident suggesting other GC-induced mechanisms 
are more important under these conditions. 
 
4.7 Discussion 
TNF is an important pro-inflammatory cytokine expressed in chronic arthritis and has been 
shown, amongst other pro-inflammatory cytokines, to drive bone resorption resulting in joint 
deformation in RA. Results presented in the previous chapter suggested a role of DUSP1 in 
regulating OCL activity in the presence of TNF. Hence, to investigate whether DUSP1 has a 
crucial role in limiting bone resorption in arthritis, CIA was induced in Dusp1+/+ and Dusp1-/- 
mice. CIA shares several pathological features with RA, like inflammation of the synovial joints 
and bone erosions. Moreover, unlike CIA in susceptible DBA/1 mouse strains, which show an 
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acute but relatively short lived immune response, C57BL/6 mice present with a chronic immune 
response (Inglis et al, 2007). 
 
4.7.1 DUSP1 controls susceptibility to CIA 
Following immunisation with CFA and chicken type II collagen Dusp1-/- mice showed a 
significantly increased incidence rate and earlier onset compared to Dusp1+/+ mice (Figure 4.1) 
supporting previous studies in Dusp1-/- mice of the mixed stain background (Salojin et al, 2006). 
The incidence rate and time of disease onset was comparable to susceptible mouse strains like 
DBA/1 mice. Susceptibility of different mouse strains to the induction of CIA is usually 
accounted for by different MHC haplotypes. While the H-2q haplotype is expressed in DBA/1 
mice, C57BL/6 mice express H-2b and were previously considered to be CIA resistant (Campbell 
et al, 2000). However, in CIA the initial immune reaction by the innate immune system, triggered 
by components of CFA, is crucial for the development of arthritis. Components like heat-
inactivated mycobacterium trigger TLRs of the innate immune cells, which then activate the 
adaptive immune response by enhanced secretion of pro-inflammatory cytokines (Billiau & 
Matthys, 2001). The role of DUSP1 in regulating innate immune responses has been 
demonstrated in various models by challenging Dusp1-/- mice with LPS or zymosan and in 
models of sepsis caused by cecal ligation puncture (Abraham et al, 2006; Carlson et al, 2009; 
Frazier et al, 2009; Hammer et al, 2006; Sartori et al, 2009; Zhao et al, 2006). As the role of 
DUSP1 in limiting innate immune responses has been well established, it can be speculated that 
the increased susceptibility seen in Dusp1-/- mice is likely triggered by enhanced innate immune 
responses. Innate immune responses to CFA are crucial for the development of auto-reactive T 
cells in CIA. However, the possible role of DUSP1 in the adaptive immune response, which 
could potentially increase susceptibility to CIA, has not been investigated. 
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4.7.2 DUSP1 controls inflammation of joints in CIA 
In agreement with a previous report in Dusp1-/- mice of a mixed genetic background (129 
Sv/C57BL/6) disease onset Figure 4.1b), and joint inflammation (Figure 4.2, Figure 4.3, Figure 
4.4) was higher in Dusp1-/- mice of almost pure C57BL/6 background (Salojin et al, 2006). As 
previously mentioned, several reports have demonstrated enhanced pro-inflammatory responses 
in Dusp1-/- mice challenged with innate TLR ligands like LPS or zymosan (Abraham et al, 2006; 
Carlson et al, 2009; Hammer et al, 2006; Zhao et al, 2006). TLR activation triggers the NF B and 
MAPK signalling pathways. p38 MAPK activation mediates not only transcriptional activation of 
pro-inflammatory genes but also post-transcriptional mRNA stabilisation of metalloproteinases 
and various cytokines like TNF, IL-6, IL-1β and COX2 (Clark et al, 2003; Dean et al, 2004). 
Moreover, DUSP1 deficient macrophages show prolonged p38 MAPK and JNK activation and 
overexpress TNF and IL-6 amongst other pro-inflammatory cytokines (Chi et al, 2006; Hammer 
et al, 2006; Joanny et al, 2012). DUSP1 therefore has a major role in inhibiting pro-inflammatory 
cytokine production. In RA and its experimental model, CIA, both the innate and adaptive 
immune systems are involved in disease progression. Innate cytokine production causes 
vasodilation and infiltration of neutrophils to the affected joints. In arthritic Dusp1-/- mice we 
observed increased inflammatory infiltration, increased synovial proliferation and pannus 
formation (Figure 4.5). TNF is believed to be a major contributor of synovial hyperplasia. 
Enhanced p38 MAPK activation in innate immune cells of Dusp1-/- mice, following TLR 
signalling by CFA, and subsequent enhanced pro-inflammatory cytokine production could 
potentially account for increased infiltration of innate immune cells into the joint. However, cells 
of the adaptive immune response including T and B cells are also found in the inflammatory 
infiltrate in the arthritic joint and cytokines produced by these cells have also been shown to 
contribute to inflammation observed in RA such as IL-17 from Th17 cells. IL-17 promotes 
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activation and proliferation of SF, which contribute to inflammation in CIA. Members of the 
DUSP family of phosphatases have been proposed to be involved in the adaptive immune 
system. DUSP2 and DUSP10 are highly upregulated in activated T cells and involved in their 
proliferation and cytokine production (Jeffrey et al, 2006; Lang et al, 2006; Zhang et al, 2004). 
However, the role of DUSP1 in the cells of the adaptive immune system has not been fully 
elucidated in the current literature. Induction of CIA, like most other experimental arthritis 
models, is dependent on the activation of both innate and adaptive immune responses. The role 
of T cells and B cells in the progression of CIA in Dusp1-/- mice will be addressed in the next 
chapter. 
 
4.7.3 DUSP1 limits inflammatory osteolysis in experimental arthritis 
Enhanced inflammatory osteolysis in the joint is a major cause of debilitation in RA and can lead 
to osteitis. Inflammatory osteolysis is also a major cause of joint replacement or dental implant 
failure. In order to treat this effectively, it is vital to understand the mechanisms through which 
OCLs differentiate from precursor cells and resorb bone. In vitro data described in the previous 
chapter showed enhanced OCL formation of bone marrow precursor cells from Dusp1-/- mice in 
the presence of M-CSF, RANKL and TNF (Figure 3.12) it also enhanced OCL resorptive 
activity on dentine surfaces (Figure 3.13). 
Increased TNF levels in CIA are known to promote OCL formation and bone destruction in 
arthritic joints (Redlich et al, 2002; Zwerina et al, 2007). Furthermore, treatment of arthritic mice 
with anti-TNF effectively reduces bone and cartilage damage (Saidenberg-Kermanac'h et al, 
2004). It is known that TNF-induced signalling via TNF receptor 1 activates the MAPK and 
NFκB pathways leading to the expression of genes associated with OCL activity. Furthermore, 
p38 MAPK activation has been reported in arthritic joints of mice and an increased activation of 
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p38 MAPK in CD44 deficient mice lead to more severe bone destruction (Hayer et al, 2005). 
Engagement of the CD44 surface molecules by LPS or TNF is known to activate the JNK and 
p38 MAPK signalling pathways in monocytes but also upregulates DUSP1 in OCLs (Gee et al, 
2002; Hayer et al, 2005). Like in CD44 deficient mice DUSP1 deficient OCLs show increased 
p38 MAPK activation (Carlson et al, 2009). 
Furthermore, DUSP1 deficient mice challenged with LPS in vivo also showed increased OCL 
activity (Carlson et al, 2009; Yu et al, 2011). Results presented here show Dusp1-/- mice with CIA 
have increased OCL activity (Figure 4.5) and excessive bone erosions in arthritic joints (Figure 
4.6). The data presented in this thesis showed enhanced OCL activity in DUSP1 deficient cells in 
the presence of TNF in vitro and increased OCL formation and bone erosions in arthritic Dusp1-/- 
mice in vivo, further confirming a crucial role of DUSP1 in limiting inflammatory bone 
resorption. Together with previous findings of overexpression of pro-inflammatory cytokines by 
DUSP1 deficient macrophages (Abraham et al, 2006; Hammer et al, 2005; Salojin et al, 2006), 
these data suggest enhanced sensitivity and hyperactivation of DUSP1 deficient OCLs in the 
context of inflammatory responses (Figure 4.11). However, in order to test this hypothesis in vivo 
you would need to restrict the deletion of Dusp1 to OCLs. Whether human DUSP1 in OCLs has 
a similar role to its murine counterpart still needs to be investigated. Differences in DUSP1 
expression might contribute to bone erosions in RA and other chronic inflammatory diseases, 
whilst sustaining DUSP1 expression might effectively reduce bone erosions. Studies in RA 
patients would be necessary to address these questions. 
Chapter Four DUSP1 limits osteolysis and mediates therapeutic effects of dexamethasone in CIA
 
125 
 
Figure 4.11 Enhanced osteoclast activation in arthritic joints of DUSP1 deficient mice 
In arthritic joints synovial fibroblasts express increased levels of M-CSF and RANKL and TNF is 
produced by immune cells including macrophages. Enhanced p38 MAPK activation in DUSP1 deficient 
macrophages leads to increased expression of TNF. Subsequently TNF activate the p38 MAPK pathway 
in osteoclasts, which is prolonged in DUSP1 deficient cells. M-CSF and RANKL produced by the 
synovial fibroblasts acts together with increased levels of TNF prolonging the activation of p38 MAPK in 
osteoclasts leading to increased activity and resorption in arthritic Dusp1-/- mice. 
 
4.7.4 Therapeutic effects of dexamethasone in CIA are partly dependent on 
DUSP1 
Endogenous and synthetic GCs limit and resolve inflammatory processes by inhibiting the 
synthesis of pro-inflammatory cytokines (Rhen & Cidlowski, 2005). GC-mediated activation of 
DUSP1 has been shown to contribute to its anti-inflammatory effects (Clark, 2007; Furst et al, 
2008; Quante et al, 2008) and GC treatment of Dusp1-/- mice challenged with LPS showed 
impaired suppression of pro-inflammatory cytokines TNF, COX2 and IL-1α (Abraham et al, 
2006). The treatment of CIA in mice with dexamethasone has been shown to effectively reduce 
signs of joint inflammation in DBA and C57BL/6 mice (Inglis et al, 2007; Kang et al, 2000). 
Treatment with dexamethasone 0.5mg/kg/every second day effectively reduced clinical score by 
43% and paw swelling by 25% in Dusp1+/+ mice compared to vehicle treated mice (Figure 4.3a, 
Figure 4.4a). However, dexamethasone-mediated reduction in joint inflammatory did not 
significantly reduce bone erosions and bone loss. At this dosage the GC-induced effect was 
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significantly reduced in Dusp1-/- mice (17% reduction of clinical score and 11% reduction in paw 
diameter) (Figure 4.3b, Figure 4.4b). This data further indicates an important role of DUSP1 in 
mediating anti-inflammatory effects of GCs. However, daily treatment of CIA with 
dexamethasone not only further decreased clinical score and paw swelling in Dusp1+/+ mice 
(Figure 4.10a), but also effectively reduced disease progression in Dusp1-/- mice (Figure 4.10b). 
This would suggest that DUSP1 regulated inactivation of the MAPKs is not the only mechanism 
involved in GC-mediated anti-inflammatory effects. 
GC-mediated anti-inflammatory effects were reported to be largely independent of DUSP1 in 
mast cells. DUSP1 deficient mast cells displayed enhanced degranulation but this was down-
regulated by GCs (Maier et al, 2007) suggesting that DUSP1 activation by GCs is not an 
exclusive anti-inflammatory mechanism employed by GCs and that anti-inflammatory actions of 
GCs are cell type dependent (i.e. different mechanisms are employed in different cell types). GCs 
have also been shown to up-regulate the expression of GC-induced leucine zipper protein 
(GILZ). GILZ activation leads to inactivation of multiple signalling pathways involved in the 
expression of pro-inflammatory genes, most prominently the NFκB and AP-1 signalling but also 
PI3K-Akt and ERK pathway (Beaulieu & Morand, 2011). Furthermore, GCs up-regulate GILZ 
in synovial cells in CIA and can function as an endogenous inhibitor of inflammation (Beaulieu 
et al, 2010). The role of GC-induced DUSP1 activity is well described in macrophages but still 
needs to be investigated in other cell types involved in the pathogenesis of CIA, like T cells, B 
cells and DCs which are crucial for the activation of adaptive immune responses. 
 
In conclusion, the results discussed in this chapter demonstrate a regulatory role of DUSP1 in 
both susceptibility and inflammation in CIA and is particularly crucial in limiting inflammatory 
bone resorption by OCLs in arthritic joints. Furthermore, therapeutic responses of GC in CIA 
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are partly mediated by DUSP1. However, the exact mechanisms involved in GC-mediated 
therapeutic responses in inflammatory or chronic arthritis still remain poorly understood and will 
be investigated further in the next chapter. 
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5 The role of  DUSP1 in adaptive immune responses in 
CIA 
5.1 Introduction 
Mice deficient in DUSP1 showed an enhanced sensitivity to CIA, increased cellular infiltrates 
and dramatic osteolytic bone loss in affected joints suggesting that there is enhanced OCL 
activity. The role of DUSP1 in cells of the innate immune system, like macrophages and mast 
cells, is well described (Abraham & Clark, 2006; Chen et al, 2002; Kassel et al, 2001; Salojin & 
Oravecz, 2007; Salojin et al, 2006; Wang & Liu, 2007). There is increasing evidence that cells of 
the adaptive immune response are involved in bone regulation however, the role of DUSP1 in 
the adaptive immune system is incompletely defined. In RA and CIA both the innate and 
adaptive immune responses play a crucial role in disease presentation and progression. The 
inflamed synovium in inflammatory or chronic arthritis is infiltrated by innate and adaptive 
immune cells. Neutrophils, monocytes, macrophages and DCs modulate and activate the 
responses of the different subsets of T and B cells. DCs are found in high numbers in both RA 
synovial fluid and tissue. They are of particular importance as they form the fundamental link 
between the innate and adaptive immune response (Iwasaki & Medzhitov, 2010). In general, 
when DCs in peripheral tissue become activated, they upregulate MHC and co-stimulatory 
molecules and then migrate to the regional lymph nodes where they present peptide:MHC class I 
to naïve CD8+ T cells and peptide:MHC class II complexes to naïve CD4+ T cells. In addition, 
DCs form close contacts with T and B cells in ectopic lymphoid organs in synovial tissue of RA 
patients and can modulate antigen-driven B and T cell responses (Corsiero et al, 2012; Weyand & 
Goronzy, 2003). 
Importantly, during the interaction between DCs and naïve CD4+ T cells in the regional lymph 
nodes, CD4+ Th cells are educated to become Th1, Th2, Th17 or Treg cells (Banchereau & 
Steinman, 1998; Glimcher & Murphy, 2000; Joffre et al, 2009). In general, IL-12 promotes Th1 
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cell differentiation, IL-4 promotes Th2 cells, IL-6 in the presence of TGFβ induces Th17 cell 
differentiation and TGFβ alone stimulates Treg differentiation. In addition, IL-23 is necessary 
for proliferation and maturation of Th17 cells (Mangan et al, 2006; Veldhoen et al, 2006; Weaver 
& Murphy, 2007). After activation in the lymph nodes, CD4+ T cells up-regulate selectin ligand 
molecules and chemokine receptors and migrate back along a chemokine gradient into the 
inflamed tissue (Suzuki et al, 1999; Xie et al, 1999). In the synovial tissue, Th cell effector 
functions then play a crucial role in promoting effector functions of other important cell types 
known to play pathogenic role in RA for example macrophages, OCLs, fibroblasts and B cells.  
Secretion of IFNγ from activated Th1 cells stimulates macrophages to produce IL-1, IL-6 and 
TNF. IL-17 secreted from Th17 cells promotes OCL formation as well as activation of synovial 
fibroblasts in the arthritic joint (Lubberts et al, 2003; Pollinger et al, 2011). Th1 cells also 
promote the differentiation of B cells into antibody secreting plasma cells by expressing CD40 
ligand and secreting IFNγ (Snapper & Paul, 1987). Through the secretion of B cell activating 
factor (BAFF), Th1 cells (but also DCs) further support plasma cell proliferation (Huard et al, 
2004). 
All three major MAPKs play a role in T cell activation and proliferation (Dong et al, 2002; 
Salvador et al, 2005). However, whether DUSP1 activity affects T and B cell effector functions in 
inflammatory disease such as RA/CIA is not clear (Liu et al, 2007). The aim of this chapter was 
to addresses the role of DUSP1 in B and T cell responses in CIA. 
 
5.2 Distribution of  CD4+ and CD8+ lymph node cells is not 
affected by DUSP1 deficiency in naïve mice 
Progenitor cells from the bone marrow or foetal liver give rise to T cells by entering the thymus 
and developing into mature naïve T cells. Selection processes (positive, negative selection, central 
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tolerance) in the thymus give rise to a self-tolerant population of CD4+ and CD8+ cells, which 
express specific chemokine receptors through which the mature cells are attracted back into the 
circulation and exit the thymus via the perivascular space (Anderson & Takahama, 2012; 
Matloubian et al, 2004; Takahama, 2006). Naïve T cells then enter the secondary lymphoid 
tissues via high endothelial venules.  
DUSP1 is the most prominent phosphatase expressed in the murine thymus and is highly 
expressed in developing CD4-CD8- and CD4+ thymocytes (Mustelin et al, 2004; Tanzola & 
Kersh, 2006). Despite this, the ratio of both CD4-CD8- thymocytes and single-positive CD4+ or 
CD8+ T cells in the thymus are not affected in the DUSP1 deficient mouse. In addition, there are 
no differences in single-positive CD4+ or CD8+ T cell distribution in the spleen. It was 
speculated the absence of DUSP1 activity is compensated by other MAPK phosphatases in 
developing CD4-CD8- cells (Zhang et al, 2009). However, before investigating the role of 
DUSP1 in the adaptive immune response in arthritic Dusp1+/+ and Dusp1-/- mice, it was first 
important to confirm that the distribution of mature single positive CD4+ and CD8+ populations 
present in the lymph nodes were not altered in naïve Dusp1-/- mice. As such, the ratios of mature 
CD4+ and CD8+ T cells in the inguinal lymph nodes were determined by flow cytometry. In 
naïve Dusp1+/+ and Dusp1-/- mice there was no discernible difference in the distribution of CD4+ 
Th cells and CD8+ cytotoxic T cells in the lymph nodes (Figure 5.1) indicating that DUSP1 
activity is not required for CD4+ or CD8+ lineage commitment and generation of mature CD4+ 
and CD8+ peripheral T cells or their ability to populate regional lymph nodes. 
Chapter Five The role of DUSP1 in adaptive immune responses in CIA
 
132 
 
Figure 5.1 Similar CD4+ and CD8+ T cell distribution in naïve Dusp1+/+ and Dusp1-/- mice 
Cells of inguinal lymph nodes of male naïve Dusp1+/+ and Dusp1-/- aged 12-15 weeks were analysed by 
flow cytometry for the expression of CD4 and CD8. Graphs represent mean frequency of cells as 
percentage of the whole lymph node cell population ± SEM of 3 individual mice per group. Statistical 
analysis was performed using ANOVA following Bonferroni post hoc test (n.s. not significant). 
 
5.3 Normal proliferation of  Dusp1-/- lymph node cells  
Following activation of naïve T cells expression of JNK mRNA and subsequently protein levels 
are increased and implicated in T cell differentiation (Dong et al, 2000). DUSP1 has been 
implicated in the regulation of JNK signalling during T cell activation (Zhang et al, 2009). To test 
whether the proliferative ability of lymph node cells was affected in Dusp1-/- mice, cells were 
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analysed for in vitro proliferation in response to polyclonal stimulation with anti-CD3. In 
response to anti-CD3 stimulation, lymph node cells from Dusp1-/- mice proliferated to a similar 
degree to cells from Dusp1+/+ mice (Figure 5.2). Together with the previous result which showed 
DUSP1 activity to be dispensable for normal distribution of CD4+ and CD8+ T cells in 
peripheral lymphoid organs, the data thus far suggest the function of lymph node cells from 
naïve Dusp1-/- mice has not been affected. Next the role of DUSP1 in lymph node cells of 
arthritic mice will be investigated. 
 
Figure 5.2 Normal in vitro proliferation of lymph node cells of naïve Dusp1+/+ and Dusp1-/- mice 
Cells from the inguinal lymph nodes of male naïve Dusp1+/+ and Dusp1-/- aged 12-15 weeks were 
stimulated with anti-CD3. Incorporated thymidine (3H-TdR) is expressed as counts per minute (cpm). 
Graphs show mean ± SEM of 5 independent experiments per group. Statistical analysis was performed 
using ANOVA following Bonferroni post hoc test (n.s. not significant) 
 
5.4 The ratio of  CD4+ to CD8+ T cells did not differ between 
arthritic Dusp1+/+ and Dusp1-/- mice 
Naïve T cells differentiate into either CD4+ Th cells or CD8+ cytotoxic T cells in the thymus 
after interaction with MHC molecules on thymic epithelial cells or other APCs as part of T cell 
selection and development. Both CD4+ and CD8+ T cells are present in the arthritic joint. 
However, CD4 T cells, particularly Th1 and Th17 cells have been shown to play a major role in 
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the adaptive immune response in both RA and CIA.  Although it should be noted that in murine 
arthritis models the presence of IL-17 secreting CD4- γδT cells also contributes to the disease 
phenotype (Pollinger et al, 2011). Previous results showed that the distribution of CD4+ and 
CD8+ T cell populations did not differ between naïve Dusp1+/+ and Dusp1-/- mice. In order to 
confirm whether the CD4+ and CD8+ T cell distribution differed in arthritic Dusp1+/+ and Dusp1-
/- mice, their distribution in draining lymph nodes 10 days after the onset of CIA was assessed. 
Mice were treated with dexamethasone to reduce inflammation or PBS as a control every second 
day after disease onset. 
There were no significant differences between arthritic Dusp1+/+ and Dusp1-/- mice in the 
distribution of CD4+ and CD8+ T cells in the lymph nodes. Additionally, dexamethasone 
treatment of these mice did not alter the ratio of CD4+ and CD8+ T cells in the draining lymph 
nodes (Figure 5.3). 
 
Figure 5.3 Lymph node cells of arthritic Dusp1-/- mice show no differences in T cell distribution 
compared to lymph node cells of arthritic Dusp1+/+ mice 
Cells of draining lymph nodes of male arthritic Dusp1+/+ and Dusp1-/- mice treated either with PBS or 
dexamethasone every other day (Dex) were analysed by flow cytometry for the expression of CD4 and 
CD8. Graph represents mean frequency of cells as percentage of the whole lymph node cell population ± 
SEM of 10 individual mice in the PBS treated groups and 6 individual mice in the dexamethasone treated 
groups. Statistical analysis was performed using ANOVA (n.s. not significant). 
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5.5 In vitro proliferation is decreased in arthritic Dusp1+/+ lymph 
node cells but not in cells from Dusp1-/- mice following GC 
treatment 
As previously mentioned, due to their anti-inflammatory effects, GCs are frequently used as a 
treatment in RA and other chronic inflammatory diseases (Townsend & Saag, 2004). DUSP1 has 
been shown to be integrally involved in the response of innate cells to GC treatment by 
inactivating MAPKs (Abraham et al, 2006), however the role of DUSP1 in the response of cells 
of the adaptive immune response to GC treatment has not been investigated. Having shown the 
distribution of CD4+ and CD8+ T cells and the proliferative response of lymph node cells were 
not affected by DUSP1 deficiency in naïve Dusp1+/+ and Dusp1-/- mice, next it was investigated 
whether the proliferative response of lymph node cells during CIA was affected and whether 
DUSP1 deficiency affected the proliferative response of lymph node cells taken from arthritic 
mice treated with GC. Mice were treated every second day with PBS or dexamethasone. 10 days 
after disease onset mice were sacrificed and the proliferation of cells from draining lymph nodes 
to the affected paws was assessed in response to both antigenic (chicken collagen type II) and 
polyclonal (anti-CD3) stimulation. 
Lymph node cells from arthritic mice proliferated in response to both antigenic (chicken collagen 
type II stimulation) and polyclonal (anti-CD3) stimulation in both genotypes (Figure 5.4). No 
significant difference in the proliferative response to antigenic or polyclonal stimulation was 
evident between arthritic Dusp1+/+ and Dusp1-/- mice. However, dexamethasone treatment of 
arthritic Dusp1+/+ mice lead to a significantly reduced proliferation of lymph node cells in 
response to antigenic but not polyclonal stimulation. The same trend was observed in Dusp1-/- 
mice however, this did not reach statistical significance. 
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Figure 5.4 Dexamethasone treatment inhibits collagen-induced proliferation of Dusp1+/+ but not 
Dusp1-/- lymph node cells 
Cells of draining lymph nodes of arthritic Dusp1+/+ and Dusp1-/- treated with either PBS or 
dexamethasone every other day (Dex) were isolated 10 days after disease onset and stimulated with 
chicken collagen type II (cCII) or anti-CD3. Incorporated thymidine (3H-TdR) is expressed as counts per 
minute (cpm). Graphs show mean ± SEM of lymph node cells of 5 to 15 individual mice per group. 
Statistical analysis was performed using ANOVA following Bonferroni post hoc test (*p<0.05; n.s. not 
significant) 
 
5.6 Reduced IFNγ expression in arthritic Dusp1-/- mice 
IFNγ is the prototypical Th1 cytokine but is also expressed by other cells including CD8+ 
cytotoxic T cells, NKT cells and NK cells (Frucht et al, 2001; Glimcher et al, 2004; Stetson et al, 
2003). IFNγ plays an important role in the maturation and activation of APCs, and together with 
IL-12, it promotes Th1 cell differentiation via a positive feedback loop (Bradley et al, 1996). In 
RA patients, IFNγ is found at low levels in the synovium and the synovial fluid (Firestein & 
Zvaifler, 1987; Simon et al, 1994). However, observations in IFNγ and IFNγ-receptor deficient 
mice suggest it has a protective role in CIA (Chu et al, 2003; Manoury-Schwartz et al, 1997; 
Vermeire et al, 1997). 
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GCs are known to supress T cell activation via inhibiting the expression of MHC class II and co-
stimulatory molecules, and also by altering cytokine expression from DCs (Matyszak, M.K. 
2000). Furthermore, interactions between activated GR and the Th1 cell transcription factor T-
bet, result in the inhibition of Th1 cell specific cytokine production, including IFNγ 
(Franchimont, D. 2000; Liberman, A.D. 2007). A role for DUSP1 in determining Th1 cell 
proliferation via IL-12 expression from DCs has also been reported (Huang et al, 2011). To 
determine whether the ability of lymph node cells to produce IFN  was influenced by DUSP1, 
cells of draining lymph nodes from arthritic Dusp1+/+ and Dusp1-/- mice treated with 
dexamethasone (or PBS control) were assessed. During on-going immune responses, further 
antigenic stimulation of T cells can induce anergy. In case of this, a polyclonal stimulus was used 
in addition to the antigenic stimulation. Figure 5.5 shows lymph node cells from both arthritic 
Dusp1+/+ and Dusp1-/- mice in both PBS and dexamethasone treated animals are capable of 
producing IFN . No significant differences between the groups were detected. 
 
Figure 5.5 Similar IFNγ expression from draining lymph node cells of arthritic Dusp1+/+ and 
Dusp1-/- mice 
Cells of draining lymph nodes of male arthritic Dusp1+/+ and Dusp1-/- mice treated either with PBS or 
dexamethasone every other day (Dex) were isolated 10 days after disease onset and stimulated with 
chicken collagen type II (cCII) (a) or anti-CD3 (b). Supernatant was collected after 48 hours of 
stimulation and analysed for IL-17 expression by ELISA. Graphs show mean expression ± SEM of 4 
individuals per group. Statistical analysis was performed using one-way ANOVA and bonferroni post hoc 
test (n.s. not significant). 
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Having shown Dusp1-/- lymph node cells retained the ability to produce IFN  I then wanted to 
test whether the increased disease severity observed in Dusp1-/- mice was reflected in a change in 
serum IFNγ levels and whether dexamethasone had any effects in suppressing these. As such, 
serum IFNγ levels were measured using a Meso Scale Discovery (MSD) multi-array assay. MSD 
assays are highly sensitive and have a wide detection range. The detection rage for IFNγ was 
from 2pg/ml to 10ng/ml. Serum from arthritic Dusp1+/+ and Dusp1-/- mice treated with PBS or 
dexamethasone was taken 10 days after disease onset. As IFNγ is produced by activated immune 
cells during inflammatory processes, unsurprisingly, IFNγ was not detected in the serum of naïve 
Dusp1+/+ and Dusp1-/- mice. In contrast, IFNγ was detected in arthritic mice of both genotypes 
regardless of dexamethasone treatment (Figure 5.6). Arthritic Dusp1+/+ mice treated with PBS 
had the highest levels of IFNγ in the serum. This was significantly reduced in dexamethasone 
treated Dusp1+/+ mice. Furthermore, serum levels of IFNγ in arthritic Dusp1-/- mice treated with 
PBS were significantly lower compared to arthritic Dusp1+/+ mice. Unlike in Dusp1+/+ mice, 
dexamethasone treatment had no significant effect on serum IFNγ levels in Dusp1-/- mice. 
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Figure 5.6 Dexamethasone treatment reduces serum IFNγ levels in arthritic Dusp1+/+ but not 
Dusp1-/- mice 
Serum of male arthritic Dusp1+/+ and Dusp1-/- mice treated either with PBS or dexamethasone every other 
day (Dex) was taken 10 days after disease onset and tested for IFNγ. Graphs show mean ±SEM of 6 
samples per group. Statistical analysis was performed using ANOVA (**p<0.005; n.s. not significant). 
 
5.7 B cell responses in arthritic mice 
Following activation and co-stimulation, primarily via CD40 ligation by CD40L on the surface of 
Th cells, naïve B cells, which preferentially express IgM antibodies, undergo antibody class 
switching leading to production of a single specific Ig isotype (IgG, IgE or IgA antibodies). IFNγ 
produced by Th1 cells is known to stimulate B cell activation and production of IgG2a 
antibodies in mice, while IL-4 and IL-5 secreted by Th2 cells promote the synthesis of IgG1 or 
IgE antibodies, and TGFβ secreted by T reg cells has been shown to promote IgG2b or IgA 
(Bacharier & Geha, 2000; McIntyre et al, 1993; Snapper & Paul, 1987). Humoral responses play 
an important role in the pathogenesis of RA. RA patients have an increased frequency of naïve B 
cells bearing autoreactive B cell receptors (BCRs) (Bosello et al, 2008). These individuals have 
detectable levels of autoantibodies including anti-CCP, RF, and anti-collagen in both serum and 
affected joints. The presence of autoantibodies in these individuals correlates with disease 
severity (Aletaha et al, 2010; Mewar & Wilson, 2006; Rantapaa-Dahlqvist et al, 2003). Further 
evidence implicating B cells in disease pathogenesis come from murine studies that have 
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depleted CD20+ B cells. These studies show that B cell depletion at the time of immunisation 
delays the onset of CIA and reduces collagen-specific antibody production (Yanaba et al, 2007). 
To investigate whether DUSP1 deficiency or dexamethasone treatment of arthritic mice had an 
effect on collagen-specific antibody production, serum antibody levels were measured 10 days 
after disease onset. 
As expected, collagen-specific IgG2a levels were higher than collagen-specific IgG1 levels in 
Dusp1+/+ mice (Figure 5.7), since Th1 responses are higher than Th2 responses in CIA. 
Interestingly, despite increased disease severity in Dusp1-/- mice, levels of collagen-specific IgG2a 
were markedly decreased. Further, dexamethasone treatment did not significantly alter antibody 
production in either Dusp1+/+ or Dusp1-/- mice. 
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Figure 5.7 Collagen specific IgG2a is reduced in serum of arthritic Dusp1-/- mice compared to 
arthritic Dusp1+/+ mice 
Serum of male arthritic Dusp1+/+ and Dusp1-/- mice treated either with PBS or dexamethasone every other 
day (Dex) or every day (Dex e.d.) was collected 10 days after disease onset and analysed for collagen 
specific IgG1 and IgG2a antibodies by ELISA. Serial dilutions of serum IgG1 (a) and serum IgG2a (b). 
Values are shown as OD relative to positive control serum of PBS treated Dusp1+/+ arthritic mice ±SEM 
of 5 to 9 serum samples per group (c). Antibody concentrations for each serum sample were obtained by 
reference to the standard curve. Statistical analysis was performed using ANOVA and Bonferroni post hoc 
test (*p<0.05, **p<0.005; n.s. not significant) 
 
5.8 Increased IL-17 expression in lymph node cells of  arthritic 
Dusp1-/- mice 
In contrast to IFNγ, the role of IL-17 secreted by Th17 cells in CIA has been reported to 
enhance cell infiltration into the affected joints and to promote pannus formation. In CIA IL-17 
has been shown to be secreted by both Th17 and γδT cells (Takahama, 2006). However, it 
Chapter Five The role of DUSP1 in adaptive immune responses in CIA
 
142 
should be noted that production of IL-17 by γδT cells has not been reported in RA (Ito et al, 
2009). In both RA and CIA, IL-17 production by Th17 cells is believed to drive the observed 
osteoclastic bone erosions (Pollinger et al, 2011). To investigate whether DUSP1 plays a role in 
IL-17 production from CD4 T cells, the production of IL-17 by lymph node cells of arthritic 
Dusp1+/+ and Dusp1-/- mice was determined by flow cytometry 10 days after disease onset. 
Compared to PBS treated arthritic Dusp1+/+mice, both PBS treated and dexamethasone treated 
Dusp1-/- mice showed a two-fold increase in the percentage of CD4+IL-17+ cells in the draining 
lymph nodes (Figure 5.8a, b). Dexamethasone treatment in both Dusp1+/+ and Dusp1-/- mice did 
not alter the percentage of CD4+IL-17+ cells significantly (Figure 5.8b). Interestingly, a 
proportion of CD4- cells, most likely γδT cells, also expressed IL-17 (Figure 5.8c). However, the 
role of IL-17 production by γδ T cells was not further investigated in this present study and still 
needs to be confirmed. 
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Figure 5.8 Increased intracellular IL-17 expression in lymph node cells of arthritic Dusp1-/- mice 
compared to arthritic Dusp1+/+ mice 
Cells of draining lymph nodes of male arthritic Dusp1+/+ and Dusp1-/- mice treated either with PBS or 
dexamethasone every other day (Dex e.o.d.) were analysed by flow cytometry for the expression of CD4, 
and intracellular IL-17 (a). Frequency of CD4+IL-17+ cells is shown as percentage of the whole lymph 
node cell population (b). Frequency of CD4-IL-17+ cells is shown as percentage of the whole lymph node 
cell population (c). Graphs represent mean ± SEM of 6 mice per group. Statistical analysis was performed 
using ANOVA and Bonferroni post hoc test (**p<0.005; n.s. not significant) 
 
Significantly increased IL-17 production was also observed following in vitro stimulation of 
lymph nodes cells (Figure 5.9). This was not affected by dexamethasone treatment in either 
Dusp1+/+ and Dusp1-/- cells. Having shown LN cells were capable of producing IL-17 in vitro, I 
next wanted to determine whether the levels of IL-17 production were altered in vivo. To address 
this, serum levels of IL-17 were measured 10 days after disease onset in both Dusp1+/+ and 
Dusp1-/- mice with and without dexamethasone treatment. Unfortunately at this time point IL-17 
was below the level of detection. 
In conclusion, IL-17 production from draining lymph node cells was enhanced in arthritic Dusp1-
/- mice, indicating a partial role for DUSP1. However, whether DUSP1 has a direct or indirect 
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effect on IL-17 production by Th cells and the contribution of other cells such as γδT cells to 
the overall IL-17 response has yet to be investigated. 
 
Figure 5.9 Increased IL-17 production from draining lymph node cells of arthritic Dusp1-/- mice 
compared to Dusp1+/+ mice 
Cells of draining lymph nodes of male arthritic Dusp1+/+ and Dusp1-/- mice treated either with PBS or 
dexamethasone every other day (Dex) were isolated 10 days after disease onset and stimulated with 
chicken collagen type II (cCII) (a) or anti-CD3 (b). Supernatant was collected after 48 hours of 
stimulation and analysed for IL-17 expression by ELISA. Graphs show mean expression ± SEM of 7 
individuals in PBS treated groups and 4 individual mice in dexamethasone treated groups. Statistical 
analysis was performed using one-way ANOVA and Bonferroni post hoc test (**p<0.005, ***p<0.001; n.s. 
not significant) 
 
5.9 Dexamethasone treatment increased serum IL-12p40 levels 
Activation of Th cell responses by APCs requires three different signals, namely recognition of 
the MHC:peptide complex by TCRs (signal 1), co-stimulation via CD80/86 and CD28 (signal 2), 
and expression of cytokines (signal 3). Full activation leads to effector T cell polarization and 
proliferation. IL-12 (IL-12p70) secreted by APCs promotes the development of naïve CD4 T 
cells into Th1 cells and also stimulates IFNγ production by differentiated Th1 cells (Scott, 1993; 
Seder et al, 1993). IL-12p70 is a heterodimer made up of the IL-12p35 and IL-12p40 subunit, 
which are encoded by two different genes (Gubler et al, 1991). However both these subunits can 
heterodimerise with other subunits for example, IL-12p40 can dimerise with the IL-12p19 
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subunit to make up IL-23 (Lupardus & Garcia, 2008). It should also be noted that IL-12p40 can 
form homodimers, capable of binding to the IL-12 receptor and functioning as an IL-12 
antagonist (Gillessen et al, 1995; Heinzel et al, 1997). In CIA, IL-12p70 deficiency has been 
shown to reduce incidence and disease severity(Joosten et al, 1997). Interestingly however, 
depletion of the IL-12p35 subunit leads to exacerbated disease, while IL-23 deficiency protects 
from joint damage. Together these studies suggest the predominant role of IL-12p40 in CIA is to 
function as part of the IL-23 complex (Murphy et al, 2003). A major function of IL-23 is to 
enhance Th17 cell proliferation and cytokine production, which includes RANKL as well as IL-
17 (Ju et al, 2008; Stritesky et al, 2008; Yago et al, 2007). A role of DUSP1 in mediating 
dexamethasone induced reduction of IL-12p40 has been reported in macrophages stimulated 
with LPS in vitro (Hammer et al, 2005). To test whether GC reduced IL-12p40 in vivo serum taken 
from arthritic Dusp1-/- and Dusp1+/+ mice treated either with PBS or dexamethasone 10 days after 
disease onset were assessed for IL-12p40 production. IL-12p40 was detected in both the serum 
of naïve and arthritic Dusp1-/- and Dusp1+/+ mice (Figure 5.10). Interestingly, dexamethasone 
treatment of arthritic mice significantly increased IL-12p40 levels in both Dusp1-/- and Dusp1+/+ 
mice. Further investigation of cytokines expressed by DCs needs to be done as IL-12p40 levels 
could be indicative of both IL-12p70 as well as IL-23 and therefore either support Th1 or Th17 
differentiation and proliferation. 
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Figure 5.10 Increased serum IL-12p40 levels in dexamethasone treated mice 
Serum from male naïve or arthritic Dusp1+/+ and Dusp1-/- mice treated either with PBS or dexamethasone 
(Dex) was taken 10 days after disease onset and tested for IL-12p40. Graphs show mean ±SEM of 6 
serum samples per group. Statistical analysis was performed using ANOVA and Bonferroni post hoc test 
(**p<0.005) 
 
5.10 Cytokine expression by DUSP1 deficient dendritic cells 
In general, the role of DCs as APCs is crucial for the activation of adaptive immune responses. 
As mentioned upon TLR stimulation, DCs secrete IL-6, IL-12 and IL-23 amongst other 
cytokines and determine Th effector function. IL-12 promotes the differentiation of naïve T cells 
into Th1 cells, while IL-6 and IL-23 in presence of TGFβ favour the differentiation and 
proliferation of Th17 cells. A recent report highlighted the important role of p38α MAPK 
activation in DC in Th17 differentiation (Huang et al, 2012). Activated DCs deficient of p38α 
MAPK showed a diminished ability to induce Th17 differentiation and following curdlan (an 
agonist of the PRR dectin-1) stimulation in vivo, antigen specific T cells from mice with p38α 
deficient DCs had reduced expression of IL-17 a and f, IL-21, IL-22 and IL-23 receptor. 
Furthermore, IL-6 expression of activated DCs deficient of p38α was reduced. 
Serum levels of IL-12p40 indicated increased expression following dexamethasone treatment in 
vivo, to test whether DUSP1 affects cytokine patterns in DCs in vitro, bone marrow cells of 10-12 
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week old Dusp1+/+ and Dusp1-/- mice were isolated from femur and tibiae and cultured in the 
presence of GM-CSF for seven days to differentiate into DCs. Cells were collected and 
stimulated with 100ng/ml LPS with or without 100nM dexamethasone. Supernatant was taken at 
different time points and assessed for IL-6 and IL-23 by ELISA. Following LPS stimulation, IL-
23 production increased, peaking at 24hours post-stimulation. However, IL-23 production did 
not differ in Dusp1+/+ and Dusp1-/- DCs in the absence of dexamethasone (Figure 5.11). 
However, in the presence of dexamethasone, IL-23 production increased three-fold in Dusp1-/- 
DCsafter two hours of LPS stimulation and reached similar levels to untreated DCs after 24 
hours (Figure 5.11). 
 
Figure 5.11 Dexamethasone increases IL-23 in Dusp1-/- but not in Dusp1+/+ dendritic cells 
Bone marrow cells of Dusp1+/+ and Dusp1-/- mice aged 10-12 weeks were cultured in 20ng/ml GM-CSF 
and then stimulated with 10ng/ml LPS ± 100nM dexamethasone (Dex). IL-23 secretion in supernatant 
was measured by ELISA. Graphs represent mean ± SEM of 3 independent experiments. Statistical 
analysis was performed using ANOVA and Bonferroni post hoc test (**p<0.005) 
 
Activation of p38 MAPK, ERK and NFκB have been shown to play an important role in IL-6 
production by various cells including monocytes and macrophages (Craig et al, 2000; Leonard et 
al, 1999; Liu et al, 2003; Son et al, 2008). To determine whether deficiency of DUSP1, as a 
negative regulator of p38 MAPK, affects IL-6 production in DCs, supernatants of LPS-
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stimulated DCs were assayed for IL-6. IL-6 production was detectable in all cell supernatants 
after four hours of LPS stimulation peaking in both Dusp1+/+ and Dusp1-/- DCs 24 hours post-
stimulation. Dexamethasone treatment significantly reduced IL-6 levels in both Dusp1+/+ and 
Dusp1-/- DCs (Figure 5.12a). However, the induced inhibition was stronger in Dusp1+/+ (65%) 
than in Dusp1-/- DCs (54%) at 8 hours (Figure 5.12c). 
 
Figure 5.12 Dexamethasone treatment strongly decreases IL-6 secretion in Dusp1+/+ dendritic 
cells 
Bone marrow cells of Dusp1+/+ and Dusp1-/- mice aged 10-12 weeks were cultured in 20ng/ml GM-CSF 
and then stimulated with 10ng/ml LPS ± 100nM dexamethasone (Dex). The amount of IL-6 in 
supernatants was measured by ELISA. Graphs represent mean ± SEM of 3 independent experiments. 
Statistical analysis was performed using ANOVA and Bonferroni post hoc test (*p<0.05, **p<0.005) 
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5.11 Discussion 
Inflammation in CIA involves both the innate and adaptive immune responses. Immunisation of 
mice with CFA and heterologous collagen type II triggers activation and pro-inflammatory 
cytokine production by innate immune cells like neutrophils, monocytes, macrophages and DCs 
which subsequently activate T cell and B cell responses. Next to the NFκB signalling pathway 
activation of MAPK signalling in immune cells is the most important. As a negative regulator of 
the MAPK pathway, a role of DUSP1 in limiting innate immune responses has been reported 
(Abraham & Clark, 2006; Lang et al, 2006; Salojin & Oravecz, 2007). The aim of this chapter was 
to address whether DUSP1 also limits adaptive immune responses in CIA. 
 
5.11.1 DUSP1 is important in determining T helper subset responses in CIA 
Despite a reported increase of Dusp1 expression in the thymus and especially in developing 
CD4+CD8+ thymocytes and CD4+ T cells (Tanzola & Kersh, 2006) no differences were found in 
the frequency of CD4+ and CD8+ T cells in the lymph nodes of naïve and arthritic Dusp1-/- mice 
compared to Dusp1+/+ mice (Figure 5.1, Figure 5.3), indicating that a lack of DUSP1 does not 
affect the ability of CD4 or CD8 T cells to populate the regional lymph nodes. As the activity of 
10 different tyrosine phosphatases has been reported in murine thymus, several of which are 
important in T cell physiology, it is possible that in the absence of DUSP1 other phosphatases of 
MAPKs are able to regulate single positive CD4+ and CD8+ T cell development (Mustelin et al, 
2004; Tanzola & Kersh, 2006). For example, DUSP2, 4, 5, 6, 7, 10 have also been shown to 
regulate either ERK, JNK or p38 MAPK activation in the thymus. 
Activation of the MAPK pathway has been described to play a role in T cell proliferation and 
activation (Conze et al, 2000; Rincon et al, 2000). Furthermore, DUSP1 has been previously 
reported to regulate p38 MAPK activation during T cell proliferation (Zhang et al, 2009). 
Chapter Five The role of DUSP1 in adaptive immune responses in CIA
 
151 
However, lymph node cells from naïve Dusp1-/- mice proliferated to the same degree as lymph 
node cells from Dusp1+/+when stimulated with anti-CD3 (Figure 5.2), further indicating that the 
regulation of MAPKs in T cells is not exclusively dependent on DUSP1. However, these data are  
in contrast to another study that showed DUSP1 deficiency resulted in a reduction in 
proliferation of isolated CD4+ and CD8+ T cells following anti-CD3 and anti-CD28 stimulation 
(Zhang et al, 2009). One possible explanation for the observed difference is that non- T cells 
present in the lymph node cultures proliferated in a bystander manner in response to cytokines 
derived from stimulated T cells. As it is not possible to differentiate the proliferating populations 
using the current experimental set up, repeating the assay with isolated CD4 and CD8 T cells 
would enable a direct comparison between the current study and that of Zhang et al. to be made. 
Similarly to naïve mice, DUSP1 was shown to be dispensable for the proliferation of lymph node 
cells isolated from collagen-immunised mice in response to a polyclonal stimulus. Next the 
ability of LN cells to mount an antigen-specific response was investigated by stimulating lymph 
node cells isolated from collagen immunised mice with chicken collagen type II. These 
experiments also found DUSP1 was not required for mounting an antigen-specific T cell 
response (Figure 5.4). 
Upon stimulation with chicken collagen type II, lymph node cells isolated from Dusp1+/+ and 
Dusp1-/- collagen-immunised mice, secreted IFNγ and IL-17 (Figure 5.5, Figure 5.9) indicating 
cells from Dusp1-/- mice had retained the ability to produce cytokines upon stimulation. The 
production of IL-17 was significantly higher in lymph node cells from arthritic Dusp1-/- mice 
compared to Dusp1+/+ mice following both polyclonal and antigenic stimulation (Figure 5.8). IL-
17 has been shown to aid differentiation of OCLs in a COX-2 dependent manner (Kotake et al, 
1999). Further, IL-17 has been shown to increase expression of RANKL in the inflamed 
synovium resulting in increased OCL formation and bone erosions in murine inflammatory 
arthritis (Lubberts et al, 2003). These effects of IL-17 on OCL activation and its increased 
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production by Dusp1-/- lymph node cells might explain why osteolysis is enhanced in arthritic 
Dusp1-/- mice. In the present study, a small but significant increase in the percentage of CD4+IL-
17+ cells were found in the lymph nodes of arthritic Dusp1-/- compared with Dusp1+/+ mice 
(Figure 5.8), indicating enhanced potential for Th17 cell activation and a role of DUSP1 in 
restraining Th17 responses. This observation is in accordance with a recent report showing 
increased activation of Th17 cells by Dusp1-/- DCs (Huang et al, 2011). 
In the present study, IFNγ production by lymph node cell cultures from arthritic Dusp1-/- mice 
were reduced following both specific and polyclonal stimulation compared to arthritic Dusp1+/+ 
mice, although this did not reach statistical significance (Figure 5.5). However there was a 
significant decrease serum IFNγ levels from these mice (Figure 5.6). Together these results 
indicate a role of DUSP1 in regulating cytokine production. IFNγ has been shown to be 
protective in mouse models of RA as both IFNγ and IFNγ-receptor knockout mice show 
enhanced disease (Manoury-Schwartz et al, 1997; Vermeire et al, 1997). Similarly, Dusp1-/- mice 
have been shown to have reduced Th1 cell activity in CIA but display accelerated disease onset 
and increased disease severity (Vattakuzhi et al, 2012). Furthermore, IFNγ expressed by Th1 cells 
can inhibit Th17 differentiation via activation of STAT1 (Feng et al, 2008). Reduced IFNγ levels 
in arthritic Dusp1-/- mice might result in a reduced suppression of Th17 differentiation reflected 
in increased IL-17 expression in the draining lymph nodes of these mice. 
Furthermore, IFNγ expression from activated Th1 cells can trigger class-switch to IgG2a in 
activated B cells (Snapper & Paul, 1987). Anti-collagen IgG2a antibodies were significantly 
reduced in sera of arthritic Dusp1-/- mice (Figure 5.7). Regardless of dexamethasone treatment, 
arthritic Dusp1-/- mice displayed consistently reduced levels of collagen specific IgG2a compared 
to arthritic Dusp1+/+ mice. Furthermore, the disease limiting role of DUSP1 in CIA does not 
appear to restrain the humoral immune response to collagen immunisation but rather play a role 
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in triggering the production of high levels of collagen-specific IgG2a. This observation might 
indirectly suggest defective Th1 cell activation in DUSP1 deficient mice. Indeed, DUSP1 activity 
in DCs has recently been shown to induce IL-12 secretion and subsequent STAT4 activation in 
T cells leading to Th1 cell proliferation (Huang et al, 2011). Together these results highlight a 
role of DUSP1 in determining different Th cell responses. However, the role of DUSP1 in B 
cells remains poorly understood and needs to be addressed in future. DUSP1 does not seem to 
be absolutely essential for antigen-specific antibody production since levels of anti-collagen IgG1 
and IgG2a were detectable in arthritic Dusp1-/- mice, however, high expression of DUSP1 in 
naïve and memory B cells as well as in plasma cell has been reported (Jeffrey et al, 2007). 
Activation and proliferation of T helper cell subsets is strongly influenced by cytokine 
production by DCs. Activated DCs, up-regulate co-stimulatory molecules CD80, CD86, present 
peptide:MHC class II complexes and secrete cytokines.  IL-12 is known to promote Th1 cell 
differentiation, IL-4 promotes Th2 differentiation, IL-6 in the presence of TGFβ induces Th17 
cell differentiation In addition to differentiation DC-derived IL-23 plays an important role in the 
proliferation and maturation of Th17 cells (Joffre et al, 2009). Activation of p38α in DCs is the 
main driver of IL-6 production and is also important for Th17 cell activation (Huang et al, 2012). 
Furthermore, defective IL-12 production by DUSP1 deficient DCs has been reported and is 
consistent with defective Th1 expression described here in CIA (Huang et al, 2011). 
Serum IL-12p40 levels were not altered in arthritic Dusp1-/- mice compared to Dusp1+/+ mice 
(Figure 5.10). However, the IL-12p40 subunit is shared by IL-12 and IL-23. Further analyses of 
IL-12p70, IL-12p35, IL-23p19 levels are still required to confirm IL-12 and IL-23 expression in 
arthritic Dusp1-/- mice. IL-23 in CIA has been shown to promote disease development and IL-17 
expression, whereas deficiency of IL-23 is protective, highlighting the important role of IL-23 in 
determining adaptive immune responses (Murphy et al, 2003). In vitro IL-23 expression from 
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activated DCs showed no significant differences between cell deficient of DUSP1 and wild type 
cells (Figure 5.11). 
An increase in IL-6 production from DUSP1 deficient DCs compared to wild type cells in vitro 
following LPS stimulation was observed, however, this did not reach statistical significance 
(Figure 5.12). However, a role of DUSP1 in regulating IL-6 expression in macrophages, which 
share the same precursor cells as DCs, has been reported (Abraham et al, 2006; Hammer et al, 
2006; Joanny et al, 2012). A proposed role of DUSP1 deficiency in DCs on adaptive immune 
responses in CIA is shown in Figure 5.13. 
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Figure 5.13 Defective T helper cell activation in the absence of DUSP1 
Absence of DUSP1 in dendritic cells (DCs) leads to decreased activation of Th1 cells and therefore 
IgG2a production by plasma cells. Increased expression of IL-6 by DUSP1 deficient DCs promotes Th17 
activation and proliferation, which express high levels of IL-17, which in turn increases RANKL 
expression in the synovium and enhances osteoclast activity. Cytokines expressed by Th1 and Th17 cells 
are able to crossregulate proliferation of each other. 
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5.11.2 DUSP1 regulates dexamethasone induced suppression of IFNγ 
production in arthritic Dusp1+/+ mice and suppression of IL-6 by DCs 
GCs are still frequently used in the treatment of RA due to their potent anti-inflammatory 
properties. Treatment of arthritic mice with dexamethasone has been shown to effectively reduce 
signs of inflammation in C57BL/6 mice (Inglis et al, 2007). Lymph node cells from 
dexamethasone treated arthritic Dusp1+/+ mice showed reduced proliferation ex vivo compared to 
cells from PBS treated mice following antigenic-stimulation (Figure 5.4). This suggests the 
therapeutic effects of dexamethasone could be partially attributed to reduced activation of 
antigen-specific T cells. This reduction was not observed in cells from DUSP1 deficient mice 
treated with dexamethasone, hence it can be hypothesised that DUSP1 is involved in GC-
mediated suppression of the antigen-specific T cell responses after immunisation. This 
observation is in agreement with a recent study, which proposes the anti-inflammatory effects of 
GC therapy in antigen-induced arthritis (AIA) are mediated via T cells (Baschant et al, 2011). 
Baschant et al. demonstrated that dimerization of GRs is crucial for inhibiting Th1 and Th17 cell 
activation which results in immunosuppression in AIA. GC induced activation of GR and 
subsequently DUSP1 might drive therapeutic effects of dexamethasone in animal models of 
arthritis. Whether indeed GR dimerization in T cells, following dexamethasone treatment, 
activates Dusp1 expression and leads to reduced antigen-specific T cell activation could be 
further confirmed using mice with defective GR dimerization due to a point mutation in the 
DNA-binding motif (GRdim mouse) (Reichardt et al, 1998). As GC-induced expression of Dusp1 
is dependent on GR dimerization and transactivation, T cells of arthritic GRdim mice treated with 
GCs might show reduced DUSP1 activation resulting in abrogated or reduced ability of GC-
induced reduction of antigen-specific T cell activation. 
In addition to reduced lymph node cell proliferation, dexamethasone-induced reduction of 
serum IFNγ levels was observed in arthritic Dusp1+/+ mice (Figure 5.5). This might arise from 
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decreased proliferation or activation of Dusp1+/+ Th1 cells, CD8+ T cells, NK cells or 
macrophages, which are all activated in involved in the pathogenesis of CIA. A reduction in 
IFNγ serum levels was not observed in DUSP1 deficient mice treated with dexamethasone, 
hence it can be hypothesised that DUSP1 is involved in GC-mediated-reduction of IFNγ 
production after immunisation with chicken collagen type II. A recent study, suggests anti-
inflammatory effects of GC therapy in antigen-induced arthritis are mediated via reduced T cell 
activation and cytokine production (Baschant et al, 2011). However, it should be noted that 
serum IFNγ levels were found to be lower in arthritic Dusp1-/- regardless of dexamethasone 
treatment. 
Surprisingly dexamethasone treatment lead to an increase in serum IL-12p40 levels in arthritic 
Dusp1+/+ as well as Dusp1-/- mice (Figure 5.10). Previous reports have shown that dexamethasone 
decreased IL-12p40 gene transcription in activated monocytes and macrophages in vitro by 
downregulating JNK signalling (Ma et al, 2004). Whether IL-12p40 production by DCs is 
differentially affected by dexamethasone is yet to be investigated. It is possible that IL-12p40 
production by APCs may modulate Th cell responses; however, whether a dexamethasone 
induced increase in IL-12p40 expression promotes Th1 or Th17 responses requires further 
investigation. 
It was hypothesised that decreased IL-6 production by activated Dusp1+/+ DCs in vitro following 
dexamethasone treatment (Figure 5.12) would lead to a subsequent decrease in Th17 
development thereby contributing to the therapeutic effects of GCs in CIA. However, IL-17 
secretion from lymph node cells of Dusp1+/+ mice was not significantly reduced following 
dexamethasone treatment (Figure 5.8, Figure 5.9). Furthermore, slight reduction of IL-6 
secretion by Dusp1-/- DCs suggests activation of DUSP1 by dexamethasone is only partly 
responsible for the inhibition of IL-6 by GCs. GC-induced reduction in IL-23 levels by human 
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macrophages in vitro following the down-regulation of p38 MAPK and up-regulation of DUSP1 
has been reported (Palma et al, 2011). IL-23 production by DCs shown here also indicates a role 
of DUSP1 in GC mediated regulation, as Dusp1-/- cells secrete increased amounts of IL-23 in the 
presence of dexamethasone (Figure 5.11). 
Whether dexamethasone treatment affects activation of T cells and their differentiation into 
different effector Th cells in DUSP1 dependent manner still remains to be investigated. Cultures 
of mixed lymphocyte reactions could highlight the role of DUSP1 in DCs following 
dexamethasone pre-treatment. 
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6 Final Discussion 
The MAPK signalling pathway is involved in a vast variety of cellular processes including cell 
survival and differentiation, apoptosis, physical or chemical stress responses and activation of 
inflammatory reactions (Johnson & Lapadat, 2002). Tight regulation of this pathway is therefore 
important especially in inflammation as enhanced or prolonged inflammatory responses can 
cause tissue damage and are believed to trigger allergies and autoimmune diseases. Inflammatory 
disorders are frequently treated with GCs and their anti-inflammatory properties are partly 
mediated by the suppression of the MAPK signalling (Clark, 2003). Multiple protein-tyrosine 
phosphatases have been identified to regulate the activation of the MAPK pathway, amongst 
which DUSPs are critical in regulating inflammatory responses and GC-induced DUSP1 
activation and subsequent p38 MAPK inactivation has been shown to impair TNF, COX2 and 
IL-1α expression from macrophages (Abraham et al, 2006; Hammer et al, 2005; Joanny et al, 
2012). GCs are frequently used in chronic inflammatory diseases like RA, SLE and asthma. 
However, long-term therapeutic use of GCs is known to cause decreased OB and increased 
OCL activity resulting in bone loss and GIO in patients. The present study aimed to investigate 
the role of DUSP1 in GIO and inflammatory bone loss. 
The main findings of this study are: 
1. Sensitivity to experimental GIO in mice is strain dependent 
2. DUSP1 limits TNF-induced osteoclastogenesis 
3. DUSP1 limits joint inflammation and osteolysis in CIA 
4. DUSP1 is involved in determining Th cell responses in CIA 
5. Therapeutic effects of dexamethasone in CIA are partly dependent on DUSP1 
The importance of the MAPK pathway in OCL differentiation and activation, and particularly 
the activation of p38 MAPK by RANKL, has been well established (Huang et al, 2006; 
Chapter Six Final Discussion
 
161 
Matsumoto et al, 2000b). Also in OBs MAPK activation promotes ALP and osteocalcin 
expression (Guicheux et al, 2003; Hu et al, 2003; Rey et al, 2007). Inhibition of tyrosine 
phosphatases that inactivate MAPKs, prevents GC-induced bone loss in rats (Hulley et al, 2002). 
To test the hypothesis that activation of DUSP1 by GCs triggers bone loss, Dusp1+/+ and Dusp1-/- 
mice were treated with slow release prednisolone pellets to induce GIO. This method has been 
reported to induce GIO in Swiss Webster mice (Balooch et al, 2007; Yao et al, 2008). 
Surprisingly, experimental GIO was not established in either Dusp1+/+ or Dusp1-/mice after 
prolonged prednisolone treatment whereas long-term prednisolone treatment in CD1 mice, an 
outbred strain related to the Swiss Webster mice, resulted in the loss of both bone volume and 
strength. 
Reduced sensitivity to GC-induced decrease of calcium metabolism has been reported previously 
in C57BL/6 mice (Ambrus et al, 1978). C57BL/6 mice are also reported to maintain lower levels 
of stress-induced corticosterone levels compared to other mouse strains (Dhabhar et al, 1993; 
Jones et al, 1998). Exogenous GCs interfere with the HPA axis by competing with endogenous 
GCs like corticosterone resulting in its suppressed secretion from the adrenal cortex. The 
generation of different mouse or rat strains deficient in DUSP1 could be used in future to test 
whether DUSP1 drives bone loss. Also DNA and SNP analysis of genes involved in the control 
of the HPA axis, like adrenocorticotropic hormone (ACTH) secreted by the anterior pituitary 
gland, or expression of 11β-hydroxysteroid dehydrogenase type 1 or 2 (11β-HSD), which 
convert inactive cortisone into active cortisol or reverse, might reveal strain dependent 
differences and help to understand why long-term prednisolone treatment did not induce GIO 
in C57BL/6 mice. 
The question whether induction of DUSP1 mediates GIO could not be addressed due to 
difficulties establishing experimental GC-induced bone loss in both Dusp1+/+ mice as well as 
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Dusp1-/- mice. The role of activated protein tyrosine phosphatases in mediating GIO has been 
suggested by a previous report, where administration of sodium orthovanadate, an inhibitor of 
protein tyrosine phosphatases and DUSPs, successfully reversed negative effects of GCs on OB 
proliferation in vitro and to effectively counteract bone loss induced by GCs in vivo (Hulley et al, 
2002; Hulley et al, 1998). Long term GC treatment results in decreased bone mineral density due 
to decreased OB function and subsequently reduced bone formation (Canalis et al, 2007). GCs 
induce apoptosis and decreased responses to growth factor in OB (O'Brien et al, 2004; Weinstein 
et al, 1998). 
Osteogenic growth factors like insulin-like growth factor (IGF) -1 and IGF-2 activate the MEK-
ERK signalling pathway following activation of membrane protein tyrosine kinases (Marshall, 
1995). ERK activation in differentiating OBs activates the transcription factor Runx2, which is 
crucial for the activation of various OB-specific genes like osteocalcin (Ducy & Karsenty, 1995; 
Ge et al, 2007). Furthermore, inhibition of ERK activation blocks ostegenic differentiation in 
mesenchymal stem cells, from which OBs differentiate, and promotes the expression of 
adipocyte-specific genes (Horsch et al, 2007; Jaiswal et al, 2000). Although DUSP1 targets p38 
MAPK, JNK and ERK, it preferentially inactivates p38 MAPK and JNK (Franklin & Kraft, 
1997). It is likely that the effects of sodium orthovanadate on ERK activity due to DUSP1 
inhibition are smaller compared to other protein tyrosine phosphatases and DUSPs that have 
higher preference to ERK. Knock-down of DUSP1 in OBs has been shown to prevent GC-
induced inactivation of ERK in vitro, however, effects of DUSP1 deficiency in vivo has not been 
established to date (Horsch et al, 2007). 
Effects of GCs on OCLs have also been reported to contribute to loss of bone mineral density. 
Transgenic mice overexpressing 11β-HSD type 2 in OCL, are protected from rapid loss of bone 
mineral density following prednisolone treatment (Jia et al, 2006). However, in the present study 
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no effects of GCs on in vitro OCL formation and activity were observed in both Dusp1+/+ and 
Dusp1-/- cells.  The role of DUSP1 activation by GCs in OCLs might not promote GC-induced 
bone loss.  
Activation of p38 MAPK is crucial for TNF-induced osteoclastogenesis (Bohm et al, 2009). 
Other pro-inflammatory cytokines like IL-1α and IL-17 are also known to promote OCL activity 
in vitro and in diseases like periodontal disease or RA (Assuma et al, 1998; Bertolini et al, 1986; 
Danks et al, 2011; Zhang et al, 2001). RANKL-induced p38 MAPK activation in OCL is partly 
regulated by DUSP1 as RANKL stimulation of bone marrow cells triggers expression of Dusp1 
mRNA in Dusp1+/+ cells and p38 MAPK expression is prolonged in Dusp1-/- cells (Carlson et al, 
2009). Prolonged p38 MAPK activity in DUSP1-deficient OCL can therefore enhance sensitivity 
to TNF driven osteoclastic bone resorption. TNF-induced bone resorption is of particular 
interest in RA, as high amounts of TNF are expressed by macrophages and other innate immune 
cells in the inflamed joint. The increased resorptive activity of Dusp1-/- OCL in the presence of 
TNF observed in this study is therefore most likely due to ineffective inactivation of p38 MAPK 
leading to increased sensitivity to TNF-induced resorption. Furthermore, bone erosions were 
prominent in arthritic Dusp1-/- mice confirming the excessive OCL activity in vivo. 
IL-1α and IL-17 production is also associated with bone erosions in CIA (Assuma et al, 1998; 
Joosten et al, 1999; Pollinger et al, 2011). TNF and IL1α are expressed by macrophages and 
neutrophils in RA or CIA and previous work on Dusp1-/- macrophages has shown increased 
expression of these pro-inflammatory cytokines following LPS stimulation (Abraham et al, 2006; 
Hammer et al, 2005; Joanny et al, 2012). Also, increased cellular infiltrate was observed in 
arthritic Dusp1-/- mice compared to Dusp1+/+ mice, which most likely contained a high number of 
T cells and innate immune cells capable of expressing TNF. However, to confirm the increased 
expression of TNF from macrophages in the arthritic joints of Dusp1-/- mice, 
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immunohistochemical staining for TNF and the macrophage marker F4/80 would need to be 
performed on paw sections. Increased inflammation and hypersensitivity of OCL to TNF leads 
to dramatically augmented osteolytic lesions in CIA of Dusp1-/- mice, identifying DUSP1 as an 
important regulator of bone erosions in arthritis. 
High levels of IL-17 expression from draining lymph node cells of arthritic Dusp1-/- mice 
following collagen stimulation were observed, suggesting the presence of active Th17 or γδT 
cells in the arthritic joints of these mice. IL-17 not only enhances OCL activity but is also a 
major contributor to inflammation as it induces RANKL and TNF expression from SFs and can 
act as a chemo-attractant for neutrophils (Ferraccioli & Zizzo, 2011; Lemos et al, 2009). IL-17 
expression from CD4+ Th17 cells is generally regarded as the potent stimulator of OCL activity 
in RA patients, rather than IL-17 expression by γδT cells (Pollinger et al, 2011). However, IL-17 
secretion from γδT cells might contribute to other inflammatory responses like induction of 
RANKL production. Further studies to determine a role of DUSP1 in the activation of γδT cells 
need to be done to verify this hypothesis. 
Recent studies by Huang et al. have demonstrated that p38α signalling in DCs is crucial for 
driving Th17 differentiation and DUSP1 activation blocks Th17 and promotes Th1 
differentiation (Huang et al, 2011; Huang et al, 2012). In those studies p38α activation induced 
by TLR signalling promotes IL-6 and dampen IL-27 expression. Similar to macrophages, 
DUSP1-deficient DCs express elevated levels of IL-6 following LPS activation. IL-6 expression 
is critical in priming Th17 cell responses, whereas IL-27 drives Th1 cell proliferation and inhibits 
Th2 cell, Th17 cell and Treg cell development (Fitzgerald et al, 2007; Lucas et al, 2003; 
Yoshimoto et al, 2007). Whether DUSP1 dependent inactivation of p38 MAPK in DCs has any 
effects on IL-27 expression still needs to be investigated. TGFβ expressed by DCs in the 
presence of either IL-6 or IL-23 triggers Th17 cell proliferation, while TGFβ alone promotes 
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inducible Treg activation. The role of Th17 cells in RA or animal models of arthritis has gained 
interest as they have been identified as strong promoters of inflammation via IL-17 expression. 
However, Th1 cells are also abundantly present in affected joints in CIA and are triggered by IL-
12 expression from DCs. Unlike IL-17 the secretion of the Th1 cytokine IFNγ by draining 
lymph node cells of arthritic Dusp1-/- mice following collagen stimulation showed no difference 
compared to Dusp1+/+ cells. However, serum IFNγ levels were reduced in arthritic Dusp1-/- mice 
compared to arthritic Dusp1+/+ mice. Furthermore, IFNγ seems to have a protective role in CIA 
as mice deficient for IFNγ or IFNγ-receptor show accelerated and more severe symptoms to 
CIA (Chu et al, 2003; Manoury-Schwartz et al, 1997; Vermeire et al, 1997). The role of Th1 cells 
in the pathogenesis of CIA might therefore be to control inflammation rather than enhance it. 
These protective effects might arise from IFNγ-mediated suppression of Th17 cells and IL-17 
expression (Chu et al, 2007). Th1 stimulus on B cells elicits the production of collagen specific 
IgG2a antibodies in CIA. Surprisingly, in arthritic Dusp1-/- mice serum levels of collagen specific 
IgG2a antibodies were strongly reduced, despite presenting with a more severe disease 
progression. Collagen specific auto-antibodies are crucial for the induction of CIA as serum of 
immunized DBA/1 mice can induce the onset of arthritis in healthy unimmunized mice (Stuart 
& Dixon, 1983). However, arthritis induction is not dependent on the levels of collagen specific 
auto-antibodies (Holmdahl et al, 1985). However, arthritis induction is not dependent on the 
levels of collagen specific auto-antibodies (Holmdahl et al, 1985). 
 
Enhanced innate immune responses from macrophages and deregulated activation of Th17 and 
Th1 cells together with hypersensitivity of OCLs to TNF are the likely causes of increased 
inflammation and bone erosions seen in arthritic Dusp1-/- mice. A schematic summary of the 
immune responses leading to inflammation and bone erosions is shown in (Figure 6.1). 
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Determining whether the observed effects of DUSP1, regulating inflammation and bone 
erosions in mice, are valid for humans is of great interest. In case that behaviour is also observed 
in humans, one would expect that variations in DUSP1 expression would contribute to varying 
degrees of bone erosion seen in chronic inflammatory conditions such as RA. A quantification 
of those variations and performing SNP analysis or investigations of epigenetic modifications of 
the DUSP1 locus, is likely to be useful for predicting the progression of RA. On the other hand, 
maintaining or increasing the expression of DUSP1 might result in a decrease in bone erosion, 
thereby alleviating the severity of joint damage seen in RA. However, general increased 
inactivation of the MAPK signalling pathway can lead to decreased immune responses towards 
other infections. 
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Figure 6.1 DUSP1 regulates innate and adaptive immune responses in CIA 
In arthritic joints synovial fibroblasts express M-CSF and RANKL. Mitogen-induced activation of 
monocytes, neutrophils and macrophages leads to activation the p38 MAPK pathway resulting in pro-
inflammatory cytokine expression (TNF, IL-1α amongst others). Stimulation of DC triggers the activation 
of naïve T cells. IL-12 expression by DC, mediated by p38 MAPK activation, promotes Th1 cell 
differentiation while TFGβ together with IL-6 or IL-23 promotes Th17 cell differentiation. Th1 cells 
express IFNγ and IL-2 which triggers differentiation of naïve B cells to IgG2a secreting plasma cells. 
Th17 cells express IL-17, which further promote M-CSF and RANKL expression by synovial fibroblasts 
and enhances inflammation. TNF, IL-1α and IL-17 also promote OCL activation. In OCL TNF activates 
the p38 MAPK pathway leading to enhanced OCL activity and subsequent bone resorption. Red arrows 
indicate increased or decreased expression in the absence of DUSP1 
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Since the 1950s GCs have extensively been used in the treatment of RA and other inflammatory 
diseases due to their anti-inflammatory effects. The inhibition of MAPK dependent pro-
inflammatory gene expression by DUSP1 activation contributes to the anti-inflammatory actions 
of GCs (Clark, 2007; Joanny et al, 2012). Dexamethasone treatment of CIA in DBA/1 and 
C57BL/6 mice has been shown to effectively reduce signs of joint inflammation (Inglis et al, 
2007; Kang et al, 2000). In this study dexamethasone treatment of arthritic Dusp1+/+ and Dusp1-/- 
mice reduced clinical signs of paw swelling in Dusp1+/+ mice and to a lesser extent also in Dusp1-/- 
mice. This observation suggests that therapeutic effects of GCs are partly dependent on DUSP1. 
GC-mediated induction of DUSP1 has been shown to reduce expression of TNF, IL-1α and 
COX2 in macrophages in vitro (Abraham et al, 2006). In CIA reduced expression of TNF from 
macrophages, present in the inflammatory infiltrate in affected joints, might contribute to the 
therapeutic effects of dexamethasone. Whether dexamethasone-induced DUSP1 activity also 
mediates reduced expression of TNF in neutrophils or SFs has not been investigated to date. 
Other mechanisms involved in anti-inflammatory actions of GC are GC-induced leucine zipper 
(GILZ)-mediated gene inactivation. Endogenous GCs present in inflamed joints have been 
shown to up-regulate GILZ in synoviocytes in CIA which functions as an endogenous inhibitor 
of inflammation (Beaulieu et al, 2010). Endogenous GC production is of particular importance 
in RA as TNF and other pro-inflammatory cytokines have been shown to induce the expression 
of 11β-HSD type 1 in SFs, which converts inactive endogenous GCs into their active form. On 
the other hand TNF dose-dependently inhibits 11β-HSD type 2, which inactivates activated GCs 
(Cooper et al, 2001; Escher et al, 1997). Furthermore, high 11β-HSD type 1 activity has been 
observed in SFs of RA patients (Cooper et al, 2001; Escher et al, 1997; Hardy et al, 2008). 
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In this study the effects of dexamethasone treatment on adaptive immune responses in CIA were 
investigated. Lymph node cells from arthritic Dusp1+/+ mice treated with dexamethasone showed 
a diminished proliferative response to collagen stimulation ex vivo compared to PBS treated mice, 
which may indicate reduced T cell activity in the arthritic joint. Also, a reduction in the secretion 
of the Th1 specific cytokine IFNγ was observed in lymph node cultures of dexamethasone 
treated arthritic Dusp1+/+ mice after collagen stimulation compared to PBS treated mice, this was 
however not significant. Serum levels of IFNγ were also reduced in these mice compared to PBS 
treated mice. Differences in proliferation or IFNγ expression were not apparent in Dusp1-/- mice 
treated with dexamethasone and might indicate a DUSP1 dependent mechanism in reducing Th1 
responses and of other IFNγ secreting cells like CD8+ T cells. No differences in the expression 
of IL-17 or the levels of collagen specific antibodies were detected following GC treatment. 
Other reports on GC treatment of AIA models have shown GR dependent suppression of IFNγ 
and IL-17 as early as one day after disease onset (Baschant et al, 2011). 
GC-induced activation of GR in T cells reduced cytokine expression. Baschant and colleagues 
treated mice at 4, 24 and 48h after arthritis induction in the knee, which suggests that early T cell 
responses were inhibited by GC. In the experiments described in this thesis, mice were treated 
with dexamethasone every second day after disease onset for 10 days before T cell responses 
were analysed ex vivo. The timeframe and dosing protocol used does not reflect early T cell 
responses. T cell responses after 1 day of disease onset need to be investigated in future to 
determine whether GC induced DUSP1 alters Th1 and Th17 cell responses. However, T cell 
responses in CIA are active before the first physical symptoms of disease can be seen in affected 
paws, as effective immunisation with CFA breaks tolerance and collagen type II triggers T cell 
responses and only several weeks later are the first symptoms of joint inflammation visible. 
Therefore, in DBA/1 mice immunised with collagen it is a common practice to test T cell 
responses 10 days after immunisation regardless of symptoms of joint swelling. To do so in 
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C57BL/6 mice would cause a problem when analysing the data as only 40-60% of immunized 
mice successfully develop the disease. 
DCs are crucial for appropriate activation of adaptive immune response as they provide all three 
signals needed for T cell proliferation and activation, antigen presentation by MHC molecules, 
co-stimulation (e.g. CD80, CD86) and cytokine release. Dexamethasone treatment of arthritic 
Dusp1+/+ mice resulted in a decreased proliferation of lymph node cells ex vivo, which might 
suggest reduced activation of T cells by DCs in the lymph node. Indeed IL-6 expression from 
LPS-activated Dusp1+/+ DCs was reduced following dexamethasone treatment in vitro. 
Furthermore CD86 expression following TLR stimulation has been reported to be p38 MAPK 
dependent (Huang et al, 2012). Together with the finding that DUSP1 in DCs is important in 
cross-regulation of Th1 and Th17 activation a possible role of GC-induced regulation of p38 
MAPK via DUSP1 seems possible, however, further experiments are needed to validate this 
hypothesis. 
The effects of GCs on DCs have been shown in murine bone marrow derived DCs as well as 
human monocyte derived DCs by various groups and revealed GC-induced reduced expression 
of co-stimulatory molecules CD40, CD86 as well as MHC class II molecules (Larange et al, 2012; 
Pan et al, 2001; Piemonti et al, 1999; Rozkova et al, 2006). Furthermore, production of IL-12p70, 
IL-6 and TNF is known to be reduced in these DCs following activation via TLR2, 3, 4, 7, and 8 
(Larange et al, 2012; Rozkova et al, 2006). Together this results in decreased stimulation of 
allogeneic T cells in vitro. Furthermore, GC-induced activation of GILZ has been reported to 
modulate expression of CD80 and CD86 preventing DC maturation and to induce increased 
secretion of anti-inflammatory cytokine IL-10 and decreased secretion of IL-12p70 in human 
CD40-triggered DCs (Cohen et al, 2006). Similarly to GCs IL-10 also prevents DC maturation 
by inhibiting expression of co-stimulatory molecules, secretion of IL-12 and allogeneic T cell 
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proliferation (Steinbrink et al, 1997). Combined treatment of DCs with dexamethasone and the 
GR-antagonist RU486 reverses dexamethasone-induced inhibition of maturation, indicating GR-
induced gene transcription (Larange et al, 2012). The role of GC-induced DUSP1 in DCs is less 
clear. In the present study GC-induced reduction in IL-6 secretion of bone marrow derived DCs 
indicated the involvement of DUSP1 activation. Furthermore, Dusp1 mRNA and protein levels 
have been shown to be up-regulated following dexamethasone treatment in human DCs 
resulting in inhibition of JNK activity (Larange et al, 2012). However, re-establishing JNK 
activity by silencing Dusp1 did not affect GC-mediated inhibition of DC maturation. The effects 
of DUSP1 activation on p38 MAPK activity in DCs could also influence DC maturation as 
expression of CD86 is dependent on this pathway. Further investigation of the expression of 
CD86 and IL-10 by GC-treated DCs is required to determine a possible role of DUSP1 in 
mediating inhibition of DC maturation. 
Taken together the findings presented in this thesis provide strong evidence for a role of DUSP1 
in restraining inflammatory OCL activity and in limiting exacerbated inflammatory responses in 
CIA and contribute to the understanding of pathogenic bone loss. Targeting DUSP1 activation 
might provide a tool in controlling exacerbated T cell responses and limiting bone erosions seen 
in RA. To fully characterise the role of DUSP1 in adaptive immune responses and how it 
mediates therapeutic effects of GCs further investigation in its function in DCs, T cells and B 
cells is required. 
 
6.1 Future directions 
The results presented in this study give room for other experiments to further characterise the 
role of DUSP1 in the adaptive immune responses as well as the anti-inflammatory role of GC-
induced DUSP1 activation in cells of the adaptive immune system: 
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- Investigating the ability of GC-treated DCs to stimulate T cell polarisation and 
proliferation in vitro. This can be tested using mixed lymphocyte reaction assays. 
Dexamethasone treated DCs from Dusp1+/+ and Dusp1-/- mice can be co-cultured with T 
cells of allogeneic mice and cytokine expression as well as proliferation determined. 
Decreased IL-6 expression of GC-treated Dusp1+/+ DCs might reduce the activation of 
Th17 cells and may be reflected in reduced IL-17 expression. This outcome would 
confirm a role of DUSP1 in mediating GC-induced anti-inflammatory effect via 
dampened Th17 cell activation. Other cytokines that determine T cell activation and 
proliferation are IL-23, IL-27, IL-12, TGFβ and need to be tested along with cytokines 
expressed by T cells that characterise effector cell function like IFNγ, TGFβ, IL-4, IL-10, 
and IL-17. 
- Examining whether GC-induced inhibition of DC maturation is DUSP1 dependent by 
confirming expression of maturation markers CD80, CD86, MHC class II molecules and 
cytokine expression (especially IL-12p70, IL-10 and TGFβ). 
- To confirm whether inhibited DC maturation, following dexamethasone treatment, and 
subsequent altered T cell activation and polarisation modulates inflammatory responses 
in vivo cytokine expression in inflamed paws of arthritic mice can be determined in future 
by immunohistochemistry or flow-cytometric analysis. 
- Further investigation of T effector cell populations in the arthritic paw by 
immunohistochemistry or flow-cytometric analysis could also confirm a proposed role of 
DUSP1 in determining T cell responses in vivo. 
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Dual-Specificity Phosphatase 1–Null Mice Exhibit
Spontaneous Osteolytic Disease and Enhanced
Inflammatory Osteolysis in Experimental Arthritis
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Objective. Bone formation and destruction are
usually tightly linked; however, in disorders such as
rheumatoid arthritis, periodontal disease, and osteo-
porosis, elevated osteoclast activity leads to bone de-
struction. Osteoclast formation and activation are con-
trolled by many signaling pathways, including p38
MAPK. Dual-specificity phosphatase 1 (DUSP-1) is a
factor involved in the negative regulation of p38 MAPK.
The purpose of this study was to examine the effect of
Dusp1 deficiency on bone destruction.
Methods. Penetrance, onset, and severity of
collagen-induced arthritis were recorded in DUSP-1/
and DUSP-1/ mice. Bone destruction was assessed by
histologic and micro–computed tomographic examina-
tion of the joints. The in vitro formation and activation
of osteoclasts from DUSP-1/ and DUSP-1/ precur-
sors were assessed in the absence or presence of tumor
necrosis factor (TNF).
Results. The formation and activation of osteo-
clasts in vitro in the presence of TNF were enhanced
by Dusp1 gene disruption. DUSP-1/ mice exhibited
higher penetrance, earlier onset, and increased severity
of experimental arthritis, accompanied by greater
numbers of osteoclasts in inflamed joints and more
extensive loss of bone. A DUSP-1/ mouse colony of
mixed genetic background also demonstrated striking
spontaneous osteolytic destruction of distal phalanges.
Conclusion. DUSP-1 is a critical regulator of
osteoclast activity and limits bone destruction in an
experimental model of rheumatoid arthritis. Defects in
the expression or activity of DUSP1 in humans may
correlate with a propensity to develop osteolytic lesions
in arthritis.
The delicate balance between osteoblast-mediated
bone synthesis and osteoclast-mediated bone destruc-
tion is disturbed in many chronic inflammatory con-
ditions, such as rheumatoid arthritis (RA), psoriatic
arthritis, periodontal disease, and cachexia (1,2). Osteo-
clast activity becomes excessive, causing a net loss of
bone, either at localized sites of inflammation, at sites
throughout the body, or both. Skeletal homeostasis
normally depends upon a continuous process of remod-
eling, in which 3% of cortical bone and 25% of
trabecular bone are replaced per year of adult life (3).
This process is dependent upon the tightly coupled and
mutually regulated activities of osteoblasts and osteo-
clasts.
In healthy individuals, several mechanisms of
communication between osteoblasts and osteoclasts en-
sure the tight coupling of their respective activities and
the homeostatic maintenance of bone mass and integ-
rity. The most important mechanism of communication
involves RANK, a member of the tumor necrosis factor
receptor (TNFR) superfamily that is expressed on the
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cell surface of osteoclast precursors. RANKL, the ligand
for RANK, is expressed on the cell surface of osteo-
blasts, and it provides a mechanism for contact-
dependent communication between osteoblasts and
osteoclasts (4,5). RANKL can also be expressed by other
mesenchymal cells, such as fibroblasts, and by T lympho-
cytes (6–8). In RA and in experimental models such as
collagen-induced arthritis (CIA), proinflammatory cyto-
kines, including TNF, interleukin-1 (IL-1), and IL-17,
stimulate RANKL expression in synovial fibroblasts
and, hence, promote osteoclast activation. The same
proinflammatory cytokines may also directly activate
osteoclasts, particularly in cooperation with RANKL
(9,10). These indirect or direct mechanisms are thought
to contribute to the periarticular bone erosions that are
often observed in RA.
When engaged by its ligand, RANK recruits
TNFR-associated factor 6 and initiates the activation of
the NF-B and MAPK signaling pathways. The p38
MAPK pathway mediates the up-regulation of the tran-
scription factor NF-ATc1, a factor that is crucial for
osteoclast differentiation (11). In addition, p38 MAPK
phosphorylates microphthalmia-associated transcription
factor (MITF), assisting the recruitment of NF-ATc1 to
target sites in chromatin (12,13). Both NF-ATc1 and
MITF regulate expression of genes that are necessary
for osteoclast function, cooperating with other transcrip-
tion factors, such as PU.1 and upstream stimulatory
factor, which is itself a target of the p38 MAPK pathway
(13,14). Hence, p38 MAPK plays a crucial role in
osteoclast activation.
Inhibitors of p38 MAPK block the formation of
mature osteoclasts from precursor cells in vitro (15–17)
and decrease the expression of cathepsin K, tartrate-
resistant acid phosphatase (TRAP), and osteoclast-
associated receptor (12–14,18,19). Not surprisingly, p38
MAPK inhibition or genetic ablation of the pathway
reduces bone loss in experimental models of arthritis
and other inflammatory diseases (20–24). Inhibitors of
p38 MAPK have long been considered potential treat-
ments for inflammatory osteolysis (25). Regrettably,
due to toxicity or unsustained efficacy, none have yet
reached the market (26).
Endogenous mechanisms of constraint of p38
MAPK function may point the way toward new treat-
ments for inflammatory bone loss. Activation of p38
MAPK is mediated by upstream MKKs, which phos-
phorylate both a threonine and a tyrosine residue in
the activation loop. DUSP-1, a member of a family of
dual-specificity phosphatases, catalyzes the dephosphor-
ylation of both threonine and tyrosine residues, causing
the inactivation of p38 MAPK (27). In macrophages, the
expression of DUSP-1 was found to be essential for
limiting the strength and duration of p38 MAPK signal-
ing and the expression of proinflammatory gene prod-
ucts (28–33). Both the incidence and severity of CIA
were increased in mice in which the Dusp1 gene was
disrupted (32). Recently, these mice were reported to
display increased bone loss in response to ovariectomy
(34) or lipopolysaccharide injection (35). Adenovirus-
mediated overexpression was shown to protect against
bone loss in the latter experimental model of periodon-
tal disease (36). We describe herein an unusual sponta-
neous osteolytic condition in a DUSP-1/ mouse line
and provide evidence that DUSP-1 limits inflammatory
cytokine–induced osteoclastogenesis and the develop-
ment of osteolysis in an experimental model of RA.
MATERIALS AND METHODS
Animals. DUSP-1/ and DUSP-1/ mice were
maintained at a temperature of 21°C (2°C) on a 12-hour
light/12-hour dark cycle and were given food and water ad
libitum. All experimental procedures were approved by the
local Ethical Review Process Committee and by the UK Home
Office.
In vitro osteoclast TRAP assay. Bone marrow was
isolated from 10–13-week-old mice by flushing femora and
tibiae with -minimum essential medium (-MEM). Cells
were counted and plated at a density of 5  105 cells/well in
96-well plates (3 wells per treatment) and incubated in -MEM
supplemented with 10% fetal bovine serum, 1% L-glutamine,
and 1% penicillin/streptomycin and containing 25 ng/ml of
soluble murine macrophage colony-stimulating factor (M-
CSF) either alone (as a control) or with 5 ng/ml of RANKL
and with or without 2 pg/ml of TNF. Cells were cultured for
7 days with partial changes of the medium every 3 days. At the
end of the culture period, cells were fixed with 4% formalde-
hyde, permeabilized with a 1:1 (volume/volume) mixture of
acetone:ethanol, and osteoclast formation was measured by
TRAP staining (0.1 mg/ml naphthol-AS-MX phosphate,
0.4 mg/ml of fast red violet LB salt, 1% dimethylformamide
in TRAP buffer) for 15 minutes at 37°C. The numbers of
TRAP-positive multinucleated cells containing 3 nuclei were
counted at 20 magnification.
In vitro osteoclast resorption assay. The resorptive
activity of osteoclasts was determined by a lacunar resorption
assay on dentin slices. Cells were cultured for 14 days on dentin
slices in the presence of 25 ng/ml of M-CSF either alone
(control) or with 5 ng/ml of RANKL and with or without
2 pg/ml of TNF. Osteoclasts were then lysed, and the dentin
slices were rinsed in distilled H2O. Resorption lacunae were
marked with a marker pen, and the resorption area was
analyzed using ImageJ software version 1.45d.
Induction of CIA. Male mice ages 10–12 weeks were
immunized by subcutaneous injection of 100 l of chicken type
II collagen (2 mg/ml) emulsified in Freund’s complete adju-
vant; 2 sites at the base of the tail were injected as previously
described (37). Beginning at the onset of arthritis, animals
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were scored for clinical signs of inflammation. Each limb was
scored on a scale of 0–3, where 0 normal, 1 slight swelling,
2  pronounced edematous swelling, and 3  pronounced
swelling and joint rigidity.
Histologic assessment. Hind paws from arthritic mice
and mice with toe swelling were assessed histologically by
TRAP staining for osteoclasts and by hematoxylin and eosin
(H&E) staining for inflammatory infiltration and joint dam-
age. Hind paws were fixed in 10% neutral buffered formalin
and decalcified in 10% EDTA for 21 days. Paws were then
embedded in paraffin and cut into 3-m sections. Sections
were deparaffinized in xylene, rehydrated, and stained for
TRAP or with H&E (38). Histologic changes on H&E-stained
sections were scored on a scale of 0–3, where 0  normal, 1 
mild inflammation with no joint damage, 2  moderate
inflammation with some joint erosions, and 3  severe inflam-
mation and loss of joint architecture. Sections of hind paws
affected by toe swelling were also stained with Masson’s
trichrome or neutrophil elastase, and nuclei were stained with
hematoxylin.
Micro–computed tomography (micro-CT). Hind paws
from mice with psoriatic onychopachydermoperiostitis (POPP)
and from mice with arthritis were harvested 10 days after the
onset of disease and imaged using a SkyScan 1072 scanner at a
resolution of 16. Micro-CT scanning was performed by Kevin
MacKenzie (University of Aberdeen, Aberdeen, UK). Images
were analyzed using SkyScan CT Analyzer software version
1.9.3.0. For measurement of bone volume, a 1.5-mm region of
the paws that included all 5 metacarpal joints was selected. A
threshold of 115 density units was selected to distinguish
mineralized from nonmineralized tissue.
Statistical analysis. Data are reported as the mean 
SEM. GraphPad Prism software was used for all statistical
analyses. Disease onset, histologic scores, and TRAP-positive
cell counts in histologic sections were analyzed by Student’s
unpaired 2-tailed t-test. The in vitro TRAP and resorption
assay results, the clinical scores, and the bone volume mea-
surements were analyzed by one-way analysis of variance
followed by Bonferroni post hoc test. Disease incidence was
analyzed by chi-square test. P values less than 0.05 were
considered significant.
RESULTS
Spontaneous osteolytic disease in a DUSP-1/
mouse colony. DUSP-1/ mice were provided by
Bristol-Myers Squibb (39), and the strain was rederived
by implantation of embryos into pseudopregnant
C57BL/6 females. At this point, the genetic background
of the strain was found to be 75% C57BL/6 and 25%
129Sv, typical of knockout strains that have not been
extensively backcrossed to create a pure genetic back-
ground. A breeding colony from these mixed back-
ground mice was established from 6 animals obtained
in the rederivation. To investigate the function of the
Dusp1 gene, we backcrossed the DUSP-1/ mice
against the C57BL/6 background and then interbred
heterozygotes and performed genotyping to identify
DUSP-1/ and DUSP-1/ littermates for use in ex-
periments (29). Subsequently, 8 further generations of
backcrossing against C57BL/6 were also used to gener-
ate DUSP-1/ and DUSP-1/ strains with a 99.9%
C57BL/6 genetic background, and these strains have
recently been used in the study of DUSP-1 function (40).
In the original DUSP-1/ breeding colony of
mixed genetic background (C57BL/6 and 129Sv), we noted
a spontaneous phenotype characterized by severe swell-
ing of the toes, giving a “drumstick” appearance (Figure
1A). The number of affected digits ranged from 1 to 20,
and the toenails were typically dystrophic or even absent
from the affected digits. The swelling did not resolve,
although erythema noted during the early phase tended
to disappear, over time. In a cohort of 73 female mice
kept for 20 months, the median age at onset was 6
months, and the cumulative incidence was close to 60%
(Figure 1B). In 6 years since the phenotype was first
observed, only 2 males from the same breeding colony
have developed similar symptoms. This phenotype is
absent from the DUSP-1/ line that has been exten-
sively backcrossed against C57BL/6. Other researchers
who have maintained DUSP-1/ mouse strains on
different genetic backgrounds have not observed any
similar condition (Cato A, Bennett A: personal commu-
nications).
Patterns of behavior of affected and unaffected
females were studied using a Laboratory Animal Be-
havior Observation Registration and Analysis System
(LABORAS) instrument, which measures time spent
immobile, grooming, eating, drinking, running, and climb-
ing. The only difference detected was an absence of
climbing in mice with swollen toes, probably a simple
reflection of physical incapacity (data not shown). There
was no evidence that the condition caused significant
discomfort, and affected females were also of similar
weight as unaffected females (data not shown).
Micro-CT was used to assess bone structure in affected
mice. This technique dramatically illustrated the cata-
strophic breakdown of the architecture of the terminal
phalanges, with extensive osteolysis as well as uncoordi-
nated bone formation leading to the stellate appearance
of the bone (Figure 1C).
Radiographic imaging showed a rather diffuse,
“fluffy” signal in the region of the affected digits (Figure
2A). As expected from the micro-CT imaging results,
histologic inspection showed that the distal phalanges
were extensively eroded and fragmented (Figure 2C).
Figure 2B shows sagittal sections of unaffected and
affected toes stained with Masson’s trichrome, showing
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keratin as red and showing bone and collagen as blue or
green. There was general enlargement of the affected
toe (Figure 2B, bottom), with hypertrophy of the nail-
bed, thickening of the dermis, fragmentation of the
distal phalanx, and with preservation of the distal inter-
phalangeal joint, all of which are consistent features of
the condition.
We did not detect inflammation of the interpha-
langeal joints, pannus formation, periarticular bone ero-
sion, or indeed osteolysis of any bone other than the
distal phalanx. Vestigial bone fragments were embedded
in large masses of connective tissue that stained pale
green (Figure 2C, top). Scanning electron microscopy
confirmed the presence of abundant collagen fibers
within this tissue (results not shown). Affected toes were
markedly infiltrated by neutrophils, as demonstrated by
neutrophil elastase staining (Figures 2A and C). Neu-
trophils were particularly abundant around the nailbed,
but were also closely associated with bone fragments
(Figure 2C, middle). TRAP staining demonstrated the
presence of multinucleated osteoclasts decorating the
surfaces of bone fragments (Figure 2C). In some cases,
erosion of the distal phalanges could be detected by
radiographic imaging or histologic examination in the
absence of macroscopically obvious swelling. In all cases
where swollen toes were inspected, extensive bone de-
struction was found, even if the mice were killed within
Figure 1. Spontaneous toe swelling in a DUSP-1/ mouse colony of
mixed genetic background. A, Photographs of a female DUSP-1/
mouse at 24 months of age, showing all 4 affected paws (top) and a
close-up view of the left hind paw (bottom). B, Cumulative incidence
of toe swelling in a cohort of 73 female DUSP-1/ mice over a period
of 20 months. C, Micro–computed tomography image of an affected
hind paw of a 20-month-old female DUSP-1/ mouse.
Figure 2. Characterization of toe swelling. A, A mouse hind paw with macroscopic swelling of 1 toe was radiographed, and transverse sections of
the same paw were prepared and stained with hematoxylin and eosin (H&E), Masson’s trichrome, or neutrophil elastase. B, Unaffected (top) and
affected (bottom) digits were sagittally sectioned and stained with Masson’s trichrome. Consistent features of affected toes (arrows) were the general
enlargement of the digit, with hypertrophy of the nailbed (1), thickening of the dermis (2), fragmentation of the distal phalanx (3), and preservation
of the distal interphalangeal joint (4). C, Various sections of affected toes were stained with Masson’s trichrome, neutrophil elastase, or
tartrate-resistant acid phosphatase (TRAP). Outlined areas in the TRAP-stained section show bone fragments. Original magnification  20.
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24 hours of the appearance of swelling and histologic
assessment performed. It is therefore likely that osteol-
ysis is a very early event, followed later by fibrosis and
swelling.
Negative regulation of in vitro osteoclast activa-
tion by DUSP-1. The low penetrance of the condition
and its variable age at onset made it difficult to capture
the early stages of pathology. The absence of similar
symptoms in other DUSP-1/ lines also made it diffi-
cult to be certain about the contribution of Dusp1 gene
disruption. Because hyperactivation of osteoclasts ap-
peared to be an early event in the pathologic changes of
the disease, we investigated the function of osteoclasts
derived from DUSP-1/ and DUSP-1/ colony mice
on a pure C57BL/6 background (99.9% C57BL/6).
Osteoclasts were differentiated from bone marrow cells
in the presence of M-CSF and soluble RANKL, with or
without TNF. The proinflammatory cytokine TNF
was included in these experiments because it had previ-
ously been shown to stimulate the formation of human
osteoclasts in the presence of suboptimal concentrations
of RANKL (41). Differentiation of osteoclasts was as-
sessed by counting multinucleated cells staining positive
for TRAP, a marker of osteoclast activation. Function
was assessed by plating the cells on dentin slices and
then measuring the area of resorption after 14 days.
As expected, the formation of osteoclasts was not
promoted by M-CSF alone, but required the addition of
RANKL (Figures 3A and B). As previously described
(34), RANKL induced both the activation of p38 MAPK
and the up-regulation of Dusp1 gene expression in
cultures of cells from wild-type mice (data not shown).
Again, consistent with previous findings (34) and with
the known function of the DUSP-1 protein, RANKL-
induced p38 MAPK activation appeared to be prolonged
in cultures of cells from DUSP-1/ mice (data not
shown). In the presence of both M-CSF and RANKL,
the numbers of multinucleated, TRAP-positive osteo-
clasts and the area of dentin resorption were not signif-
icantly different in cultures of cells from DUSP-1/
mice as compared to wild-type mice (Figures 3B and D).
However, the addition of TNF (2 pg/ml) showed a
striking cooperation with M-CSF and RANKL to pro-
mote the formation and activation of osteoclasts in
cultures of cells from DUSP-1/ mice, whereas a
similar synergy was not observed in cultures of cells
Figure 3. Increased differentiation and activation of bone marrow osteoclasts from DUSP-1/ mice in response to tumor necrosis factor (TNF).
Bone marrow cells from DUSP-1/ and DUSP-1/ mice were isolated from tibiae and femora and cultured with the indicated combinations of
macrophage colony-stimulating factor (M-CSF; 25 ng/ml), RANKL (5 ng/ml), and TNF (2 ng/ml). A, Staining for tartrate-resistant acid phosphatase
(TRAP). Original magnification  20. B, Numbers of TRAP-positive mononuclear cells (MNCs) containing 3 nuclei. C, Osteoclast activity, as
determined by plating cells on dentin slices in the presence of the indicated cytokines. Resorption lacunae were marked with ink and photographed.
Original magnification 20. D, Area of resorption in dentin slices, as measured using ImageJ software. Values in B and D are the mean  SEM
of 4 independent experiments.   P  0.005;   P  0.001 by one-way analysis of variance with the Bonferroni post hoc test. NS  not
significant. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131.
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from DUSP-1/ mice (Figure 3). Thus, in the presence
of all 3 agonists, M-CSF, RANKL, and TNF, the num-
bers of TRAP-positive osteoclasts and the area of dentin
resorption were both significantly greater in cells from
DUSP-1/ mice than in those from DUSP-1/ mice.
Therefore, DUSP-1 normally limits the activation of
osteoclasts in vitro, a function that is likely to be particu-
larly important under proinflammatory conditions.
Enhanced osteolysis in mice with Dusp1 gene
disruption and CIA. Arthritis was induced by immuni-
zation of age-matched male C57BL/6 DUSP-1/ and
DUSP-1/ mice with chicken type II collagen. This
protocol (37) is a variation on the classic CIA model, in
which arthritis is induced using bovine type II collagen in
susceptible mice of the DBA/1 genetic background. CIA
is driven by proinflammatory cytokines (particularly
TNF) that are expressed by activated macrophages and
infiltrating lymphocytes in the joint. It is characterized
by joint inflammation and progressive destruction of
cartilage and bone.
Consistent with a previous report (32), we found
that disease penetrance was significantly higher in
DUSP-1/ mice than in DUSP-1/ mice (Figure 4A).
In a total of 4 independent experiments, 75% of the
immunized DUSP-1/ mice (42 of 56) developed dis-
ease, whereas only 35% of the DUSP-1/ mice (24 of
69) did so. The latter is fairly typical of disease incidence
in wild-type C57BL/6 mice, suggesting that disruption of
the Dusp1 gene increases susceptibility to experimental
arthritis. The onset of disease was significantly earlier
in DUSP-1/ mice (Figure 4B) and the initial progres-
sion significantly more rapid (Figure 4C). The maximum
clinical score was reached within 3 days of disease onset
in DUSP-1/ mice, whereas DUSP-1/ mice reached
this level of disease severity only after 6 or 7 days. At the
macroscopic level, swelling of the affected limbs ap-
peared to be more severe in DUSP-1/ mice 6 days
after disease onset, suggesting that increases in disease
severity may not be reflected most effectively by the
standard clinical scoring method (Figure 5A).
Ten days after disease onset, the mice were
killed, and their paws were harvested and processed for
histologic (Figure 5) or micro-CT (Figure 6) analysis.
According to the standard histologic scoring system
evaluating H&E-stained sections of the proximal inter-
phalangeal joints, the disease was more severe in DUSP-
1/ mice than DUSP-1/ mice (Figures 5B and D).
Inflammatory infiltration of the joint, hyperplasia of the
synovium, and erosion of the cartilage (Figure 5B,
higher-magnification view) and bone (Figure 5C, higher-
magnification view) were all enhanced in DUSP-1/
mice. In DUSP-1/ mice, the majority of osteoclasts
detected by TRAP staining were on the interior surface
of cortical bone and were therefore possibly engaged
in normal bone turnover rather than periarticular ero-
sion (Figure 5C). In DUSP-1/ mice, the numbers of
TRAP-positive osteoclasts in the joint were 3 times
higher than in DUSP-1/ mice (Figure 5D), with many
of these osteoclasts being clearly associated with the
interface between the pannus and the periosteal surface
of the bone (Figure 5C, higher-magnification view),
consistent with the principal sites of bone erosion in RA
and its experimental models.
Further analysis by micro-CT illustrated en-
hanced bone erosion in DUSP-1/ mice as compared
Figure 4. Accelerated onset and increased incidence and severity of
collagen-induced arthritis in DUSP-1/ mice. Male DUSP-1/ and
DUSP-1/ mice ages 10–12 weeks were immunized with chicken
type II collagen emulsified in Freund’s complete adjuvant. A, Percent-
age of immunized mice that developed arthritis. B, Time from
immunization to onset of arthritis. C, Clinical arthritis scores in 19
DUSP-1/ mice and 25 DUSP-1/ mice. The first paw affected with
arthritis was inspected every day for 10 days and scored on a scale of
0–3 as described in Materials and Methods. Results in A and B are
from 6 independent experiments. Values are the mean  SEM.
  P  0.05;   P  0.001 by chi-square test in A, by Student’s
unpaired 2-tailed t-test in B, and by one-way analysis of variance with
the Bonferroni post hoc test in C.
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to DUSP-1/ mice (Figure 6A). The erosions were
particularly evident around the metacarpophalangeal
(MCP) joint, which was therefore used to calculate the
net loss of bone volume by comparison to nonimmu-
nized mice of the same age (Figure 6B). We found no
significant difference in the appearance of paws from
the nonimmunized DUSP-1/ and DUSP-1/ mice.
The induction of experimental arthritis was associated
with a significant decrease in bone volume at the MCP
joint in DUSP-1/ mice but not in DUSP-1/ mice.
These images highlight the significantly enhanced bone
disease in the DUSP-1/ mice and strengthen the case
for a role of DUSP-1 in the control of inflammatory
osteolysis.
DISCUSSION
Although the DUSP-1–knockout mouse was ini-
tially described as having no discernible phenotype (39),
several recent publications indicate an important role
for this phosphatase in the limitation of inflammatory
responses (28,42), thus emphasizing the importance of
challenging gene-deficient animals. For example, DUSP-
1/ mice displayed exaggerated responses in experi-
mental models of sepsis (43–45), asthma (46), and
pulmonary hypertension (47). Together with previously
published data (32,34,35), our findings indicate that
DUSP-1 is also an important negative regulator of
inflammatory bone loss.
Figure 5. Characterization of experimental arthritis in DUSP-1/ and DUSP-1/ mice. A, On day 6 after disease onset, the affected hind paws
of DUSP-1/ and DUSP-1/ mice were photographed. B and C, Ten days after disease onset, proximal interphalangeal joint sections from
DUSP-1/ (left) and DUSP-1/ (right) mice were stained with hematoxylin and eosin (H&E) (B) or tartrate-resistant acid phosphatase (TRAP)
(C) and analyzed. Boxed areas in the top images are shown at higher magnification in the bottom images. Open arrowhead indicates an area of
cartilage erosion; solid arrowhead indicates an inflammatory infiltrate. D, Histologic scoring was performed on H&E-stained sections of the
proximal interphalangeal joints from the two groups of mice (see Materials and Methods) (left), and the numbers of TRAP-positive cells per field
of view at 10 magnification were counted (right). Values are the mean  SEM of 6 affected DUSP-1/ mice and 10 affected DUSP-1/ mice.
  P  0.05;   P  0.005 by Student’s unpaired 2-tailed t-test.
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Although interesting, the unusual osteolytic phe-
notype in our mixed genetic background DUSP-1/
mouse colony is clearly not a straightforward conse-
quence of disruption of the Dusp1 gene. To our knowl-
edge, no similar phenotype has been observed in several
laboratories that maintain either the original DUSP-1–
deficient mice (39) on different genetic backgrounds or
a second, independently derived knockout (32). It is
formally possible that an entirely different genetic alter-
ation occurred during our rederivation and reestablish-
ment of the DUSP-1/ colony from small numbers of
animals and that this unknown mutation has become
fixed in the population, directly causing the osteolytic
phenotype. Although this cannot be ruled out without an
extensive program of breeding and genetic analysis, it
seems unlikely. DUSP-1/ osteoclast precursors of
almost pure (C57BL/6) genetic background are hyper-
responsive to proinflammatory stimuli, DUSP-1/mice
of the same genetic background display strong increases
in osteoclast activity in an experimental model of RA,
and the unusual, spontaneous osteolytic phenotype of
our mixed-background DUSP-1/ mouse colony is
characterized by enhanced osteoclast activity in the
context of neutrophil infiltration, a classic hallmark of
inflammation. The most conservative hypothesis is that
disruption of the Dusp1 gene and consequent dysregu-
lation of MAPK signaling contribute to (but do not
entirely explain) an increased susceptibility to spontane-
ous inflammatory osteolysis.
POPP, a very rare variant of psoriatic arthritis, is
characterized by onychodystrophy, connective tissue
thickening, periostitis of the distal phalanx, and com-
plete sparing of the interphalangeal joints. The toes of
affected individuals have a macroscopic drumstick ap-
pearance and a fuzzy appearance on radiographs, with
evident erosion of the terminal phalanx but no damage
to other bones or interphalangeal joints (48,49). All of
these features are common to the spontaneous osteolytic
phenotype we observed in the mixed-background
DUSP-1/ strain. While POPP appears to be resistant
to conventional psoriatic arthritis treatments, such as
methotrexate, it has been successfully treated with neu-
tralizing antibodies against TNF (50). It would be
premature to suggest that the mixed-background DUSP-
1/ strain is an experimental model of POPP, or even
that a disease with fewer than 20 reported cases world-
wide is seriously in need of an experimental model.
However, it may be interesting to investigate whether
there are any abnormalities of expression of the DUSP1
gene in humans with POPP.
Importantly, disruption of the Dusp1 gene may
increase susceptibility to inflammatory osteolysis in two
different ways. First, activated macrophages lacking
DUSP-1 overexpress TNF and other mediators of in-
flammation (30–33,40). Second, we recently reported
that TNF enhances osteoclast formation in the presence
of low concentrations of RANKL (41), and we show
here that DUSP-1/ osteoclast precursors are particu-
larly sensitive to the combination of RANKL and TNF.
We suggest that hyperactivation of osteoclasts in the
context of an inflammatory response is likely to be a
consequence of both overexpression of inflammatory
cytokines by macrophages and enhanced sensitivity of
osteoclasts to the effects of these factors. Osteoclast-
specific deletion of Dusp1 is required for further valida-
tion of these findings in vivo. It is possible that an
unknown mutation or genetic combination in our origi-
nal mixed-background DUSP-1/ colony causes an
increased susceptibility to inflammation of the toes, for
example by impairing the clearance of infections of the
nailbed. According to this hypothesis, hypersensitivity of
osteoclast precursors then leads to a striking, but highly
localized, osteolytic reaction.
DUSP-1/mice with experimental arthritis were
previously shown to express elevated levels of serum TNF
Figure 6. Increased bone loss at the metacarpophalangeal (MCP)
joints in DUSP-1/ mice with collagen-induced arthritis (CIA). A,
Reconstructed micro–computed tomography images of the hind paws
of nonimmunized (naive) and immunized, arthritic DUSP-1/ or
DUSP-1/mice obtained on day 10 after CIA onset. B, Measurement
of bone volume in a 1.5-mm region of interest (ROI) centered on the
MCP joints. Values are the mean  SEM of 3 age-matched non-
immunized control mice and 6 arthritic mice of each genotype.
  P  0.05 by one-way analysis of variance with the Bonferroni
post hoc test. NS  not significant.
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(32). This, combined with the enhanced sensitivity of
DUSP-1/ osteoclast precursors to TNF, is likely to
contribute to the increased numbers of activated peri-
articular osteoclasts and the enhanced erosion of peri-
articular bone seen in DUSP-1/ mice with experimen-
tally induced arthritis. An obvious and interesting
question is whether the DUSP-1 protein in humans has
the same function as its murine counterpart. If this were
the case, differences in the expression or function of
DUSP-1 could contribute to different rates of progres-
sion of bone erosion in RA and other chronic inflam-
matory diseases, and measurement of such differences
could have some predictive utility: further studies in RA
and osteoarthritis cohorts are required. Conversely,
treatments aimed at increasing or sustaining the expres-
sion of DUSP-1 might effectively reduce the bone
erosion that is such a debilitating feature of RA.
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